PAL-18 polypeptides, nucleic acids encoding the same and methods for screening for or modulating the same

ABSTRACT

Methods of screening for and/or detecting the presence or absence of cancers or treating cancers are described. In an aspect of the present invention, the screening methods are based on the detection of the PAL-18 protein, variants thereof, or a nucleic acid molecules encoding the same, found to be associated with the presence of cancer. Additional methods for imaging using antibodies for PAL-18 or modulating PAL-18 are provided. Preferred embodiments to the methods include detection based on immunological properties, physical properties, enzymatic properties and combinations thereof, or detection of a nucleic acid molecule encoding antigen (e.g., PAL-18) based on nucleic acid amplification.

CROSS REFERENCE TO RELATED APPLICATION

[0001] The present application claims priority to U.S. Provisional Application No. 60/188,586, filed Mar. 10, 2000.

TECHNICAL FIELD

[0002] The present invention is generally directed toward the discovery of novel nucleic acid molecules and PAL-18 polypeptides encoded thereby. More specifically, the invention is directed to these nucleic acid molecules and polypeptides encoded thereby for screening for or modulating a PAL-18 polypeptide in vitro and/or in vivo. In addition, the invention is related to detecting a PAL-18 polypeptide, or a nucleic acid molecule encoding such a protein, associated with the presence of cancer, and to modulating the presence or activity of such a protein.

BACKGROUND OF THE INVENTION

[0003] Over the past twenty years many elements of the biochemical pathways associated with abnormal growth and dysregulation of programmed cell death (also known as apoptosis) in human cancer have been elucidated; however, our knowledge of these pathways is far from comprehensive. Gaps in our understanding include the fact that the catalog of genes and proteins affecting these pathways is incomplete. Such incompleteness is evidenced in that proteins have been found in various eukaryotes which have been shown to be involved with Mitogen Activated Protein Kinase (MAPK) associated pathways, but closely similar human proteins related to these MAPK-associated proteins, which might perform parallel functions in humans, have not yet been identified. MAPKs are related to cancer through their interactions with the so-called “RAS-initiated” pathways. In the normal growth-regulation pathway, RAS is activated directly by proteins that interact with growth factors. Activated RAS brings about a cascade of kinase activation, including activation of the MAPKs, followed by phosphorylation of many other proteins involved in growth regulation, including the well-known oncoproteins ETS, MYC, FOS, and JUN. Proteins which directly interact with MAPKs could therefore modulate these signaling pathways and profoundly influence growth regulation, and, by extension, the development of cancer. Another important mechanism whereby cancer cells escape the normal checks on growth is by dysregulation of apoptosis, and MAPKs such as p38 have also been shown to be involved in regulation of the apoptotic process. However, the proteins mentioned above that are active in modulating MAPK pathways in other eukaryotes, but for which no strongly similar human homologs are known, represent a gap in the understanding of these growth-regulation and apoptotic pathways in humans, and therefore in the ability to intervene in patients with aberrant regulation associated with cancer.

[0004] Accordingly, there is a need in the art for advancing the understanding of such proteins and for methods for detection and utilization of such genes as related to disease indications. In particular, such genes and gene products may be utilized in the treatment, detection, and/or prevention of cancer and related disorders. The present invention fulfills this need and further provides other related advantages.

SUMMARY OF THE INVENTION

[0005] The surprising discovery and characterization of a particular human gene, PAL-18 are presented herein. This gene exhibits significant homologies to a number of proteins from other species which are implicated in MAPK signaling pathways. The present invention discloses that upregulation of the PAL-18 message is associated with all colon cancers studied and expression levels and/or certain single nucleotide polymorphisms may also be associated with familial predisposition to certain types of cancer such as prostate cancer. Briefly stated, the present invention provides a variety of methods and compositions for screening for cancer, and for treating tumor cells. The screening methods and compositions may be used on a one-time basis when cancer is suspected or on a periodic basis, e.g., to monitor an individual with an elevated risk of acquiring or reacquiring cancer.

[0006] In one aspect, the present invention provides an isolated PAL-18 polypeptide comprising an amino acid sequence that is encoded by a polynucleotide sequence selected from a sequence recited in SEQ ID NOs: 1-71, sequences that hybridize to a sequence recited in SEQ ID NOs:1-71 or 75-79 under moderately stringent conditions and complements of the polynucleotide sequences of (a) and (b).

[0007] In a related aspect an isolated polypeptide that comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in SEQ ID NOs:75-79 or a complement thereof is provided as are polypeptides comprising SEQ ID NOs:72-74 and fragments thereof of at least 15 contiguous amino acid residues of SEQ ID NOs:72-74.

[0008] In another aspect, the present invention provides isolated polynucleotides encoding at least 15 amino acid residues of a PAL-18 polypeptide, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the PAL-18 polypeptide comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in SEQ ID NOs:1-71, 75-79 or a complement thereof. Also provided are isolated polynucleotides encoding a PAL-18 polypeptide or a variant thereof, wherein the PAL-18 polypeptide comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in SEQ ID NOs: 1-71, 75-79, a complement thereof, or a sequence having at least 70% identity with SEQ ID NOs: 1-71 or 75-79. In related aspects the isolated polynucleotide comprises a sequence recited in SEQ ID NOs: 1-71 or 75-79 or complement thereof or isolated polynucleotides comprising a sequence that hybridizes to a sequence recited in SEQ ID NOs:1-71 or 75-79 under moderately stringent conditions or isolated polynucleotides comprising a sequence having at least 70% identity with SEQ ID NOs:1-71 or 75-79. Expression vectors containing any of the above polynucleotide sequences are also provided as are host cell containing these vectors.

[0009] In a further aspect the invention provides an isolated antibody, or antigen-binding fragment thereof, that specifically binds to a PAL-18 polypeptide or fragment thereof that comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in SEQ ID NOs: 1-71, 75-79 or a complement thereof.

[0010] Yet other aspects of the present invention provide pharmaceutical compositions comprising a physiologically acceptable carrier and at least one PAL-18 polypeptide, a fragment of a PAL-18 polypeptide, a PAL-18 encoding polynucleotide, or an antibody reactive with a PAL-18 polypeptide.

[0011] Also provided are methods for determining the presence or absence of a cancer in a patient, comprising contacting a biological sample obtained from a patient with a binding agent that binds to a PAL-18 polypeptide, wherein the PAL-18 polypeptide comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in SEQ ID NOs: 1-71, 75-79 or a complement thereof, detecting in the sample an amount of polypeptide that binds to the binding agent and comparing the amount of polypeptide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. In related aspects the binding agent is an antibody and/or the antibody is a monoclonal antibody. In further aspects, the cancer being detected is breast, prostate or colon cancer.

[0012] In yet other related aspects the detecting step involves detection of various molecular weight isoforms of PAL-18 or expression levels of PAL-18. Other related aspects utilize a biological sample selected from a tissue sample, a urine sample, a blood sample, and a stool sample.

[0013] In yet other embodiments a method for monitoring the progression of a cancer in a patient is provided and comprises contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a PAL-18 polypeptide or fragment thereof, wherein the PAL-18 polypeptide or fragment thereof comprises at least 15 contiguous amino acid residues encoded by a polynucleotide sequence recited in SEQ ID NOs:1-71, 75-79 or a complement thereof, detecting in the sample an amount of polypeptide that binds to the binding agent, repeating the previous steps using a biological sample obtained from the patient at a subsequent point in time and comparing the amount of polypeptide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient. In certain embodiments the binding agent is an antibody and in yet other embodiments the antibody is a monoclonal antibody. In yet other related embodiments, the cancer being detected is breast, colon, or prostate cancer.

[0014] Additional related aspects of the methods comprise a detecting step that involves detection of various molecular weight isoforms of PAL-18 or that involves detection of expression levels of PAL-18.

[0015] In still yet other aspects, the present invention provides methods for determining the presence or absence of a cancer in a patient, comprising contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a PAL-18 polypeptide or fragment thereof, wherein the PAL-18 polypeptide comprises at least 15 contiguous amino acid residues encoded by a polynucleotide sequence recited in SEQ ID NOs:1-71, 75-79 or a complement thereof and wherein the at least 15 contiguous amino acid residues retain the ability to react with an a PAL-18-specific antisera, detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide and comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient. Related aspects include wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a polymerase chain reaction, wherein the polymerase chain reaction is RT-PCR, orwherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.

[0016] Also provided by the present invention are methods for monitoring the progression of a cancer in a patient, comprising contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a PAL-18 polypeptide or fragment thereof, wherein the PAL-18 polypeptide comprises at least 15 contiguous amino acid residues encoded by a polynucleotide sequence recited in SEQ ID NOs:1-71, 75-79 or a complement thereof and wherein the at least 15 contiguous amino acid residues retain the ability to react with an a PAL-18-specific antisera, detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide, repeating the above steps using a biological sample obtained from the patient at a subsequent point in time and comparing the amount of polynucleotide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

[0017] Further provided are diagnostic kits comprising one or more antibodies according to claim 13 and a detection reagent comprising a reporter group. In related embodiments the antibodies are immobilized on a solid support and/or the detection reagent comprises an anti-immunoglobulin, protein G, protein A or lectin. In yet additional related aspects the kit may contain a reporter group such as radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.

[0018] Aspects of the invention are also related to an oligonucleotide comprising 10 to 40 contiguous nucleotides that hybridize under highly stringent conditions to a polynucleotide that encodes a PAL-18 polypeptide or fragment thereof, wherein the PAL-18 polypeptide or fragment thereof comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOs:1-71, 75-79 or a complement thereof.

[0019] Further aspects of the invention provide diagnostic kits comprising an oligonucleotide as described above and a diagnostic reagent for use in a polymerase chain reaction or hybridization assay.

[0020] Another aspect of the present invention provides a method of treating a tumor cell comprising the step of modulating a tumor-associated PAL-18 polypeptide or a nucleic acid molecule encoding said polypeptide, said nucleic acid molecule characterized by the ability of said nucleic acid molecule to hybridize under moderate stringency with any one of SEQ ID NOs:1-71, 75-79, or a complement thereof. Also provided are related aspects comprising the step of modulating the antigen and wherein the tumor cell is a colorectal or prostate tumor cell.

[0021] Other aspects of the present invention include an agent that modulates a tumor-associated PAL-18 polypeptide or a nucleic acid molecule encoding said polypeptide, said nucleic acid molecule characterized by the ability of said nucleic acid molecule to hybridize under moderate stringency with any one of SEQ ID NOs:1-71, 75-79, or a complement thereof as well as compositions comprising an agent that modulates a PAL-18 polypeptide or a nucleic acid molecule encoding said polypeptide, said nucleic acid molecule characterized by the ability of said nucleic acid molecule to hybridize under moderate stringency with any one of SEQ ID NOs:1-71, 75-79, or a complement thereof, in combination with a pharmaceutically acceptable carrier or diluent.

[0022] Still yet other aspects provided are methods for diagnosing abnormal PAL-18, comprising isolating PAL-18 encoding nucleic acid molecules from a sample and subsequently screening for single nucleotide polymorphisms, whereby detection of a single nucleotide polymorphism indicates an abnormal PAL-18.

[0023] Further provided is a method for facilitating in vivo imaging, comprising administering to an animal an binding agent that specifically binds a PAL-18 polypeptide, said binding agent having an imaging agent attached thereto.

[0024] These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

[0025]FIG. 1 depicts a scanned image of agarose gel electrophoresis of culture PCR screening of TA cloned amplicons from five libraries. Colony 13 demonstrates a positive clone.

[0026]FIG. 2 depicts local homologies of PAL-18 (SEQ ID NOS: 162 & 164) with yeast calnexin (SEQ ID NO:163) and mouse rhophilin (SEQ ID NO:165).

[0027]FIG. 3 represents a scanned image of agarose gel electrophoresis of PAL-18 message detected in matched pairs of cancer (left lane of each sample) and normal (right lane of each sample) tissue from six prostate-cancer patients. Left most lane represents molecular weight markers (PCR Rulers® Biorad Corp.).

[0028]FIG. 4 represents a scanned image of agarose gel electrophoresis of the PAL-18 message presence in matched pairs of cancer (C) and normal (N) tissue from six colon cancer patients. The molecular weight markers (M) are the PCR ruler from Biorad Corp. and the Mic represents a control of microglobulin.

[0029]FIG. 5 is the sequence of contiguous sequence 1 (SEQ ID NO:75) compiled from gene walking experiments, including alignments with various other sequences (SEQ ID NOS: 114-120).

[0030]FIG. 6 is the sequence of contiguous sequence 2 (SEQ ID NO:76) compiled from gene walking experiments, including alignments with various other sequences (SEQ ID NOS: 121-137).

[0031]FIG. 7 is the sequence of contiguous sequence 3 (SEQ ID NO:77) compiled from gene walking experiments, including alignments with various other sequences (SEQ ID NOS: 138-140).

[0032]FIG. 8 is the sequence of contiguous sequence 4 (SEQ ID NO:78) compiled from gene walking experiments, including alignments with various other sequences (SEQ ID NOS: 141-148).

[0033]FIG. 9 is the sequence of contiguous sequence 5 (SEQ ID NO:79) compiled from gene walking experiments, including alignments with various other sequences (SEQ ID NOS: 149-161).

DETAILED DESCRIPTION OF THE INVENTION

[0034] The invention consists of a set of compositions of matter of PAL-18 and related genes, with encoded proteins, and the uses of these genes and proteins in diagnosing, characterizing, and treating disease, and in determining disease susceptibility. In addition the invention provides methods of analysis to detect and/or quantify alternatively expressed forms of PAL-18 or genes related to PAL-18. The invention also describes methods of finding PAL-18-related sequences by low-fidelity RT-PCR and identification of qualifying sequences by database searching with specific criteria for inclusion and exclusion of candidate related sequences.

[0035] Prior to setting forth details of the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms that will be used hereinafter.

[0036] A “PAL-18 polypeptide”, as used herein, refers to a polypeptide having at least about 70% amino acid identity with any one of SEQ ID NOS:72-74 or the Sequence set forth in Example 1 or the polypeptides encoded by SEQ ID NOS:1-71, 75-79, or the polypeptide encoded by the cDNA set forth in Example 1. The PAL-18 polypeptides of the subject invention also include variants (including alleles) of the native protein sequence. Briefly, such variants may result from natural polymorphisms or may be synthesized by recombinant methodology, and differ from wild-type protein by one or more amino acid substitutions, insertions, deletions, or the like. Variants generally have at least about 70% nucleotide identity to native sequence, preferably at least 80%-85%, and most preferably at least 90% nucleotide identity.

[0037] Typically, when engineered, amino acid substitutions will be conservative, i.e., substitution of amino acids within groups of polar, non-polar, aromatic, charged, etc. amino acids. In the region of homology to the native sequence, variants should preferably have at least 50% amino acid sequence identity, and within certain embodiments, greater than 75%, 80%, 90%, 92%, 95%, or 97% identity. More typically, the amino acid sequence identity will be at least about any percentage from (and including) 50% to 100%, such as at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% identity. Variants that nearly identical to a PAL-18 polypeptide have at least about 85% or 90% identity. Accordingly, one method for determining amino acid sequence “identity” is determined by the alignment of amino acid sequences and establishment of identical amino acid residues using the program GeneJockey II (1993) for Macintosh (Philip L. Taylor, published by Biosoft, Cambridge, UK). The program is run in the amino acid homology mode, using program default parameters. In the comparison of two sequences aligned by the program, the percent identity is calculated only for those positions where there is an amino acid residue present in both of the two sequences. Such amino acid sequence identity may be determined by other standard methodologies, including use of the National Center for Biotechnology Information BLAST search methodology available at www.ncbi.nlm.nih.gov using the BLAST 2.0 algorithm and default parameters (also available from CGC, Madison, Wis.). The identity methodologies most preferred are those described in U.S. Pat. No. 5,691,179 (specifically, the GAP algorithm) and Altschul et al., Nucleic Acids Res. 25:3389-3402, 1997, both of which are incorporated herein by reference. Typically, when such identity algorithms are used they are carried out with default parameters.

[0038] Within the context of the present invention, polypeptides may comprise at least an immunogenic portion of a PAL-18 polypeptide or a variant thereof, as described herein. As noted above, a “PAL-18 antigen” is a protein that is expressed by a variety of cell types and may be variably expressed at differing levels and/or expressed in various isoforms in cancer cells. Polypeptides as described herein may be of any length. Additional sequences derived from the native protein and/or heterologous sequences may be present, and such sequences may (but need not) possess further immunogenic or antigenic properties.

[0039] An “immunogenic portion,” as used herein is a portion of a protein that is recognized (i.e., specifically bound) by a B-cell and/or T-cell surface antigen receptor. Such immunogenic portions generally comprise at least 5 amino acid residues, more preferably at least 10, and still more preferably at least 20 amino acid residues of an PAL-18 polypeptide or a variant thereof. Certain immunogenic portions may include peptides in which an N-terminal leader sequence have been deleted. Other preferred immunogenic portions may contain a small N- and/or C-terminal deletion (e.g., 1-30 amino acids, preferably 5-15 amino acids), relative to the mature protein.

[0040] Immunogenic portions may generally be identified using well known techniques, such as those summarized in Paul, Fundamental Immunology, 3rd ed., 243-247 (Raven Press, 1993) and references cited therein. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are “antigen-specific” if they specifically bind to an antigen (i.e., they react with the protein in an ELISA or other immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein, and using well known techniques. An immunogenic portion of a PAL-18 polypeptide is a portion that reacts with such antisera and/or T-cells at a level that is not substantially less than the reactivity of the full length polypeptide (e.g., in an ELISA and/or T-cell reactivity assay). Such immunogenic portions may react within such assays at a level that is similar to or greater than the reactivity of the full length polypeptide. Such screens may generally be performed using methods well known to those of ordinary skill in the art, such as those described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. For example, a polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ¹²⁵I-labeled Protein A.

[0041] In certain embodiments a PAL-18 polypeptide variant differs from a native PAL-18 polypeptide sequence in one or more substitutions, deletions, additions and/or insertions, such that the immunogenicity of the polypeptide is not substantially diminished. In other words, the ability of a variant to react with antigen-specific antisera may be enhanced or unchanged, relative to the native protein, or may be diminished by less than 50%, and preferably less than 20%, relative to the native protein. Such variants may generally be identified by modifying one of the above polypeptide sequences and evaluating the reactivity of the modified polypeptide with antigen-specific antibodies or antisera as described herein. Preferred variants include those in which one or more portions, such as an N-terminal leader sequence, have been removed. Other preferred variants include variants in which a small portion (e.g., 1-30 amino acids, preferably 5-15 amino acids) has been removed from the N- and/or C-terminal of the mature protein.

[0042] As will be appreciated by those skilled in the art, a nucleotide sequence encoding a PAL-18 polypeptide or variant thereof may differ from known native sequence, due to codon degeneracies, nucleotide polymorphisms, or amino acid differences. In certain embodiments, variants will preferably hybridize to the native nucleotide sequence at conditions of normal (moderate) stringency, which is approximately 25-30° C. below Tm of the native duplex (e.g., 5×SSPE, 0.5% SDS, 5×Denhardt's solution, 50% formamide, at 42° C. or equivalent conditions; see generally, Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, 1989; Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing, 1995). By way of comparison, low stringency hybridizations utilize conditions approximately 40° C. below Tm, and high stringency hybridizations utilize conditions approximately 10° C. below Tm. Accordingly, within certain embodiments, moderate stringency hybridization and PCR amplification conditions are defined as those performed at the calculated melting temperature (Tm) of the probe/primer with the target. The recommended formula for calculating Tm, and its limitations, are well known in the art (i.e., are found in Sambrook, J., Fritsch, E. F. and T. Maniatis, Molecular Cloning, 2d Edition, Cold Spring Harbor Laboratory press, pp. 9.51-9.52, 1989). Highest stringency conditions are defined within this application as hybridization/amplification performed at least 4° C. above the calculated Tm. Further illustrative conditions for suitable moderately stringent conditions include, for example, prewashing in a solution of 5×SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50° C.-70° C., 5×SSC for 1-16 hours; followed by washing once or twice at 22-65° C. for 20-40 minutes with one or more each of 2×, 0.5× and 0.2×SSC containing 0.05-0.1% SDS. For additional stringency, conditions may include a wash in 0.1×SSC and 0.1% SDS at 50-60° C. for 15 minutes.

[0043] As known to those having ordinary skill in the art, variations in stringency of hybridization conditions may be achieved by altering the time, temperature and/or concentration of the solutions used for prehybridization, hybridization and wash steps, and suitable conditions may also depend in part on the particular nucleotide sequences of the probe used, and of the blotted, PAL-18 nucleic acid sample. Accordingly, it will be appreciated that suitably stringent conditions can be readily selected without undue experimentation where a desired selectivity of the probe is identified, based on its ability to hybridize to one or more certain sequences while not hybridizing to certain other sequences.

[0044] It will also be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotide s bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention.

[0045] An “isolated nucleic acid molecule” refers to a polynucleotide molecule in the form of a separate fragment or as a component of a larger nucleic acid construct, that has been separated from its source cell (including the chromosome it normally resides in) at least once, and preferably in a substantially pure form. Nucleic acid molecules may be comprised of a wide variety of nucleotides, including DNA, RNA, nucleotide analogues, or combination thereof and may include variants as noted above.

[0046] The term “in vitro” refers to systems outside the body including organ culture.

[0047] The term “in vivo” refers to whole cell systems, which include, for example, primary and secondary cell culture, whole organs culture, whole organisms, and similar systems as known to those of ordinary skill in the art.

[0048] The term “predetermined cut-off value”, as used herein, refers to a background value or a value normally present in the tissue type or biological sample.

[0049] A. PAL-18 Nucleic Acid Molecules and Encoded Products Thereof

[0050] 1. PAL-18 Nucleic Acid Molecules

[0051] The present invention unexpectedly provides PAL-18 nucleic acid molecules which, in certain embodiments, are derived from human or animal libraries. PAL-18 nucleic acid molecules used in the subject invention may be isolated from either genomic DNA or preferably cDNA sources. Isolation of PAL-18 nucleic acid molecules from genomic DNA or cDNA typically can proceed by, first, generating an appropriate DNA library through techniques for constructing libraries that are known in the art (see Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, 1989) or purchased from commercial sources (e.g., Clontech, Palo Alto, Calif.). Briefly, cDNA libraries can be constructed in bacteriophage vectors (e.g., λZAPII), plasmids, or others, which are suitable for screening, while genomic DNA libraries can be constructed in chromosomal vectors, such as YACs (yeast artificial chromosomes), bacteriophage vectors, such as λEMBL3, λgt10, cosmids, or plasmids.

[0052] In one embodiment, PAL-18 sequences set forth herein may be utilized to design an oligonucleotide hybridization probe suitable for screening genomic or cDNA libraries. Preferably, such oligonucleotide probes are 20-35 bases in length. To facilitate hybridization detection, the oligonucleotide may be conveniently labeled, generally at the 5′ end, with a reporter molecule, such as a radionuclide, (e.g., ³²P), enzymatic label, protein label, fluorescent label, or biotin. Such libraries are then generally plated as phage or colonies, depending upon the vector used. Subsequently, a nitrocellulose or nylon membrane, to which the colonies or phage have been transferred, is probed to identify candidate clones which contain the gene. Such candidates may be verified as containing the desired DNA by any of various means including, for example, DNA sequence analysis or hybridization with a second, non-overlapping probe.

[0053] Once a library is identified as containing a PAL-18 nucleic acid molecule, the molecule can be isolated by amplification. Primers for amplification are preferably derived from sequences in the 5′ and 3′ untranslated region in order to isolate a full-length cDNA. The primers preferably have a GC content of about 50% and contain restriction sites to facilitate cloning and do not have self-complementary sequences nor do they contain complementary sequences at their 3′ end (to prevent primer-dimer formation). The primers are annealed to cDNA or genomic DNA and sufficient amplification cycles are performed to yield a product readily visualized by gel electrophoresis and staining. The amplified fragment is purified and inserted into a vector, such as λgt10 or pBS(M13+), and propagated. Confirmation of the nature of the fragment may be obtained by DNA sequence analysis, or indirectly through amino acid sequencing of the encoded protein.

[0054] Other methods may also be used to obtain a PAL-18 encoding nucleic acid molecule. For example, a nucleic acid molecule encoding a PAL-18 polypeptide may be obtained from an expression library by screening with an antibody or antibodies reactive to such a PAL-18 polypeptide or fragment thereof (see, Sambrook, et al. Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, NY, 1989; Ausubel, et al. Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley-Interscience, NY, 1995).

[0055] PAL-18 nucleic acid molecules from a variety of species may be isolated using the compositions provided herein. For closely related species, the human sequence or portion thereof may be utilized as a probe on a genomic or cDNA library. For example, a fragment of nucleic acid that encodes a portion of the PAL-18 polypeptide may be labeled and used as a probe on a library constructed from mouse, primate, rat, dog, or other vertebrate, warm-blooded or mammalian species. An initial hybridization at normal stringency may yield candidate clones or fragments. If no hybridization is initially observed, varying degrees of stringency may be used (see Sambrook et al., supra, and other well-known sources for stringency conditions). While such probes may also be used to probe libraries from evolutionarily diverse species, such as Drosophila, hybridization conditions will likely be less stringent.

[0056] While relaxed hybridization conditions using probes designed from human sequences may identify PAL-18 nucleic acid molecules of evolutionarily diverse species, it may be more beneficial to attempt to directly isolate these molecules from a library using methods which do not require the human sequence per se. These methods include, but are not limited to, amplification using primers derived from conserved areas, amplification using degenerate primers from various regions, antibody probing of expression libraries, and the like. For example, random-primed amplification (e.g., polymerase chain reaction) may be employed (see, e.g., Methods Enzymol. 254:275, 1995; Trends Genet. 11:242, 1995; Liang and Pardee, Science 257:967, 1992; Welsh et al., Nucl. Acids Res. 20:4965, 1992). In addition, variations of random-primed PCR may also be used, especially when a particular gene or gene family is desired. In such a method, one of the amplification primers is an “anchored oligo(dT) (oligo(dT)dN)” and the other primer is a degenerate primer based upon amino acid or nucleotide sequence of a related gene. A gene sequence is identified as a PAL-18 molecule by amino acid similarity and/or nucleic acid similarity. Generally, amino acid similarity is preferred.

[0057] Variants of PAL-18 nucleic acid molecules provided herein may be engineered from natural variants (e.g., polymorphisms, splice variants, mutants), synthesized or constructed. Many methods have been developed for generating mutants (see, generally, Sambrook et al, supra; Ausubel, et al., supra, and the discussion above). Briefly, preferred methods for generating nucleotide substitutions utilize an oligonucleotide that spans the base or bases to be mutated and contains the mutated base or bases. The oligonucleotide is hybridized to complementary single stranded nucleic acid and second strand synthesis is primed from the oligonucleotide. The double-stranded nucleic acid is prepared for transformation into host cells, typically E. coli, but alternatively, other prokaryotes, yeast or other eukaryotes. Standard screening and vector growth protocols are used to identify mutant sequences and obtain high yields.

[0058] Similarly, deletions and/or insertions of a PAL-18 encoding nucleic acid molecule may be constructed by any of a variety of known methods as discussed supra. For example, the nucleic acid molecule can be digested with restriction enzymes and religated, thereby deleting or religating a sequence with additional sequences, such that an insertion or large substitution is made. Other means of generating variant sequences may be employed using methods known in the art, for example those described in Sambrook et al., supra; Ausubel et al., supra. Verification of variant sequences is typically accomplished by restriction enzyme mapping, sequence analysis, or probe hybridization.

[0059] As one of skill in the art can readily appreciate, once DNA sequences for a gene have been identified the production of antisense nucleic acid molecules is trivial. Such complementary antisense polynucleotides may include substitutions, additions, deletions, or transpositions, as long as specific hybridization to the relevant target sequence in any one of SEQ ID NOs:1-71 or 75-79 (or the sequences set forth in Example I) is retained as a functional property of the polynucleotide. Antisense polynucleotides that prevent transcription and/or translation of mRNA corresponding to PAL-18 may enhance or inhibit apoptosis or a MAP kinase signaling pathway and/or inhibit cancer progression. Antisense polynucleotides of various lengths may be produced and used, however, the sequence length is typically at least 20 consecutive nucleotides that are substantially or wholly identical to a sequence contained within any one of SEQ ID NOs:1-71 or 75-79. (see U.S. Pat. No. 5,691,179 and Antisense RNA and DNA, D. A. Melton, Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. 1988, each of which is incorporated herein by reference).

[0060] 2. PAL-18Polypeptides and Fragments Thereof

[0061] PAL-18 polypeptides vary in exon lengths as indicated by SEQ ID NOs:72-74 and nucleic acid sequences SEQ ID NOs:75-79 which represent composites of various clones. PAL-18 polypeptides of the present invention have calculated amino acid lengths of 379 and 411 amino acids (SEQ ID NOs:72-74) which exhibit homologies with known genes. In addition, as is clear form the various sequences, PAL-18 polypeptides of other lengths are encoded by splice variant forms. For diagnostic purposes all fragments even those disclosed in the art are applicable with this newly identified use. This includes all sequences identified in Example 1.

[0062] The polypeptides appear to be a human homolog to the Bro1 family of proteins, which interact with MAP kinase signaling pathway proteins (see, e.g., Nickas and Yaffe, Mol. Cell. Biol. 16(6):2585-2593, 1996). When using, the 411 amino acid sequence for searching databases using the BLAST 2.0 Algorithm, the protein homologies are: BRO1 25% identity and 41% conservation over 229 residues; C. elegans YNK1 23% identity, 40% conservation over 286 residues; PTP-TD14 (a rodent protein-tyrosine phosphatase involved in ras-dependent pathways; Cao et al., J. Biol. Chem. 273(33):21077-21083, 1998) 21% identity, 42% conservation over 213 residues; C. elegans B0507.2 39% identity, 58% conservation over the full 411 residues of SEQ ID NO:79/74. Further, searching with the full 411 residue PAL-18 polypeptide using the BLASTP 2.1.2 Algorithm (Altschul et al., Nuc. Acid Res. 25:3389-3402, 1997) reveals 89% identity, 93% conservation over 101 residues with putative mouse protein AK002489; 25% identity, 41% conservation over 247 residues of palA (Z83333, accession); 21% identity, 39% conservation over 258 residues of Yor275cp; and 27% identity, 43% conservation over 159 residues of programmed cell death 6-interacting protein and ALG-2 interacting protein 1 (NP037506.1 and AF151793, accession numbers); and 22% identity, 34% conservation over 333 residues of Alix (mus musculus, programmed cell death 6 interacting protein, AJ005073). Accordingly, the PAL-18 polypeptide is likely involved in the MAP kinase signaling pathway and/or in related apoptotic pathways as is predicated for BRO1, see Vito et al., J. Biol. Chem. 274(3):1533-1540, 1999; Che et al., J. Biol. Chem. 274(9):5522-5531, 1999; Missotten et al., Cell Death Differ 6(2):124-129, 1999. As such, modulation of PAL-18 may be critical in controlling cell-death and/or signaling pathways and thus related indications such as cancer. In this regard the crossover of the MAP kinase pathways and apoptotic pathways as well as the relation of the same to cancer progression has been the discussion of several recent journal articles, see e.g., Miki et al., Anticancer Res. 19(6B):5283-5291, 1999; Yin et al., Anticancer Res. 19(5B):4297-4303, 1999; Marushige et al., Anticancer Res. 19(5B):3865-3871, 1999. Accordingly, PAL-18 polypeptides are of interest as not only as modulators of cancer growth and progression, but also as a potentially drug target for MAP kinase signaling pathway and apoptotic pathway related indications such as autoimmune diseases etc.

[0063] In other embodiments, a PAL-18 polypeptide is fused to other polypeptide sequences to aid in expression and/or purification. For example, fusions with His6, T7, and Flag tags may aid in purification and/or immunoidentification.

[0064] PAL-18 polypeptides of the subject invention may be constructed from the described PAL-18 sequences by a variety of methods known in the art. A preferred method is amplification (e.g., polymerase chain reaction (PCR)) to selectively amplify the individual regions and place these in cloning vectors such as pUC. Moreover, such PCR reactions can be performed in a variety of ways such that the primers used for amplification contain specific restriction endonuclease sites to facilitate insertion into a vector.

[0065] Further, a variety of other methodologies besides PCR may be used to attain the desired construct. For example, one skilled in the art may employ isothermal methods to amplify the nucleotide sequence of interest, using existing restriction endonuclease sites present in the nucleotide sequence to excise and insert sequences, or by the introduction of distinct restriction endonuclease sites by site-directed mutagenesis followed by excision and insertion. These and other methods are described in Sambrook et al., supra; Ausubel, et al., supra. Briefly, one methodology is to generate single-stranded cDNA encoding PAL-18, followed by annealing a primer, which is complementary except for the desired alteration (e.g., a small insertion, deletion, or mutation such that a unique restriction site is created between the domains). Bacterial cells are transformed and screened for those cells which contain the desired construct. This construct is then digested to liberate the desired sequences, which can then be purified and religated into the appropriate orientation.

[0066] In addition, the invention provides fragments of SEQ ID NOs:72-74 and sequences with at least about 70% identity therewith. A fragment of SEQ ID NOs:72-74 may be defined both structurally and functionally in that it has the same contiguous sequence as a portion of SEQ ID NOs:72-74 and those sequences with at least about 70% identity therewith and at least one activity characteristic of PAL-18. Such activities can be binding and/or activating or deactivating MAP kinase pathway proteins and/or apoptotic pathway proteins, or acting as an antigen or as a tag for imaging. More specifically the PAL-18 polypeptide or fragment thereof as defined above, may enhance or inhibit phosphorylation or apoptosis, or may bind or induce the production of an anti-PAL18 antibody. A fragment of SEQ ID NOs:72-74 and those sequences with at least about 70% identity therewith comprise at least 8 contiguous residues. In other embodiments of the invention, a fragment comprises an amino acid sequence of at least 10 or 12 contiguous residues. In further embodiments of the invention, a fragment comprises an amino acid sequence of at least 15 or 20 contiguous residues. In yet other embodiments of the invention, a fragment comprises an amino acid sequence of at least 25 or 30 contiguous residues. In another embodiment of the invention, a fragment comprises an amino acid sequence of at least 50 contiguous residues. However, an amino acid sequence that consists of the identical amino acid sequence encoded by ESTs having GenBank accession numbers AA386306, AI243754, AA295847, AA994364, AI911339, AA884496, AI243754 or any contiguous portion thereof, is not a functional fragment of SEQ ID NOs:72-74 and those sequences with at least about 70% identity therewith encompassed within the invention.

[0067] It is understood that fragments of a PAL-18 polypeptide include fragments with substitutions of conserved and non-essential amino acids of portions of SEQ ID NOs:72-74 and, therefore, include, for example, fragments of eukaryotic homologs of SEQ ID NO:72-74 and sequences having at least about 70% identity therewith.

[0068] B. Vectors, Host Cells and Methods of Expressing and Producing Protein

[0069] PAL-18 may be expressed in a variety of host organisms. In certain embodiments, PAL-18 is produced in bacteria, such as E. coli, or mammalian cells (e.g., CHO and COS-7), for which many expression vectors have been developed and are available. Other suitable host organisms include other bacterial species, and eukaryotes, such as yeast (e.g., Saccharomyces cerevisiae), and insect cells (e.g., Sf9).

[0070] In one embodiment, a DNA sequence encoding a PAL-18 polypeptide is introduced into an expression vector appropriate for the host cell. In certain embodiments, nucleic acid sequences encoding PAL-18 are inserted into a vector such that a fusion protein is produced. The PAL-18 sequence is derived as described herein. As discussed above, the sequence may contain alternative codons for each amino acid with multiple codons. The alternative codons can be chosen as “optimal” for the host species. Restriction sites are typically incorporated into the primer sequences and are chosen with regard to the cloning site of the vector. If necessary, translational initiation and termination codons can be engineered into the primer sequences.

[0071] At a minimum, the vector will contain a promoter sequence. As used herein, a “promoter” refers to a nucleotide sequence that contains elements that direct the transcription of a linked gene. At a minimum, a promoter contains an RNA polymerase binding site. More typically, in eukaryotes, promoter sequences contain binding sites for other transcriptional factors that control the rate and timing of gene expression. Such sites include TATA box, CAAT box, POU box, AP1 binding site, and the like. Promoter regions may also contain enhancer elements. When a promoter is linked to a gene so as to enable transcription of the gene, it is “operatively linked”.

[0072] Other regulatory sequences may be included. Such sequences include a transcription termination sequence, secretion signal sequence, origin of replication, selectable marker, and the like. The regulatory sequences are operationally associated with one another to allow transcription or translation.

[0073] The expression vectors used herein include a promoter designed for expression of the proteins in a host cell (e.g., bacterial). Suitable promoters are widely available and are well known in the art. Inducible or constitutive promoters are preferred. Such promoters for expression in bacteria include promoters from the T7 phage and other phages, such as T3, T5, and SP6, and the trp, lpp, and lac operons. Hybrid promoters (see, U.S. Pat. No. 4,551,433), such as tac and trc, may also be used. Promoters for expression in eukaryotic cells include the P10 or polyhedron gene promoter of baculovirus/insect cell expression systems (see, e.g., U.S. Pat. Nos. 5,243,041, 5,242,687, 5,266,317, 4,745,051, and 5,169,784), MMTV LTR, CMV IE promoter, RSV LTR, SV40, metallothionein promoter (see, e.g., U.S. Pat. No. 4,870,009), ecdysone response element system, tetracycline-reversible silencing system (tet-on, tet-off), and the like.

[0074] The promoter controlling transcription of PAL-18 may itself be controlled by a repressor. In some systems, the promoter can be derepressed by altering the physiological conditions of the cell, for example, by the addition of a molecule that competitively binds the repressor, or by altering the temperature of the growth media. Preferred repressor proteins include, but are not limited to the E. coli lacI repressor responsive to IPTG induction, the temperature sensitive λcI857 repressor, and the like.

[0075] In other optional embodiments, the vector also includes a transcription termination sequence. A “transcription terminator region” has either a sequence that provides a signal that terminates transcription by the polymerase that recognizes the selected promoter and/or a signal sequence for polyadenylation.

[0076] In one aspect, the vector is capable of replication in the host cells. Thus, when the host cell is a bacterium, the vector preferably contains a bacterial origin of replication. Bacterial origins of replication include the fl-ori and col E1 origins of replication, especially the ori derived from pUC plasmids. In yeast, ARS or CEN sequences can be used to assure replication. A well-used system in mammalian cells is SV40 ori.

[0077] The plasmids also preferably include at least one selectable marker that is functional in the host. A selectable marker gene includes any gene that confers a phenotype on the host that allows transformed cells to be identified and selectively grown. Suitable selectable marker genes for bacterial hosts include the ampicillin resistance gene (Amp^(r)), tetracycline resistance gene (Tc^(r)) and the kanamycin resistance gene (Kan^(r)). The kanamycin resistance gene is presently preferred. Suitable markers for eukaryotes usually require a complementary deficiency in the host (e.g., thymidine kinase (tk) in tk−hosts). However, drug markers are also available (e.g., G418 resistance and hygromycin resistance).

[0078] The sequence of nucleotides encoding PAL-18 may also include a secretion signal, whereby the resulting peptide is a precursor protein processed and secreted. The resulting processed protein may be recovered from the periplasmic space or the fermentation medium. Secretion signals suitable for use are widely available and are well known in the art (von Heijne, J. Mol. Biol. 184:99-105, 1985). Prokaryotic and eukaryotic secretion signals that are functional in E. coli (or other host) may be employed. The presently preferred secretion signals include, but are not limited to, those encoded by the following E. coli genes: pe1B (Lei et al., J. Bacteriol. 169:4379, 1987), phoA, ompA, ompT, ompF, ompC, beta-lactamase, and alkaline phosphatase.

[0079] One skilled in the art will appreciate that there are a wide variety of suitable vectors for expression in bacterial cells and which are readily obtainable. Vectors such as the pET series (Novagen, Madison, Wis.), the tac and trc series (Pharmacia, Uppsala, Sweden), pTTQ18 (Amersham International plc, England), pACYC 177, pGEX series, and the like are suitable for expression of a PAL-18 polypeptide. Baculovirus vectors, such as pBlueBac (see, e.g., U.S. Pat. Nos. 5,278,050, 5,244,805, 5,243,041, 5,242,687, 5,266,317, 4,745,051, and 5,169,784; available from Invitrogen, San Diego) may be used for expression in insect cells, such as Spodoptera frugiperda sf9 cells (see, U.S. Pat. No. 4,745,051). The choice of a bacterial host for the expression of a PAL-18 polypeptide is dictated in part by the vector. Commercially available vectors are paired with suitable hosts.

[0080] A wide variety of suitable vectors for expression in eukaryotic cells are also available. Such vectors include pCMVLacI, pXT1 (Stratagene Cloning Systems, La Jolla, Calif.); pCDNA series, pREP series, pEBVHis (Invitrogen, Carlsbad, Calif.). In certain embodiments, the PAL-18 nucleic acid molecule is cloned into a gene targeting vector, such as pMC1neo, a pOG series vector (Stratagene Cloning Systems).

[0081] PAL-18 polypeptides may be isolated by standard methods, such as affinity chromatography, size exclusion chromatography, metal ion chromatography, ionic exchange chromatography, HPLC, and other known protein isolation methods. (see generally Ausubel et al. supra; Sambrook et al. supra). An isolated purified protein gives a single band on SDS-PAGE when stained with Coomassie blue. PAL-18 polypeptides may be expressed using tags to facilitate isolation such as a hexa-his (His6) fusion protein and isolated by metal-containing chromatography, such as nickel-coupled beads. Briefly, a sequence encoding His6 is linked to a DNA sequence encoding a PAL-18 polypeptide. Although the His6 sequence can be positioned anywhere in the molecule, preferably it is linked at the 5′ end or at the 3′ end immediately preceding the termination codon. The fusion may be constructed by any of a variety of methods. A convenient method is amplification of the PAL-18 nucleic acid molecule using a downstream primer that contains the codons for His6. In a similar manner T7, Flag, and a variety of other fusions are possible.

[0082] In further embodiments, these proteins may also be crystallized and subjected to X-ray analysis to determine the 3-dimensional structure for rational drug design or utilized to generate antibodies.

[0083] C. Uses of PAL-18 Nucleic Acid Molecules and Encoded Products Thereof

[0084] As noted above, the present invention in one aspect is directed toward methods of screening for (detecting or monitoring) or treating an abnormality (such as cancer or autoimmune disorders) in which a PAL-18 polypeptide is associated. As disclosed in the present invention, PAL-18 polypeptides and/or nucleic acid molecules (including splice variants and single nucleotide polymorphisms) may be found to be associated with the presence of tumor cells and found to survive in detectable concentrations in specimens from patients with tumors. In this regard, varying levels of all or certain PAL-18 polypeptides or mRNA molecules may be present in a particular cancer, tissue type or biological sample. Furthermore, varying PAL-18 levels or varying levels of splice variants or SNPs may be found associated with a variety of cancers, including colorectal, renal, bladder and other cancers, and may be detected in a variety of ways, including by detecting PAL-18 itself or a nucleic acid molecule encoding PAL-18. Methods for detecting the presence (i.e., qualitative or quantitative) of PAL-18 include those based on physical properties, immunological properties, biochemical properties and combinations thereof (e.g., physical size of the molecule, nucleic acid sequence, amino acid sequence, binding by monoclonal or polyclonal antibodies, ligand binding, enzymatic properties, and combinations thereof). For example, relative levels of expression of PAL-18 or PAL-18 isoforms/variants may be relevant to cancer diagnosis. In one example, PAL-18 appears to be upregulated in colorectal cancers.

[0085] Purified antigen (PAL-18 or fragments thereof), partially purified antigen or biological samples containing antigen may be used to produce antibodies that specifically bind to the antigen. Antibodies that specifically bind are those with an affinity of about 10⁶ liters/mol or greater. Either polyclonal antibodies or monoclonal antibodies may be generated. Polyclonal antibodies may be produced by immunization of an animal and subsequent collection of its sera. It is generally preferred to follow the initial immunization with one or more booster immunizations prior to sera collection. Monoclonal antibodies are generally produced by the method of Kohler and Milstein (Nature 256:495-497, 1975; Eur. J. Immunol. 6:511-519, 1976). Briefly, the lymph nodes and/or spleens of an animal injected with antigen in pure or impure form are fused with myeloma cells to form hybrid cell lines (“hybridomas” or “clones”). Each hybridoma secretes a single type of immunoglobulin specific for the antigen and, like the myeloma cells, has the potential for indefinite cell division.

[0086] Antigen in pure or impure form (“immunogen”) is used for the immunization. Preferably, the animals are immunized with at least 100 ng each of the immunogen, most preferably greater than 500 ng each. For immunization, the immunogen may be adsorbed to a solid phase matrix, preferably to nitrocellulose paper. The paper is then introduced into the animal. Techniques for introduction of the adsorbed antigen preparation include implantation (U.S. Pat. No. 4,689,220) or solubilization of the solid phase and injection of the solubilized material (Knudsen, Anal. Biochem. 147:285-288, 1985). The solid phase matrix may be solubilized in an appropriate organic solvent (e.g., DMSO) and either mixed with adjuvant or saline, or injected directly.

[0087] Alternatively, the immunogen may be injected in the absence of a solid matrix and/or adjuvant. Injection or implantation may be intraperitoneal, intra-foot pad, subcutaneous, intramuscular or intravenous, but preferably intraperitoneal. The animals may also be injected with antigen complexed with adjuvant, such as Freund's adjuvant. Single or multiple booster immunizations are used. Between one and seven days prior to the fusion date, preferably on days one through four, intravenous injections of the immunogen may be given daily.

[0088] Between one and seven days, preferably four days, after the administration of the final booster immunization, spleens or portions thereof are harvested from the immunized animals. At this time, the lymph nodes may also be harvested and included in the cell preparation. The harvested organs are minced using techniques which disrupt the structure of the organ, but which are not detrimental to the lymphocytes. The organs are preferably minced with scissors, passed through a mesh screen and mixed with growth medium to enrich the preparation for lymphocytes. The minced and strained tissue is harvested by centrifugation, then mixed with growth medium to form a cell suspension. The red blood cells may be lysed by adding a hypotonic or hypertonic solution to the cell suspension. A preferred method for cell lysis is to add distilled water to the suspensions and quickly return the suspensions to an isotonic state with a hypertonic sodium chloride solution. Any remaining tissue may be removed by filtration through gauze.

[0089] The harvested cell suspension is then mixed with a myeloma cell line, preferably one which is syngeneic with the immunized animal. Myeloma cell lines from various species are widely available through, for example, American Type Culture Collection (ATCC), Rockville, Md. Myeloma cell lines commonly used include P3X63Ag8 (ATCC TIB 9), SP2/0-Ag14 (ATCC CRL 1581), FO (ATCC CRL 1646) and 210-RCY-Ag1 (Galfre et al., Nature 277:131, 1979).

[0090] The myeloma cells are cultured in an appropriate mammalian cell growth medium, a variety of which are generally known in the art and available from commercial sources. Mammalian cell lines are routinely grown between 36° C. and 40° C. under conditions which maintain an optimal pH between 6.0 and 8.0, preferably about pH 7.2. pH may be maintained through the use of a variety of buffer systems known in the art. A preferred buffer system involves growing the cells in a bicarbonate buffer in a humidified incubator containing CO₂, preferably about 7% CO₂.

[0091] The fusion between the lymphocytes from the immunized animal and the myeloma cells may be carried out by a variety of methods described in the literature. These methods include the use of polyethylene glycol (PEG) (Brown et al., J. Biol. Chem. 255:4980-4983, 1980) and electrofusion (Zimmerman and Vienken, J. Membrane Biol. 67:165-182, 1982). An electrofusion generator is commercially available from Biotechnologies and Experimental Research, Inc., San Diego, Calif.

[0092] Following the fusion, the cells are plated into multi-well culture plates, preferably 96-well plates. A reagent which selectively allows for the growth of the fused myeloma cells over the unfused cells is added to the culture medium. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. Other selection techniques may also be used depending on the myeloma cell line chosen.

[0093] Alternative methods of producing monoclonal antibodies utilize in vitro immunization techniques. Lymphocytes may be harvested from lymphoid organs, such as spleen or lymph nodes, or from whole blood as peripheral blood lymphocytes. The lymphocytes are put into culture in the presence of the appropriate immunogen. Often immunostimulatory polypeptides will be added to the culture medium concurrently. At various times following the culturing of the lymphocytes in vitro, the lymphocytes are harvested and fused with a myeloma cell line as described above.

[0094] Other techniques for producing and maintaining antibody secreting lymphocyte cell lines in culture include viral transfection of the lymphocyte to produce a transformed cell line which will continue to grow in culture. Epstein-Barr virus (EBV) has been used for this technique. EBV transformed cells do not require fusion with a myeloma cell to allow continued growth in culture.

[0095] Thymocytes may be used as a feeder layer to condition the medium for the fused cells. Alternatively, peritoneal macrophages or non-immune spleen cells may be used as a feeder layer. Another alternative is to use conditioned medium from thymocytes or macrophages. Thymocytes may be prepared from juvenile mice less than 8 weeks old. The thymus glands are harvested and minced using techniques which disrupt the thymus gland but are not detrimental to the thymocytes. This procedure is preferably carried out using scissors to mince the tissue, followed by passage of the tissue through a mesh screen. The minced and strained cell material is then harvested by centrifugation. Cell suspensions are made using growth medium. Any remaining connective tissue may be removed by filtration through gauze.

[0096] At an appropriate time following the day the cells are fused, the fused cells (hybridomas) are then analyzed for the production of antibody against the antigen. This “screening” can be done by a wide variety of techniques, including Western blot, ELISA, immunoprecipitation, effect on biological activity assays and immunocytochemical staining. These techniques and others are well described in the literature. (See, for example, J. G. R. Hurrell (ed.), Monoclonal Hybridoma Antibodies: Techniques and Applications, CRC Press Inc., Boca Raton, Fla., 1982.) Introduction of a screening procedure permits further definition of antibodies of useful reactivity. For example, antigen purified from a biological sample of a patient with a bladder cancer may be used in any of the above-named techniques to define antibodies which react, for example, to determinants which are common to patients with the disease.

[0097] Hybridomas which secrete antibodies of interest are maintained in culture. The cells are expanded in culture and at the same time may be cloned in such a manner as to obtain colonies originating from single cells. This provides for the monoclonal nature of the antibodies obtained from the hybridomas. A wide variety of techniques exist for cloning cells, including limiting dilution, soft agar cloning and fluorescence-activated cell sorting.

[0098] Once clones of cells are obtained, they are re-assayed for the production of the antibody of interest. These cells are then expanded in culture to allow for the production of larger amounts of the antibody. Methods for expansion of the cells include maintaining the cells in culture, placement of the cells in a bioreactor or other type of large-scale cell culture environment, or culturing the cells using various agar or gelatin carrier matrices. Antibodies are then isolated from the cell culture media.

[0099] Antibodies may be purified from conditioned media or ascites fluid by a variety of methods known in the art. These methods include ammonium sulfate precipitation, ion exchange chromatography (see Hurrell, ibid.) and high pressure liquid chromatography using a hydroxylapatite support (Stanker et al., J. Immunol. Methods 76:157, 1985). A preferred method for purifying antibodies from conditioned media or ascites fluid utilizes a commercially available Protein A-Sepharose® CL-4B column or Protein G Sepharose® (Pharmacia, Piscataway, N.J.; Sigma, St. Louis, Mo.) or ABX mixed ion exchange resin (J T Baker, Phillipsburg, N.J.). Antibodies may be purified with these columns using conditions suggested by the manufacturer.

[0100] As can be readily appreciated by those of ordinary skill in the art the presence of antigen may be detected by immunological means using an antibody produced as detailed above. The means for detecting the presence of antigen may be in a direct or indirect test format. In a direct test format, that which is observed or measured is proportional to (i.e., directly reflective of) antigen present in a sample. Conversely, in an indirect test format, that which is observed or measured is inversely proportional to (i.e., indirectly reflective of) antigen present in a sample. Indirect formats include competitive and inhibition assay formats. As used herein, the term “antibody” includes both polyclonal and monoclonal antibodies as well as single chain antibodies; and may be an intact molecule, a fragment thereof, or a functional equivalent thereof; and may be genetically engineered. Examples of antibody fragments include F(ab′)₂, Fab′, Fab and Fv. Detection may be, for example, by Western blot analysis utilizing antigen immobilized on nitrocellulose or Immobilon or similar matrix, in conjunction with specific antibodies to the antigen. Detection can also be achieved by immunoassay. In one embodiment, antigen is isolated from a sample and contacted with an appropriate detection antibody. Antigen may be isolated by capture on a solid support or with a “capture” antibody prior to or simultaneous with a “detection” antibody. In another embodiment, immunocomplexes are formed between an antibody and antigen, without prior purification of the antigen. Incubation of a sample with an antibody is under conditions and for a time sufficient to allow immunocomplexes to form. Detection of antigen by immunological means is also amenable to quantification where it is desired to determine the amount of antigen.

[0101] Detection of one or more immunocomplexes formed between antigen and an antibody specific for the antigen may be accomplished by a variety of known techniques, including radioimmunoassays (RIA) and enzyme linked immunosorbent assays (ELISA).

[0102] The immunoassays known in the art include the double monoclonal antibody sandwich immunoassay technique of David et al. (U.S. Pat. No. 4,376,110); monoclonal-polyclonal antibody sandwich assays (Wide et al., in Kirkham and Hunter (eds.), Radioimmunoassay Methods, E. and S. Livingstone, Edinburgh, 1970); the “western blot” method of Gordon et al. (U.S. Pat. No. 4,452,901); immunoprecipitation of labeled ligand (Brown et al., J. Biol. Chem. 255:4980-4983, 1980); enzyme-linked immunosorbant assays as described by, for example, Raines and Ross (J. Biol. Chem. 257:5154-5160, 1982); immunocytochemical techniques, including the use of fluorochromes (Brooks et al., Clin. Exp. Immunol. 39: 477, 1980); and neutralization of activity (Bowen-Pope et al., Proc. Natl. Acad. Sci. USA 81:2396-2400, 1984). In addition to the immunoassays described above, a number of other immunoassays are available, including those described in U.S. Pat. Nos.: 3,817,827; 3,850,752; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876.

[0103] For detection purposes, the antibodies may either be labeled or unlabeled. When unlabeled, the antibodies find use in agglutination assays. In addition, unlabeled antibodies can be used in combination with other labeled antibodies (second antibodies) that are reactive with the antibody, such as antibodies specific for immunoglobulin. Alternatively, the antibodies can be directly labeled. Where they are labeled, the reporter group can include radioisotopes, fluorophores, enzymes, luminescers, or visible particles (e.g., colloidal gold and dye particles). These and other labels are well known in the art and are described, for example, in the following U.S. Pat. Nos.: 3,766,162; 3,791,932; 3,817,837; 3,996,345; and 4,233,402.

[0104] Typically in an ELISA assay the target antigen (for a competitive or inhibition assay format) or immobilized capture antibody is adsorbed to the surface of a microtiter well. Residual protein-binding sites on the surface are then blocked with an appropriate agent, such as bovine serum albumin (BSA), heat-inactivated normal goat serum (NGS), or BLOTTO (buffered solution of nonfat dry milk which also contains a preservative, salts, and an antifoaming agent). The well is then incubated with a sample suspected of containing antigen. The sample can be applied neat, or, more often, it can be diluted, usually in a buffered solution which contains a small amount (0.1%-5.0% by weight) of protein, such as BSA, NGS, or BLOTTO. After incubating for a sufficient length of time to allow specific binding to occur, the well is washed to remove unbound protein and then incubated with a detection antibody labeled with a reporter group, or an anti-immunoglobulin antibody labeled with a reporter group. The reporter group can be chosen from a variety of enzymes, including horseradish peroxidase, beta-galactosidase, alkaline phosphatase, and glucose oxidase. Sufficient time is allowed for specific binding to occur, the well is again washed to remove unbound conjugate, and the substrate for the enzyme is added. Color is allowed to develop and the optical density of the contents of the well is determined visually or instrumentally.

[0105] In one preferred embodiment of the present invention, a reporter group is bound to the detection antibody. The step of detecting an immunocomplex involves removing substantially any unbound antibody and then detecting the presence or absence of the reporter group.

[0106] In another preferred embodiment, a reporter group is bound to a second antibody capable of binding to the antibody specific for antigen. The step of detecting an immunocomplex involves (a) removing substantially any unbound antibody, (b) adding the second antibody, (c) removing substantially any unbound second antibody and then (d) detecting the presence or absence of the reporter group. Where the antibody specific for the fragment is derived from a mouse, the second antibody is an anti-murine antibody.

[0107] In a third preferred embodiment for detecting an immunocomplex, a reporter group is bound to a molecule capable of binding to the immunocomplex. The step of detecting involves (a) adding the molecule, (b)removing substantially any unbound molecule, and then (c) detecting the presence or absence of the reporter group. An example of a molecule capable of binding to the immunocomplex is protein A.

[0108] It will be evident to one skilled in the art that a variety of methods for detecting the immunocomplex may be employed within the present invention. Reporter groups suitable for use in any of the methods include radioisotopes, fluorophores, enzymes, luminescers, and visible particles (e.g., colloidal gold and dye particles).

[0109] Alternatively, rather than detecting PAL-18 itself, a nucleic acid molecule encoding PAL-18, PAL-18 variants, and/or fragments of either can be detected. Such a nucleic acid molecule may be a deoxyribonucleic acid (DNA) or a ribonucleic acid (RNA). Generally, a nucleic acid molecule encoding for PAL-18 is detected by amplification of the nucleic acid. A variety of methods may be utilized in order to amplify a selected sequence, including, for example, RNA amplification (see Lizardi et al., Bio/Technology 6:1197-1202, 1988; Kramer et al., Nature 339:401-402, 1989; Lomeli et al., Clinical Chem. 35(9):1826-1831, 1989; U.S. Pat. No. 4,786,600), and DNA amplification utilizing ligase chain reaction (“LCR”) or polymerase chain reaction (“PCR”) (see U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,800,159) (see also U.S. Pat. Nos. 4,876,187 and 5,011,769, which describe an alternative detection/amplification system comprising the use of scissile linkages), or other nucleic acid amplification procedures that are well within the level of ordinary skill in the art. With respect to PCR, for example, the method may be modified as known in the art. Transcriptional enhancement of PCR may be accomplished by incorporation of bacteriophage T7 RNA polymerase promoter sequences in one of the primary oligonucleotides, and immunoenzymatic detection of the products from the enhanced emitter may be effected using anti-RNA:DNA antibodies (Blais, Appl. Environ. Microbiol. 60:348-352, 1994). PCR may also be used in combination with reverse dot-blot hybridization (Iida et al., FEMS Microbiol. Lett. 114:167-172, 1993). PCR products may be quantitatively analyzed by incorporation of dUTP (Duplàa et al., Anal. Biochem. 212:229-236, 1993), and samples may be filter sampled for PCR-gene probe detection (Bej et al., Appl. Environ. Microbiol. 57:3529-3534, 1991).

[0110] Primers for the amplification of a selected sequence should be selected from sequences that are highly specific to PAL-18 encoding nucleic acid sequences and form stable duplexes with the target sequence. The primers should also be non-complementary, especially at the 3′ end, should not form dimers with themselves or other primers, and should not form secondary structures or duplexes with other regions of DNA. In general, primers (such as those described in greater detail below) of about 20 to 35 nucleotides are preferred, and can be easily synthesized using techniques well known in the art. PCR products, and other nucleic acid amplification products, may be quantitated using techniques known in the art (Duplàa et al., Anal. Biochem. 212:229-236, 1993; Higuchi et al., Bio/Technology 11:1026-1030).

[0111] A preferred embodiment involves assaying for the presence of specific messenger RNA (mRNA) encoding a PAL-18 polypeptide. More specifically, for example, as described herein, a cell sample may be lysed and the mRNA isolated, amplified and examined for the presence of mRNA specific for PAL-18. A variety of procedures may be used to detect the presence of antigen-specific mRNA. A particularly preferred method includes RT-PCR (Reverse Transcriptase based Polymerase Chain Reaction) amplification of mRNA.

[0112] Detecting the presence of PAL-18 in a sample (for example, a cell or tissue, a fecal specimen, a voided urine sample, a biopsy sample or material extracted from a cervical swab) has a variety of uses. See, e.g., Davidson et al., Carcinogenesis 19(2):252-257, 1998; Loktionov et al., Clin. Cancer Res. 4:337-342, 1998; Machiels et al., BioTechniques 28:286-290, 2000. For example, the present invention may be used for diagnostic purposes to screen warm-blooded animals, such as humans, for cancers such as colorectal cancer, renal cancer, bladder cancer, prostate cancer or related cancers (depending upon the source of the particular sample). Preferred sample sources for a particular cancer would be evident to one of ordinary skill in the art. For example, using a voided urine sample, one may screen for renal or bladder cancer. In a similar manner, the present invention may be used to monitor warm-blooded animals. In particular, a preferred use is to follow patients who have been previously diagnosed and treated for colorectal cancer, renal cancer, bladder cancer, prostate, or cervical cancer. Patients who are in remission (or may in fact be cured) can be monitored for the reappearance of colorectal, prostate, renal, bladder or cervical cancer. It may be desirable to use the present invention in conjunction with one or more other tests for colorectal, prostate, renal, bladder or cervical cancer to confirm positive or negative results obtained from use of the present invention.

[0113] Irrespective of the exact function(s) of PAL-18 in tumor cells, the present invention provides for the modulation of PAL-18 as a means of treating cancers. As used herein, the term “treating” cancer refers to one or more of a variety of beneficial effects, including, for example killing tumor cells, arresting the growth of a tumor, or prolonging the survival time of a tumor host. It will be evident to those of ordinary skill in the art that PAL-18 may be modulated in a variety of ways. For example, PAL-18 may be modulated by interrupting the production of PAL-18 by tumor cells or “inactivating” PAL-18 (e.g., blocking PAL-18, or its effect) following production by tumor cells. A preferred method of interrupting the production of the antigen is by use of DNA, or PNA (peptide nucleic acid), constructs with base sequence complementary to the antigen's mRNA. Such an approach is generically termed antisense technology. Typically, the PAL-18 antisense DNA is inserted into an appropriate vector (virus) which delivers it to the tumor cells. Once inside the target cells, the antisense construct specifically binds to mRNA coding for the PAL-18, thereby preventing its translation. Primary among other methods which may be used to interrupt production of the antigen is the use of specific molecules which block the transcription of the specific gene or genes coding for the PAL-18. Chemicals designed to block the ability of the tumor cell to produce antigen are preferably delivered in the vicinity of the tumor, rather than systemically. An alternative to use of antisense is to utilize ribozyme technology to effectuate the same (see, e.g., Lieber and Struass, Mol. Cell Biol. 15(1):540-551, 1995).

[0114] Another approach to antigen modulation is to use reagents to inhibit the activity of, or interfere with the binding sites on, PAL-18. One family of such reagents includes monoclonal antibodies, or fragments thereof (e.g., antigen binding fragments). With such reagents, as with those described above, delivery is preferably administered to the tumor site, rather than systemically. For the antibodies described above, reagent affinities should be at least about 10⁶ liters/mole and doses should be within the range of about 0.01 μg/kg body weight to 10 mg/kg body weight. In addition, the preferred type of tumor to be treated in this manner would be distinctly separate from the circulatory system. An antibody may be replaced, or supplemented, with a small organic molecule or amino acid based molecule (such as a peptide) with similar functional properties to the antibody. Thus, PAL-18 may be modulated such that the killing of cancer cells by the complement system is promoted.

[0115] The present invention also provides for the modulation of PAL-18 as a means for treating MAP kinase pathway or apoptotic pathway related disorders.

[0116] The above-described molecules (antibodies, peptides, organic compounds and antisense nucleic acids or peptide nucleic acids) are representative examples of agents that may modulate a PAL-18 polypeptide or a nucleic acid molecule encoding said polypeptide, for use in the treatment of a tumor cell. Such agents may be combined with a pharmaceutically acceptable carrier or diluent to form a composition. Additional components, such as traditional chemotherapeutic compounds, may be included with such an agent or a composition thereof.

[0117] Additionally, PAL-18 polypeptides may be used as targets for cancer or various tissue imaging. In this regard a binding agent, such as an antibody of the invention reactive with a PAL-18 polypeptide or fragment thereof is also useful for in vivo diagnostic applications for the detection of human carcinomas. One such approach involves the detection of tumors in vivo by tumor imaging techniques. According to this approach, for example, the antibody is labeled with an appropriate imaging reagent that produces a detectable signal. Examples of imaging reagents that can be used include, but are not limited to, radiolabels such as ¹³¹I, ¹¹¹In, ¹²³I, ⁹⁹mTc, ³²P, ¹²⁵I, ³H, and ¹⁴C, fluorescent labels such as fluorescein and rhodamine, and chemiluminescers such as luciferin. The antibody can be labeled with such reagents using techniques known in the art. For example, see Wensel and Meares, Radioimmunoimaging and Radioimmunotherapy, Elsevier, N.Y. (1983) for techniques relating to the radiolabeling of antibodies (see also Colcher et al., “Use Of Monoclonal Antibodies As Radiopharmaceuticals For The Localization Of Human Carcinoma Xenografts In Athymic Mice”, Meth. Enzymol., 121:802-16 (1986)).

[0118] In the case of radiolabeled antibody, the antibody is administered to the patient, localizes to the tumor bearing the antigen with which the antibody reacts, and is detected or “imaged” in vivo using known techniques such as radionuclear scanning using, e.g., a gamma camera or emission tomography (see, e.g., Bradwell et al., “Developments In Antibody Imaging”, in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), pp. 65-85 (Academic Press 1985)). The antibody is administered to the patient in a pharmaceutically acceptable carrier such as water, saline, Ringer's solution, Hank's solution or nonaqueous carriers such as fixed oils. The carrier may also contain substances that enhance isotonicity and chemical stability of the antibody such as buffers or preservatives. The antibody formulation is administered, for example, intravenously, at a dosage sufficient to provide enough gamma emission to allow visualization of the tumor target site. Sufficient time should be allowed between administration of the antibody and detection to allow for localization to the tumor target. For a general discussion of tumor imaging, see Allum et al., “Monoclonal Antibodies In The Diagnosis And Treatment of Malignant Conditions”, Surg. Ann. 18:41-64 (1986).

[0119] The compositions and modulating agents of the present invention may also be formulated with pharmaceutical excipients. Administration of such compositions will generally follow established protocols and exact amounts will be determined by clinical trials. The compositions of the present invention may be administered either alone, or as a pharmaceutical composition. Briefly, pharmaceutical compositions of the present invention may comprise one or more of compositions or modulating agents as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may comprise buffers such as neutral buffered saline, phosphate buffered saline and the like, carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide) and preservatives. In addition, pharmaceutical compositions of the present invention may also contain one or more additional active ingredients.

[0120] Compositions of the present invention may be formulated for the manner of administration indicated, including for example, for oral, nasal, venous, intracranial, intraperitoneal, subcutaneous, or intramuscular administration. Within other embodiments of the invention, the compositions described herein may be administered as part of a sustained release implant. Within yet other embodiments, compositions of the present invention may be formulized as a lyophilizate, utilizing appropriate excipients which provide stability as a lyophilizate, and subsequent to rehydration. One skilled in the art may further formulate the enhancers or inhibitors of this invention in an appropriate manner, and in accordance with accepted practices, such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton, Pa. 1990.

[0121] Materials and reagents utilized in various aspects of the present invention may be assembled in a kit. A kit for carrying out any of the detection or screening methods set forth herein may comprise an appropriate container, binding agents or hybridizing probes, and instructions for their use. In some instances, a kit may comprise of more than one binding agent and/or hybridizing probe.

[0122] Components of the kit may be provided in a dried or lyophilized form or in one or more liquid solutions. When the components are provided in liquid solution, the liquid solution is preferably a sterile, aqueous solution. When components are provided in a dried form, the dried form may be capable of reconstitution upon addition of a suitable solvent. Kits will generally be packaged in an outer container suitable for commercial sale and distribution. Kits of the invention may also comprise or be packaged with instructions for use and instruments for assisting in use.

[0123] All of the references including patents, patent applications, journal articles, etc., cited herein are hereby incorporated by reference in their entirety.

[0124] The following examples are offered by way of illustration and not by way of limitation.

EXAMPLES Example I Cloning of PAL-18

[0125] Materials—Cloning vectors were purchased from Invitrogen (Carlsbad, Calif.) Other molecular biology materials were purchased from Clontech (Palo Alto, Calif.), Promega (Madison, Wis.), Stratagene (La Jolla, Calif.), or BioRad (Hercules, Calif.) as specified. primers were purchased from Midland Certified Reagents (Midland, Tex.) and presented in below Common reagents were purchased from Sigma Chemical Company (St. Louis Mo.). TABLE 1 Primer Primer SEQ ID name Sequence Notes 80 MCPLF01 TTTATGGTATACCAAATATGCTTCAAGACT Improved PAL-175 81 MCPLR01 CAGCCAGTCTTGAAGCATATTTGGTATACC PAL-175 reverse 82 MCPLF02 CTTGAAGATGTGTTTCTACACAGCTTATGC Forward from 541* 83 MCPLR02 GACTGTTGGTCCAGGTCCTTTGGTTTCTCC Backward from 715* 84 MCXLF01 CAGGAAACAGCTATGACCATGATTACGC TOPO-XL vector forward primer 85 MCXLR01 GTAATACGACTCACTATAGGGCGAATTGG TOPO-XL vector reverse pnmer 86 MCPLR03 AATCCCATGGAAATTAATTCAAAAACAGC Backward from 156* ATCC 87 MCPLF03 GGTGAGACTTTATTGGCTAGTGATAAATGC Forward from 584* G 88 MCPLR04 GTGCTTCTGCCTTTGCATACAATTTTTCTGC Backward from 671* 89 MCPLF04 TATTCAAAATTTCAAGTGGACTGATACATT Forward from 67* GC 90 MCPLF05 GGATGAATCTACCCAAGAAAGCAAGTTAC Forward from 34* G 91 MCPLR05 AACTTGCTTTCTTGGGTAGATTCATCCAAA Backward from 60* G 92 MCPLR06 GTATCAGTCCACTTGAAATTTTGAATATAT Backward from 93* CG 93 MCPLF06 CAGAAGATGAAGGAAAAGAAGTTCATCGA Nested vs. MCPLF01 AGCC 94 MCGTF01 GGATTGGTGGCGACGACTCCTGGAGCCCG Vector primer for HFL library 95 MCGTR01 AGACCAACTGGTAATGGTAGCGACCGGCG Vector primer for HFL C library 96 MCPLF07 GCAAAGGCAGAAGCACTGTGTAAAGAATA Forward from 656* TGG 97 MCPLF08 CTGTTCTTTAGGAAACTTGGAAACCTTGTG Forward from 731* 98 MCPLF09 CTGGAAAATTTAGTGTTATTGGAATCAAA Forward from 702 of GG 64.2.5.F03 99 MCPLR07 TGAACAGTTCAAGGAGTCGTGCCCTGGAT Forward from 474 of GACC 64.2.5.F01 inverted 100 MCPLF10 CCAGGGCACGACTCCTTGAACTGTTCACTG Backward from 500 of 64.2.5.F01 inverted 101 MCPLR08 ATCCCTTGAGTCTTATTGATTAGTACTAAC Backward from 196 of TC 64.2.5.F04 102 MCPTF01 CGAATTTAATACGACTCACTATAGGGAATT Image Consortium TGG vector forward primer 103 MCPTR01 TGCCAAGCTAAAATTAACCCTCACTAAAG Image Consortium G vector reverse primer 104 MCPLF11 TATCAAAAAGCTGATCATACTTTATCCAG 16-base exon-specific primer 105 MCPLR09 TTAGGAGATGTAGCACCCAGTGTCCTTTTG Expression primer AGGTTTGATG with stop codon 106 MCPLR10 GGAGATGTAGCACCCAGTGTCCTTTTGAG Expression primer GTTTGATG without stop codon 107 MCPLF12 ATGACCCATTGGTTTCATAGGAACCCATTA Forward from AAAGC beginning of ORF 108 MCPLF13 CAGCAGGATGCTGTTTTTGAATTAATTTCC 96-base exon-specific ATGGGATTTAATGTAGC primer 109 MCPLF14 AAGGACAGGTTCCAAGTATAACAGAAG Skips 96-base exon 110 MCPLR11 CACTTGTAGGAGGAAATTCGAAAGGTATA 160-base exon-specific GG primer 111 MCPLR12 TTCTGGTTTGGGTTTAGTATAAATCCATTT Skips 160-base exon T 112 42M GCTGGTAAATGTCCTCT Upstream Factor H primer 113 1040RT TCTGGATAATCACAAGGTTTC Downstream Factor H primer *Numbering according to original 778-base amplicon

[0126] DNA Sequencing

[0127] All DNA sequencing was performed in the laboratory of Dr. Leroy Hood, using an ABI Prisms 373 DNA Analyzer from PE Applied Biosystems (Foster City, Calif.). Sequencing reactions made use of PE Applied Biosystems big-dye terminator kits. Gels were analyzed with ABI Prism Sequencing Analysis Version 3.3 (PE Applied Biosystems).

[0128] Agarose Gel Electrophoresis (AGE)

[0129] 0.75 g refined agarose and 0.6 uL of 10 mg/mL ethidium bromide were added to 50 mL of Tris-acetate-EDTA buffer (Sigma; 0.04 M Tris acetate, 0.01 M EDTA, pH 8.3) and heated in a microwave at full power for 100 seconds with occasional mixing and poured with a ten-well comb, a 14-well comb, or both. The gels were allowed to cool for at least 20 minutes before use.

[0130] After cooling, the gels were covered with Tris-acetate-EDTA buffer and loaded with 6 uL sample or molecular weight standard (BioRad Amplisize 50-2000 bp standards or BioRad PCR ruler) mixed with 1.2 uL 6×loading buffer (0.25% bromophenol blue, 40% sucrose).

[0131] TA Cloning

[0132] A cocktail was made containing enough volume for at least 10% more than the planned reactions. This cocktail contained (per reaction):

[0133] 0.3 uL ligation buffer (60 mM Tris-HCl, pH 7.5; 60 mM MgCl₂; 50 mM NaCl; 1 mg/mL bovine serum albumin; 70 mM B-mercaptoethanol; 1 mM ATP; 20 mM dithiothreitol; 10 mM spermidine)

[0134] 0.6 uL TA vector (pCR II) (25 ng/uL in 10 mM Tris-HCl, 1 mM EDTA, pH 7.5)

[0135] 0.3 uL T4 ligase (4.0 Weiss units/uL)

[0136] 1.05 uL H₂O

[0137] After 2.25 uL of the cocktail was aliquoted into each tube on ice, 0.75 uL of the PCR product to be cloned was added and the mixture was transferred to an air incubator or thermocycler maintaining 14° C. for 4-30 hours.

[0138] It was later determined that although this method is workable, a lower background of self-ligated plasmids was obtained if the ligase was withheld from the cocktail and added after the PCR product into the individual reaction vessels.

[0139] Plasmid Growth and Preparation

[0140] 2-mL cultures of Luria-Bertani medium (1.0% tryptone, 0.5% yeast extract, 1.0% NaCl, pH 7.0) with 60 ug/mL ampicillin or carbenicillin were inoculated with well-isolated colonies of E. coli potentially containing the plasmid of interest. Cultures which proved to be positive by screening were used to prepare plasmid. 1.5 mL of the resuspended culture were transferred to a 1.5-mL microcentifuge tube and centrifuged at maximum speed in a microfuge for 30 sec. Unless otherwise specified, plasmid was prepared from the pellet according to the BioRad QuantumPrep protocol.

[0141] Initial Cloning of PAL-18 Sequences

[0142] Reverse Transcription

[0143] 20-uL Reverse Transcription reactions contained 4 uL of 25 mM MgCl₂, 2 uL of 10×PCR buffer (Promega catalog #M190A), 2 uL each of 10 mM dATP, dCTP, dGTP, and dTTP, 0.5 uL of RNAse inhibitor (Promega catalog #N251A), 1 uL of MuLV reverse transcriptase (Perkin Elmer), and 1 uL 50 uM random hexamers (Perkin Elmer). 4 ug of RNA (prepared by RNAzol B extraction, Tel-Test, Inc.) were added in 4 uL for a final volume of 20.5 uL and the reactions were incubated at 20° C. for 15 min., 42° C. for 90 min., and finally 99° C. for 5 min. The reactions were then stored at −20° C.

[0144] PCR

[0145] The PCR's contained 6 uL 25 mM MgCl₂, 8 uL 10×PCR buffer (Promega, Madison, Wis.; catalog #M190A), 0.5 uL 100 uM primer 42M, 0.5 uL 100 uM primer 1040RT, 0.5 uL Taq polymerase (Promega catalog #M186A), 64.5 uL H₂O, and 20 uL of the corresponding reverse-transcription reaction. The reactions were amplified as follows: 95° C.×1 min.; 30 cycles: 94° C.×20 sec., 50° C.×1 min., 70° C.×2 min.; 10 cycles: 94° C.×20 sec., 50° C.×1 min., 70° C.×2.5 min.; 1 cycle: 70° C.×7 min., 4° C.×∞.

[0146] The above primers were utilized to achieve discovery and amplification of the PAL-18 message in a quite unexpected manner. In this regard, it was the goal of the original experiments to identify Factor H messages in various cell types, including three different human cancer-derived cell lines: HeLaS3 (cervical), HTB9 (bladder), and LS174T (colon) using low fidelity PCR. Instead however, the PAL-18 message was identified thereby and it was later determined that only the 1040RT primer has homology to both 5′ and 3′ ends of the message, thus the 42M apparently played no role in the amplification. Contiguous sequences were then created following gene walking and expansion.

[0147] The PCR products were isolated by cutting the individual bands from a 2% agarose gel. Bands of approximately 750 bp were cut from the lane representing each of the three cell lines, and the BioRad Prep-A-Gene® DNA Purification Kit was used to purify the DNA. All three bands of ˜750 bp were visible on AGE after the purification process. The products were polished with Stratagene (La Jolla, Calif.) catalog #200409 and blunt-end cloned using Invitrogen catalog #K2700-20. The clones were screened by the same PCR method and submitted for sequencing.

[0148] Extension of Known Sequence: Genome Walking

[0149] The Genome Walker® kit (Clontech, Palo Alto, Calif.), including five human genomic libraries predigested with specified restriction endonucleases and ligated with defined adaptors, as well as primers for specific amplification of the adaptor sequences, was used. The libraries were amplified by PCR (7 cycles: 94°×2 sec., 72°×3 min.; 32 cycles: 94°×2 sec., 67°×3 min.; 1 cycle: 67°×4 min., 4°×∞), in 20 uL reactions of the composition indicated in the GenomeWalker® User Manual (Clontech PT1116-1), with 200 nM primer MCPLR01. The AGE result showed that the process yielded bands with libraries 3 and 4, of approximately 500 and 400 base pairs, respectively. Aliquots of the indicated reactions were therefore subjected to a secondary, nested PCR, using the composition recommended in the Clontech manual, with 200 nM primer MCPLR03 (a primer which is nested relative to MCPLR01), and amplification of 5 cycles: 94°×2 sec., 72°×3 min.; 20 cycles: 94°×2 sec., 67°×3 min.; 1 cycle: 67°×4 min., 4°×∞. Parallel negative-control experiments were performed in which the nested primer was absent. Faint bands are seen in the negative-control lanes, probably because small amounts of the original primer carried over from the primary PCR are sufficient to cause detectable amplification.

[0150] The secondary PCR products, designated 39.1 and 39.2, were cloned into the Invitrogen (Carlsbad, Calif.) pCR®II TA vector (see TA cloning). The clones were screened by culture PCR using the vector-specific primers MCXLF01 and MCXLR01 with amplification: 1 cycle: 94°×5 min.; 30 cycles: 94°×10 sec., 60°×30 sec., 72°×1 min.; 1 cycle: 72°×7 min., 4°×∞. In this case all colonies screened were positive for the bands of interest (the negative control was negative). Plasmid was prepared from colonies 44.1.1, 44.1.2, 44.2.2, and 44.2.3 and sequenced.

[0151] Reaction 38.10, which initially did not show a band, was amplified for a further five cycles (5×94°×2 sec., 67°×3 min.; 1×4°×∞). This was analyzed by AGE, showing that a band has appeared at >1000 bp. This reamplified 38.10 was subjected to secondary PCR as above and analyzed by AGE. The product was cloned as transformation 53.2, which was screened by culture PCR. Positive clones 53.2.3 and 53.2.4 were grown for plasmid and sequenced.

[0152] Further 5′ Extension by Genome Walking

[0153] A primer at the extreme 5′ end of the known region (MCPLR05) was used for further genome walking. This primer was used with the five Clontech libraries in GenomeWalker® PCR experiments as above, except that 37 cycles with 67° annealing were initially performed instead of 32. The reactions were analyzed by AGE. Libraries 2 and 4 both yielded bands of ˜2000 bp. These amplicons were TA cloned and screened as above (see FIG. 1). Positive clones 64.2.5 and 64.2.24 were grown for plasmid and sequenced.

[0154] Sequence Extension at 3′ End by Rapid Amplification of cDNA Ends (RACE)

[0155] Clontech SMART RACE® kit #K-1811-1 was purchased to enable further extension of the known sequence. 1 uL of RNA prepared from HeLa (9-15-97) was subjected to reverse transcription as described in the Clontech technical sheet for this product. Superscript II® (Life Technologies, Gaithersburg, Md.) was used as the reverse transcriptase. 2.5 uL of the reverse transcription reaction was then used in a 50-uL PCR with universal primer mix as described in the Clontech documentation for SMART RACE®. Amplification was 5 cycles: 94×5 sec., 72°×3 min.; 5 cycles: 94°×70°×10 sec., 72°×3 min.; 27 cycles: 94°×5 sec., 68°×10 sec., 72°×3 min., 1 cycle: 4°×∞. Gene-specific primers MCPLF01 and MCPLF02 were each used at 200 nM in separate reactions. Both primer MCPLF01 and primer MCPLF02 yielded bands of >2000 bp. The reactions were subjected to secondary amplification using the nested primer MCPLF03 and the nested universal primer mix supplied by Clontech. Fewer cycles were used than recommended for secondary PCR in the Clontech manual because undiluted primary PCR was used. The amplification was 1 cycle: 94°×5 min.; 12 cycles: 94°×5 sec., 68°×10 sec., 72°×3 min.; 1 cycle: 72°×7 min., 4°×∞. AGE analysis showed that the secondary PCR of the MCPLF02 primary reaction had produced a more distinct product than either the negative-control reaction or either of the reactions with the MCPLF01 primary reaction. This amplification product, as well as the original primary PCR product of the MCPLF02 reaction, were used for TA cloning. Colonies were screened as above. While no full-length clones of the expected amplicon size were seen, some clones (e.g., 58.1.1, 58.1.2, 58.1.6, 58.2.7) were shown to have PAL-18 specific sequences by subsequent PCR using an internal (PAL-18) primer and a vector-specific primer. These clones were grown for plasmid and sequenced.

[0156] Confirmation of Known PAL-18 Regions by Cloning and Sequencing of Fetal Liver cDNA Library

[0157] A human fetal liver cDNA library from Clontech (Product #HL5003b) was subjected to a PCR as follows: 2 uL Advantage Taq 2 buffer (Clontech), either 0.4 uL primer MCPLF01 and 0.4 uL primer MCPLR02 or 0.4 uL primer MCPLF04 and 0.4 uL primer MCPLR04, 0.4 uL 10 mM (total) dNTP's, 0.4 uL Advantage Taq 2, and 16 uL H₂O were mixed with 0.4 uL fetal liver library. Amplification was 1 cycle: 94°×5 min.; 25 cycles: 94°×10 sec., 72°×1 min.; 1 cycle: 72°×7 min., 4°×∞. Both reactions yielded bands of expected size on AGE analysis, while negative controls were negative. These PCR products were TA cloned and cultures grown from the colonies were screened with vector-specific primers. Positive cultures 72.1.1, 72.1.4, and 72.2.3 were grown for plasmid and sequenced.

[0158] Sequencing of Image Clones

[0159] Strong homologies were observed between the sequences obtained by 3′ RACE and ESTs reported in the BLAST DBest database using default settings and the algorithm described by Altschul et al., Nuc. Acids Res. 25:3389-3402, 1997. The longest clones with strong homologies were Accession #'s AA994364 and AI243754. These clones were purchased from the Image Consortium. Vector-specific primers MCPTF01 and MCPTR01 were designed to sequence into the cloning vector used. The clones were grown in 2-mL cultures and checked for inserts using these primers. Plasmids were then prepared and submitted for sequencing.

[0160] Discovery of Human Genes Related to PAL-18 by Low-Fidelity RT-PCR

[0161] The same method used in the initial discovery of PAL-18 transcripts can be modified to use in discovering genes and gene products related to PAL-18. The method involved use of 1) primers with intermediate annealing temperatures (37-52° C.), to facilitate association with genes that are related to but not identical with the known PAL-18 constructs; 2) 35-40 PCR cycles to permit appearance of minor bands; and possibly 3) synthesis and use of degenerate primers, i.e., primers synthesized with small admixtures of bases other than the homologous PAL-18 bases at each or selected positions, to permit enhanced homology with related but non-identical genes or gene products. According to our previous experience, “doping” percentages so as to yield an average of 1-3 mismatches per molecule produce primers that are readily used in low-fidelity PCR. For example, a degenerate primer of 18 bases in length containing 10 A/G bases and 8 C/T bases, designed to anneal at 51° C. (using the simple formula Tm=([AG]*4°)+([CT]*2)−5°) would be synthesized with a 4% admixture of each non-homologous base, yielding an average of 12% mutagenesis at each base position, or an expectation of 2.16 mismatches per primer molecule. These mismatches would reduce the average expected annealing temperature of the degenerate primer to ˜38-46°, and initial low-fidelity PCR experiments would be carried out with annealing temperatures in this range.

[0162] Identification of Chromosomal Location 1Q41 FOR PAL-18

[0163] Release of the sequence data from the human genome project allowed for subsequent identification of the chromosomal site for the PAL-18 gene (1q41). The significance of this particular chromosomal location is that this location is known to be associated with a variety of maladies and thus, supports the herein noted utilities for probing for progression and identification of certain cancer types, but also implicates a potential role for PAL-18 in other disease/dysfunctional states.

[0164] For example, homeobox gene in 1q41-42 homologous with Xenopus laevis Mix.1; another homeobox gene HLXB9 linked to dominant inherited sacral agenesis reported to map to 1q41-42.1.

[0165] Amplification of 1q41 in 39% of breast cancer cell lines; several other papers about amplification in breast cancer. This site is not associated with any established oncogene. Rearrangements and breakpoints are also seen in breast cancer involving 1q41.

[0166] Linkage of USH2A locus at 1q41 to User Syndrome Type II (congenital sensorineural hearing loss and retinitis pigmentosa).

[0167] MAP kinase phosphatase MKP-5 (genes DUSP10) localized to 1q41, especially in African-Americans.

[0168] Human systemic lupus erythematosus genetically linked to D1S229 at 1q41.

[0169] Rippling muscle disease linked to 1q41-42.

[0170] Poly(ADP-ribose) polymerase is located at 1q41-44; PARP overexpression is associated with low genetic instability in breast cancer specimens; another paper reports 1q41-44 amplified in breast cancer.

[0171] 53BP2: p53-binding protein 53BP2 is mapped to 1q41-42.

[0172] Human potassium channel gene TREK-1 (KCNK2) maps to 1q41.

[0173] UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyltransferase GALNT2 maps to 1q41-42.

[0174] STK6 encoding a mitotic centrosomal protein kinase Aik and/or an STK6 pseudogene maps to 1q41-42.

[0175] Toll/Interleukin-1 receptor-like gene 3 involved in cytokine-mediated IL-1 receptor/I-kappaB/NF-kappaB activation cascade maps to 1q41-42.

[0176] Histone H3F3A gene maps to 1q41.

[0177] Nuclear VCP-like protein NVL of the AAA family of ATPases maps to 1q41-42.2.

[0178] Serine/threonine protein kinase PK428 is 65% homologous in the kinase domain to the myotonic dystrophy protein kinase DM-PK and 33% homologous to cyclic AMP-dependent protein kinase; PK428 maps to 1q41-42.

[0179] A human senescence gene and a gene associate with mental retardation are reported to be in 1q41-42. I will try to get ahold of this information this week.

[0180] Human protein phosphatase 2A regulatory subunit gene b56alpha maps to 1q41.

[0181] Enolase processed pseudogene ENO1P maps to 1q41-42.

[0182] A renal transplant infected with Epstein-Barr virus had a chromosomal translocation 46, XY, inv (1)(p35; q41) involving the TGFB2 gene in 1q41.

[0183] 1q41 is reported as a heritable fragile site leading to spontaneous abortions.

[0184] Clones expressed in retinal pigment epithelium but not in any other tissue tested include two cDNAs from 1q41-42.

[0185] Homeobox HLX1 involved in hemopoietic development maps to 1q41-42.

[0186] There is a dinucleotide repeat polymorphism for D1S70 (CRI-L461) on 1q41.

[0187] Van der Woude syndrome involving clefting of the palate, hypodontia or lower lip pits maps to candidate region 1q32-1q41.

[0188] Human homeobox genes HB24 and HB9 map to 1q41-42.

[0189] Human inositol 1,4,5-trisphosphate 3-kinase B (ITPKB) maps to 1q41-43.

[0190] A partial duplication of 1q41 was observed in a case of congenital glaucoma.

[0191] A terminal deletion at 1q41 was observed. in a fetus with symptoms compatible with distal 1q deletion syndrome.

[0192] Human nuclear NAD+ADP-ribosyltransferase maps to 1q41-42.

[0193] DAPI is a compound which specifically causes breakage at AT sites in DNA; the 1q41-42 interface is one of three sites in the human genome susceptible to cleavage.

[0194] Two siblings were observed to have partial trisomy for 1q24-1q41.

[0195] As is evident from the above, listing this chromosomal location has been associated with a variety of indications. As such, the discovery of PAL-18 may lead to more effective therapies or to more readily performed diagnostics to determine the presence, absence, or progression of a disease causing gene abnormality.

[0196] Identification of the location on 1q41 was performed by the BLAST algorithm as previously defined, which identified a protein that was 93% identical and 93% conserved over 312 amino acids. The results indicated a nearly perfect match with PAL-18 containing the 96 residue exon, with the exception of the 5′ and at least one exon insertion. The portion beginning AQQDAV (SEQ ID NO:168) is a match for the 411 amino acid PAL-18 sequence, except for an A between FYQKA (SEQ ID NO:169) and KYLHL (SEQ ID NO:170).

[0197] Protein sequence of A.ctg12788-000005.2.0 as predicted from chromosome location 1q41 bases 256410710-256465015. Underlining demonstrates the overlap

[0198] MKIGPSFKANAITDAQQDAVFELISMGFNVALWYTKYASRLAGKEN ITEDEAKEVHRSLKIAAGIFKHLKESHLPKLITPAEKGRDLESRLIEAYVIQCQ AEAQEVTIARAIELKHAPGLIAALAYETANFYQKAAKYLHLKMCFYTAYA YCYHGETLLASDKCGEAIRSLQEAEKLYAKAEALCKEYGETKGPGPTVKP SGHLFFRKLGNLVKNTLEKCQRENGFIYFQKIPTEAPQIELKANYGLVEP IPFEFPPTSVQWTPETLAAFDLTKRPKDDSTKPKPEEEVKPVKEPDIKPQ KDTGCYIS (SEQ ID NO:166)

[0199] This sequence is predicted from the following cDNA: ATGAAAATCGGCCCGTCTTTTAAAGCCAATGCCATTACCGATGCCCAGCA (SEQ ID NO:167) GGATGCTGTTTTTGAATTAATTTCCATGGGATTTAATGTAGCTTTATGGT ATACCAAATATGCTTCAAGACTGGCTGGAAAAGAAAATATAACAGAAGAT GAAGCAAAAGAAGTTCATCGAAGCCTAAAGATTGCAGCTGGGATTTTTAA ACATTTAAAGGAAAGTCATCTCCCAAAACTCATTACACCTGCGGAAAAAG GAAGAGATTTAGAGTCACGACTCATAGAAGCATACGTTATTCAATGTCAG GCTGAAGCTCAAGAAGTAACAATTGCTCGAGCAATTGAACTAAAACATGC TCCTGGACTAATTGCTGCACTGGCGTATGAAACAGCCAATTTCTATCAAA AAGCTGCAAAATATCTTCACTTGAAGATGTGTTTTTACACAGCTTATGCT TACTGTTACCATGGTGAGACTTTATTGGCTAGTGATAAATGCGGTGAAGC AATCAGGTCTCTCCAAGAAGCAGAAAAATTGTATGCAAAGGCAGAAGCAC TGTGTAAAGAATATGGAGAAACCAAAGGACCTGGACCAACAGTCAAACCT TCAGGACATCTGTTCTTTAGGAAACTTGGAAACCTTGTGAAGAACACCCT AGAAAAATGTCAGAGAGAAAATGGATTTATTTACTTTCAAAAAATTCCAA CAGAAGCCCCACAGCTGGAACTCAAAGCAAATTATGGTCTCGTAGAGCCT ATACCTTTCGAATTTCCTCCTACAAGTGTTCAGTGGACACCAGAAACATT GGCTGCATTTGATCTCACCAAAAGACCCAAGGATGACAGTACTAAACCCA AACCAGAAGAAGAAGTGAAACCTGTGAAAGAACCAGACATCAAACCTCAA AAGGACACTGGGTGCTACATCTCCTAA

Example II Homology Searches Using PAL-18 Sequences

[0200] A predicted protein fragment was constructed by translating the nucleotide sequence obtained by sequencing the Factor H 1040RT primer amplicon. This protein fragment was used in a homology search of the nonredundant GenBank CDS database. This search identified B0507.2 gene of C. elegans, BRO1 of yeast, and ptp-td14 of rat, and YNK of yeast as having some degree of homology these full sequences where then compared by the BLAST algorithm available from the Genetics Computer Group of Madison Wisconsin or from the National Center for Biotechnology Information using the BLAST two sequences program, which uses the Smith-Waterman algorithm described above by Altschul et al.

[0201] A sequence of 46 nucleotides from the same amplicon was used in a search of the DBest EST GenBank database.

[0202] The entire sequence obtained with clone 64.2.5 using primer MCXLF01 was used in searches of the nonredundant nucleotide EST GenBank+EMBL+DDBJ+PDB sequence databases and DBest both of which identified small 43 and 26 base matches.

[0203] The entire sequence obtained with clone 64.2.5 using primer MCXLF03 was used in a search of DBest.

[0204] The sequence obtained with clone 58.2.7 with primer MCPLF07 was used in a search of DBest.

[0205] The translated sequence of the calculated 411-residue protein was used in searches of pdb and Swissprot.

[0206] Analysis of the homology with calnexin and calnexin-like proteins revealed a short, homologous region, including a match of seven out of eight consecutive residues (PAL-18=ESKLRYIQ vs. calnexin=ESKLRYLQ). A further search was done with the calnexin sequence as the query sequence, using a higher expectation value of 1000 in order to identify additional potentially important local homologies.

[0207] More extensive analysis was performed of the homologies with various proteins, as reflected in Table 1. TABLE 1 Examples of Protein-Level Homologies of the PAL-18 Predicted Protein (SEQ ID NO: 76). Related Comparison % % PAL-18 Protein Method Identity Conserved Region Ptp-td14 2-sequence BLAST 21 42 190-397  Bro 1 ″ 25 41 54-271  YNK1 ″ 20 36 2-361 C. elegans B0507.2 ″ 39 58 1-405

[0208] A further interesting and potentially significant feature of the PAL-18 protein is that there are adjacent strong local homologies to two known proteins: yeast calnexin and mus rhophilin. These adjacent homologies are depicted in FIG. 2.

[0209] The general criterion for significance of a homology “match” is considered to be p<0.05 of a single match of the indicated quality across the entire database under search. In other words, if the expectation of a match in the whole database is less than one in twenty, then the observed match is presumed to represent a true relationship between the two similar sequences, and not merely an adventitious similarity that is due to the very great size of the database. Examples of such adventitious similarities may be found in Search F, where, for example, a number of matches of apparent statistical significance are found for a sequence beginning at base 506 of the query sequence (PAL-18). While the a priori significance of the match is sufficient to render it of potential interest, the fact that this very sequence appears so many times in the database implies that is has been specifically amplified at some time, and therefore that its appearance within a given gene does not necessarily imply a true relationship to other genes that have the sequence. Another indication that the match is adventitious is the fact that the relationship is not “extensible”; i.e., regions outside of the similarity in the two genes exhibit no similarity. On the other hand, a good test of a true match is that the similarity often extends beyond the regions initially identified. For example, the relationship between PAL-18 and the B0507.2 protein from C. elegans was initially identified by searching with only half of the known sequence of the hypothetical PAL-18 protein as the query sequence. When the match was identified, a search with the rest of the known sequence strongly confirmed the relationship. Thus the matches which are of greatest interest (Table 1) mostly represent homologies over large stretches of the PAL-18 sequence. All of these matches also pass the statistical criterion described above.

[0210] The adjacent matches with calnexin and rhophilin are also of interest (see FIG. 2). These matches are likely to be of significance because, first, they are locally quite strong, and, secondly, because they are almost precisely adjacent—i.e., they do not overlap, yet there is only a single amino-acid residue intervening. There is therefore a good chance that they represent adjacent functional domains in the protein. Overlapping matches of equal individual significance would be less likely to imply coordinated functions.

[0211] The strong local match between the calnexin-like sequence and the tssk-1 and tssk-2 kinase substrate proteins may be significant, in spite of the fact that it fails the p<0.05 test, because sequences that modulate kinase specificity are often short domains of larger proteins; the homology may therefore indicate that this region of PAL-18 interacts with kinases or shares a similar function with tssk-1 and tssk-2 substrates. However, unlike the homologies noted above, this type of highly localized, strong homology which is not extensible is more likely to represent functional similarity (which often appears by convergent evolution) than descent from a common ancestral gene.

Example III Detection of PAL-18 Message

[0212] Any pair of primers capable of forming an amplicon within the PAL-18 message, including pairs of several of the primers listed herein, would in principle be usable in detecting the message or gene. The methods used for detection are similar to those used originally used for cloning.

[0213] Method 1

[0214] Detection of PAL-18 message in cancer cell lines by 42M and 1040RT primers.

[0215] Reverse Transcription

[0216] Reverse Transcription was performed as described under Example 1 above.

[0217] PCR

[0218] PCR was performed as described under Example 1 above.

[0219] Method 2

[0220] Detection of PAL-18 message by PCR using primers specifically designed for PAL-18.

[0221] The PCR methods used for this process are identical to that described above under CONFIRMATION OF KNOWN PAL-18 REGIONS BY CLONING AND SEQUENCING OF FETAL LIVER cDNA LIBRARY. Accordingly, any pair of primers capable of generating an amplicon can be used for this purpose.

Example IV Message Variants and Detection Thereof

[0222] The following variants of the PAL-18 message are described herein:

[0223] Full-length (main variant), represented by contig ID 1 (SEQ ID NO:75)

[0224] Full minus 96-bp exon, represented by contig ID 2 (SEQ ID NO:76)

[0225] Full minus 16-bp exon, represented by contig ID 3, sequences 72.1.1.XLR01.broad.extract and 72.1.1.XLF01.broad.extract (SEQ ID NO:77)

[0226] Full minus 160-bp exon, represented by contig ID 4, sequence 95.3.6.BDR01.rev.comp. (SEQ ID NO:78)

[0227] Full minus 104-bp and 16-bp exons, represented by contig ID 5, sequences 89.7.10.XLR01 and 89.7.10.PLF12 (SEQ ID NO:79)

[0228] The 104-bp exon consists of the 96-bp exon followed by a contiguous exon of 8bp.

[0229] The term “exon” refers to a region of the message which has been observed to be absent in certain clones. However, it is also possible that these “exons” represent transcription from different genes. The transcription products of these different genes, if they exist, may undergo splicing which is distinct from the splicing experience by the products of the primary PAL-18 gene, or the splicing may be identical. These hypothetical additional genes may have deletions and/or insertions in them which may combine with the splicing effects to give the observed effects. One tentative indication that alternative genes may be involved is the fact that the canonical “AG” sequence is observed for only a portion of the putative splice sites. However, it should be recognized that splicing at other sites is possible, such as for type II introns and the like.

[0230] Given what is known about the nature of RNA splicing, exons may be combined in various ways by multiple splicing events. For example, there may be a message in which both the 96-bp and 160-bp exons are absent, although it has not yet been observed. There may also be messages in which one or more of a set of exons which have so far been observed to be present or absent as a group may be present without some or all the other members of the group being present. An example of this is the putative 8-bp exon, which has been observed to be absent only when the 96-bp exon is absent; however, the 8-bp exon may be present without the 96-bp exon in other messages which have not been observed. The same is true of the 8-bp exon and the 16bp exon. Moreover, it is clear to one of skill in the art that these variant messages may be translated by any means of the well-known genetic code to yield further predicted proteins in addition to those specified by sequence ID 72-74.

[0231] Detection of Message Variants

[0232] Special primers were designed for detection of the presence or absence of specific exons. The presence or absence of the 96-bp exon in a given cDNA preparation or clone may be detected by mobility difference in AGE, using PCR as under CONFIRMATION OF KNOWN PAL-18 REGIONS BY CLONING AND SEQUENCING OF FETAL LIVER cDNA LIBRARY above. However, the variant missing the exon is generally present in small amounts (but see exception, below), which makes specific detection desirable. Specific detection of messages which contain the exon is accomplished by the use of a primer which anneals within the exon. Specific detection of messages which do not contain the exon of interest is accomplished by designing a primer which anneals under stringent conditions across the exon-exon boundary formed by the missing exon, but anneals only very poorly to the structure including the exon. Both of these principles are illustrated a PCR experiment. Primer 13 anneals within the 96-bp exon. A 1:10,000 dilution of a plasmid containing this exon is easily detected, while neither a 1:100 nor a 1:10,000 dilution of a plasmid missing this exon is detected. Conversely, the plasmid missing the exon is detected at 1:100 dilution (and very slightly at 1:10,000 dilution), while the plasmid containing the exon is not detected at either concentration. The same effects may be observed in cDNA from human tissues. The mid-sized variants (contig Ids 2 (SEQ ID NO:76) and 5 (SEQ ID NO:78) above) appear to be abundantly present in human prostate tissue, but nearly absent in peripheral blood leukocytes. This is conveniently confirmed by use of the variant-specific primers which detect only mid-sized variants lacking the 96-bp exon. These variants are easily detected in a 1:100 PCR of prostate cDNA, but only a very slight signal is seen with PBL cDNA.

[0233] Use of the Variants in Detection, Diagnosis, and Prognosis of Prostate and Colon Cancer

[0234] The ratio of expression of the PAL-18 variants in the prostate varies with the individual, and changing or aberrant ratios may be symptomatic of particular disease states, disease-susceptibility states, or genetic predisposition to disease. For example, cDNA made from RNA extracted from the prostate tissue of an individual (“patient B”) with prostate cancer was observed to have a noticeably higher level of lower molecular weight variants and a lower level of the normal, full-length message than tissue from other patients (FIG. 3). This patient had a strong family history of prostate cancer, with four male relatives suffering from the disease. FIG. 3 demonstrates the levels of PAL-18 in six prostate cancer positive individual using the MCPLF12 and MCPLR10 primers.

[0235] Similarly, cDNA made from RNA extracted colon cells was analyzed as below (FIG. 4 M=molecular weight marker; C=colon cancer; N=normal colon tissue from the same patients; Mic=microglobulin control for RNA uantity and quality. The three C's without matching N's are samples from cancers for which no matching normal control tissue was available).

[0236] Patients 1 & 2

[0237] PAL-18: PAL-175/1040RT primers, 95o×1′ initially, 30 cycles (94°×20″, 54°×1′, 70°×2′), 10 cycles (94°×20″, 54°×1′, 70°×2.5′), 70°×7′, 4° indefinitely. Sequence of PAL-175: ACCAAATATGCTTCAAGACT (SEQ ID NO:173)

[0238] Microglobulin: Mic148 and Mic2533 primers. Same PCR conditions as for PAL-18 except annealing step was 70°×1′ instead of 54°. Primer sequences: Mic148:  CACGTCATCCAGCAGAGAATGGAAACT (SEQ ID NO:174) Mic2533: TGACCAAGATGTTGATGTTGGATAAGAG (SEQ ID NO:175)

[0239] Patients 3-6

[0240] PAL-18: Same primers and conditions as above except 95°×2′ initially.

[0241] Microglobulin: Same primers and conditions as for microglobulin above except 95°×2′ initially.

Example V Single Nucleotide Polymorphisms

[0242] Single Nucleotide Polymorphisms (SNPs) are individual variable positions in a gene sequence. SNPs can be useful for functional analysis of a gene product, “genetic fingerprinting,” and studies of disease susceptibility, as well as the possibility of “tailoring” a disease treatment for a patient. Possible SNPs in the known regions of the PAL-18 message are as follows:

[0243] Sequences based on SEQ ID NO:76, containing all except 96-bp exon

[0244] Pos.

[0245] 359: G in clone 89.2.6, A elsewhere

[0246] 520: G in clone 89.7.10, T elsewhere

[0247] 565: G in clone 89.3.10, A elsewhere

[0248] 620: A in 95.1.4, G elsewhere

[0249] 704: C in clone 89.2.9, T elsewhere

[0250] 776: A in clone 89.3.6, G elsewhere

[0251] 800: C in clone 89.3.6, T elsewhere

[0252] 821: ambiguity-clone 95.1.5 reads C in one sequence, G in the other; elsewhere it's A

[0253] 830: T in clone 89.7.10, A elsewhere

[0254] 837: G in clone 89.3.6 and clone 89.7.10, A elsewhere

[0255] 884: A in clone 89.7.3, T elsewhere

[0256] 893: Apparently G in clones 95.1.4 and 95.1.5, A elsewhere

[0257] 943: G in clone 89.7.3, A elsewhere

[0258] 946: G in clone 89.3.6, C elsewhere

[0259] 987: G in clone 95.1.4, maybe T in Image clone 754, A elsewhere

[0260] 1015: G in clone 89.6.1, A elsewhere

[0261] 1025: G in clones 89.6.1 and 89.7.3, A elsewhere

[0262] 1039: G in Image clones, A in others

[0263] 1047: C in 3′ RACE clones, A in clone 89.7.10, T elsewhere

[0264] 1098: A in prostate clones, 3′ RACE clones and one Image clone sequence, G in another sequence of the same clone and another Image clone, G and A both found in SW480 clones (95.1.4, 95.1.5)

[0265] 1115: T in clone 89.7.3, C elsewhere

[0266] 1161: T in 95.1.4, C elsewhere

[0267] 1163: T in 95.2.1, C elsewhere

[0268] 1170: A in clone 89.2.6, T elsewhere

[0269] 1181: A or G variably; possibly some sequencing artifacts at this position

[0270] 1234-1235: CT in 89.6.1, TC in 89.7.3, TT elsewhere

[0271] (Sequence based on contig ID 1 (SEQ ID NO:75), bases 549-645) base 43 of 96-bp exon: G in clone 89.3.10, A elsewhere

[0272] Use of SNPS in Diagnosis, Prognosis, Susceptibility Determination, and Determination of Optimum Treatment in Cancer and Other Diseases

[0273] Using the methods and principles discussed above, it would be possible to characterize an individual patient such as prostate-cancer patient B above according to the exact genotype of his PAL-18 by determining all SNPs, or only those found to be relevant to disease or susceptibility status. This may constitute part or all of a “genetic profile” which may be useful in diagnosis, prognosis, determining susceptibility, and/or specifying effective treatments in prostate cancer and other diseases.

[0274] The well-known genetic code can be used to translate nucleotide sequences incorporating these SNPs to yield hypothetical proteins in addition to those specified by sequence ID 72-74. It is also clear to one of skill in the art that variation in these SNPs may be combined with splice variation to produce additional species. However, if some or all of the putative “splice variants” discussed above are in fact the products of multiple genes, then some or all of the SNPs observed may in future be seen to occur with only certain of the “splice variants” (or products of multiple genes), and the SNPs may therefore be additionally useful as an alternative means of quantifying relative or absolute expression of these gene products (i.e., in addition to RT-PCR). Similarly, the relative or absolute abundance of a given “splice variant” or product associated with one of multiple genes could be used to infer the presence or amount of one or more SNPs associated with that particular gene, and therefore also with any functional variation associated with the SNP or SNPs.

Example VI Assays for the Antigen

[0275] Given the characteristics of the antigen as described above and given the disclosure herein for generating and selecting antibodies and the development of certain assays described herein to detect the antigen, a number of additional assay formats beyond those described herein for this antigen may be readily developed by those of ordinary skill in the art. Suitable assay formats include competitive formats, sandwich formats (Examples VI.A., VI.B. and VI.C), assays based on the biological or chemical properties of the antigen (Example VI.D. and VI.E.), assays based on the simultaneous binding of the antigen to a specific macromolecule (e.g., PAL-18) and to a monoclonal antibody (Example VI.D.), assays based on the appearance of a band of appropriate size in partially-purified specimens (Example VI.F.), and RT-PCR (Example VI.G.). A preferred format involves sandwich immunoassays and the most preferred employs a monoclonal antibody immobilized on a solid surface and a second monoclonal antibody, which recognizes an epitope distinct from that of the first, conjugated to a detection agent. That detection agent could be an enzyme (Example VI.B.), colloidal gold (Example VI.C.), or any of a number of other such agents known to those of ordinary skill in the art. These include fluorescent molecules, radioisotopes, and biotin (which would subsequently bind to avidin or streptavidin-labeled detecting agent).

[0276] A. Identifying Potential Antibody Pairs

[0277] Definitions for the Section Indirect Assay Format: Antigen coated on plate; reaction with MAb; signal generation by Goat Anti-mouse conjugated to alkaline phosphatase (GAM-AP). Direct Assay Format: Antigen coated on plate; reaction with and signal generation by specific MAb-AP. Sandwich Assay Format: As usual

[0278] Initial screening of the cell culture supernatants is carried out using an ELISA in an indirect format. The assay consisted of the following in order: (1) diluted samples are adsorbed on a microtiter plate; (2) following washing, the microtiter plate wells is incubated with supernatants of cell cultures of the clones of interest; (3) following another wash, the plates are incubated with alkaline phosphatase-conjugated goat anti-mouse IgG; (4) following a final wash, the plates are incubated with p-nitrophenyl phosphate substrate (pNPP); and, finally, (5) the reactions are stopped by addition of concentrated EDTA to each well and the color measured at a wavelength of 410 mn on a microplate reader.

[0279] Initial testing of antibodies conjugated to alkaline phosphatase (AP), as described in Example VI.B.2., is carried out utilizing an assay in the direct format as follows: (1) diluted samples were adsorbed on a microtiter plate; (2) following washing, the plates were incubated with AP-conjugated antibodies from specific clones; (3) following a final wash, the plates were incubated with pNPP; and, finally, (4) the reactions are stopped and measured as above.

[0280] The sandwich ELISA format can be used as follows: (1) individual capture antibodies were adsorbed on microtiter plates; (2) following washing, diluted samples were added to the wells and incubated to allow binding of the antigen to the antibody; (3) following another wash, single conjugates (as described in B. above) are added to individual wells and incubated to allow binding to the antibody-bound antigen, if present; (4) following a final wash, the plates are incubated with pNPP; and, finally, (5) the reactions are stopped and measured as above.

[0281] B. Sandwich ELISA

[0282] The sandwich ELISA, utilizing the most preferred pair as selected above, is further optimized with respect to the following items: (1) coating level of capture antibody; (2) concentration of conjugate; (3) enzyme-to-antibody ratio in the conjugate; (4) reaction kinetics/incubation times; (4) composition of assay and wash buffers and of conjugate and specimen diluents; and (5) formulation of standards and controls. The assay as optimized is performed as follows:

[0283] 1. Preparation of Coated Plates

[0284] The plates are coated with 150 μl per well of monoclonal antibody at a concentration of 5 μg/mL in carbonate buffer at pH 9.6. The plates are then blocked with 2% bovine serum albumin in phosphate-buffered saline at pH 7.4, followed by blocking with 4% sucrose. The sucrose solution is decanted, and the plates are dried overnight at room temperature.

[0285] 2. Preparation of MAb-Alkaline Phosphatase Conjugates

[0286] Antibodies are purified by chromatography on immobilized Protein G or Protein A by standard techniques. Although antibody-enzyme conjugates could be prepared using a variety of coupling techniques (for review see Scouten, W. H., Methods in Enzymology 135:30-65, 1987), a minor variation of a method described by S. Hashida and E. Ishikawa (Anal. Lett. 18, B9:1143-1155, 1985) is preferred. Briefly, purified monoclonal antibodies are treated with excess N-acetylhomocysteine thiolactone (AHTL) at neutral pH to introduce reactive thiol groups, and then desalted to remove excess AHTL. Separately, alkaline phosphatase (AP) is treated with excess sulfosuccinimidyl 4-(N-maleimido-methyl) cyclohexane-l-carboxylate to introduce maleimido groups, and excess reagent is removed by desalting. The conjugates are prepared by mixing antibody and enzyme derivatives, which become covalently coupled via thioether bonds. Any excess maleimido groups are then capped by reaction with cysteamine.

[0287] 3. Assay Format

[0288] A volume of 175 μl of assay buffer is pipetted into each well to be utilized in carrying out the assay. The buffer is followed by 25 μl of samples, standards, or controls, thus yielding a 1/8 dilution in the well. Incubation of the covered plate is performed at 37° C. for 60 minutes. Following washing, 200 μl of working dilution of conjugate is added to the aspirated well. The covered plate is again incubated for 60 minutes at 37° C. Following a final wash, 200 μl of pNPP substrate is pipetted into each well, and the covered plate is incubated at 37° C. for 30 minutes. After pipetting, 50 μl of stop solution into each well, the reaction mixtures in each well is measured at 410 nm.

[0289] C. PAL-18-MAb ELISA

[0290] 1. Method

[0291] Immulon 4 (Dynatech, Chantilly, Va.) microtiter strip wells are coated with 50 μl per well of 5 μg/ml PAL-18 in 50 mM carbonate buffer, pH 9.6, either overnight at 4° C. or for two hours at 37° C. A control plate is coated with 50 μl per well of 2% BSA in PBS for two hours at 37° C. After a single wash with Tris-buffered saline (TBS) containing 0.1% Tween −20 (wash buffer), the plates are blocked with 100 μl per well of a 2% BSA solution in PBS for two hours at 37° C. and washed four times. Antigen, diluted in assay diluent (1% BSA in TBS with 0.15M MgCl₂, 0.15M ZnCl₂), is added at 50 μl per well and incubated for one hour at 37° C. The plates are washed four times and then the detection antibody (MAb-alkaline phosphatase) is applied at 0.25 μg/ml, 50 μl per well, and incubated at 37° C. for 30 minutes. After four washes, 50 μl per well of p-nitrophenyl phosphate (Sigma, St. Louis, Mo.) at 1 mg/ml in 1M diethanolamine (DEA) is added and the plate incubated for 30 minutes at 37° C. The reaction is stopped with 25 μl per well of stop solution (0.1 M EDTA, pH 9.8) and the plate read at 405 nm on a Dynatech MR7000 reader.

[0292] D. RT-PCR Assay

[0293] 1. Cell Lines

[0294] Several cell lines, particularly cell lines HTB-9, which is derived from Transitional Cell Carcinoma (TCC) of the bladder and HeLaS3, which is derived from adenocarcinoma of the cervix and LS174T, derived from colon carcinoma (all from American Type Culture Collection, Rockville, Md.), are tested to determine whether they produce mRNA coding for the antigen. Although the method selected for cell line analysis is RT-PCR (Reverse Transcriptase based Polymerase Chain Reaction amplification of messenger RNA, mRNA), a variety of procedures used to detect the presence of specific RNA can be used. Controls are performed using PCR target materials provided with commercial PCR kits.

[0295] 2. Preparation of mRNA

[0296] Preparation of mRNA is facilitated by the use of a Lysis Buffer containing: 7.5 M Guanidine HCl, 25 mM TES, 10 mM EDTA, 0.05% Taurodeoxycholate, 1 mM 2-mercaptoethanol, pH 7.5 (all reagents Molecular Biology grade from Sigma, St. Louis, Mo.). This buffer eliminates the necessity for grinding or icing samples and resulted in a stable preparation of DNA and RNA.

[0297] Cells are lysed in 1 mL lysis buffer per 10⁸ cells/mL cell culture media (IMDM, Irvine Scientific; Irvine, Calif.) supplemented with 15% FBS (Hyclone; Logan, Utah). The lysate is extracted with equal volumes of phenol and chloroform/isoamyl alcohol. The aqueous phase was aspirated and re-extracted with an equal volume of chloroform/isoamyl alcohol. The aqueous phase is precipitated with 7/13 volumes 10M LiCl (all reagents Molecular Biology Grade from Sigma Chemicals, St. Louis, Mo.). The mRNA is prepared from the total RNA produced in the previous steps using a PolyATtract kit (Promega, Madison, Wis.).

[0298] 3. RT-PCR Amplification

[0299] RT-PCR amplification of antigen sequences is performed on a Perkin-Elmer 2400 Thermal Cycler using a GeneAmp PCR kit (Perkin-Elmer/Roche Molecular Systems, Branchburg, N.J.). Amplification is performed with 3 μL purified mRNA, 35 cycles, for the first amplification step of each reaction. The RT primer may be any of those described above or derived from the PAL-18 sequences. For the nested PCR, 20 μL of product from the first PCR reaction is re-amplified for 35 cycles using at least one additional prime. All primer concentrations are set at 0.2 μM, and the annealing temperature is set at 48° C.

[0300] The invention is in no way limited except as set forth by the attached claims.

0 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 174 <210> SEQ ID NO 1 <211> LENGTH: 1244 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 14, 15, 33, 34, 37, 39, 45, 47, 55, 60, 70, 78, 82, 120, 142, 143, 145, 154, 206, 236, 272, 275, 276, 281, 290, 301, 304, 313, 319, 325, 327, 335, 337, 340, 341, 343, 349, 356, 358, 364, 372, 375, 377, 380, 382, 386, 389, 395, 401 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 402, 405, 413, 415, 424, 426, 433, 437, 448, 449, 452, 453, 455, 468, 476, 477, 485, 491, 496, 500, 503, 507, 511, 512, 515, 517, 522, 525, 530, 532, 533, 538, 547, 551, 555, 558, 562, 570, 574, 579, 580, 581, 587, 595, 597, 598, 605 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 624, 625, 630, 642, 644, 648, 653, 654, 657, 664, 672, 682, 684, 685, 693, 698, 708, 717, 718, 721, 722, 725, 728, 729, 733, 734, 742, 753, 765, 773, 775, 782, 789, 790, 793, 794, 798, 799, 800, 808, 815, 821, 830, 838, 839, 841, 842 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 847, 852, 856, 865, 869, 879, 882, 884, 889, 891, 894, 900, 906, 910, 911, 916, 917, 923, 924, 926, 928, 930, 931, 936, 938, 939, 947, 951, 957, 958, 964, 967, 968, 982, 984, 985, 988, 989, 994, 997, 998, 999, 1003, 1004, 1005, 1021 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1022, 1041, 1045, 1049, 1050, 1053, 1054, 1063, 1066, 1067, 1069, 1073, 1075, 1079, 1085, 1092, 1094, 1095, 1096, 1105, 1106, 1113, 1118, 1125, 1128, 1135, 1137, 1138, 1139, 1140, 1141, 1162, 1164, 1171, 1184, 1187, 1191, 1193, 1196 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1197, 1204, 1207, 1212, 1217, 1220, 1221, 1222, 1224, 1230, 1239, 1240, 1241 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 1 cttcctttta aaannccctt ttgaaaaggc ccnnacnana gtttncntca agatntgccn 60 cagggcttgn caccgagnct tngtatccac tagtaacggt cgccagtgtt ttggaatttn 120 ccttaatccc atggaaatta anngnaaaaa cagnatcctg ctgggcactg gaattataaa 180 catgatcatt aagttctgtc aattanccag acatcacacc atgaagccta ctgganatcc 240 gactcaaaat tacaaagaag catatgctaa cnggnntgta ngaggaaaan ggtcgtgttt 300 nacntagatg ggnagatang atgcncncgc ccccncncan ncncccccnc ctcccngnac 360 ccgnccgcac cncancnccn cnccgntanc cacgngcaaa nngcnctttc tcnanggtcc 420 cccngnccat ccntgcnccc tctaaacnnc cnnanccctc ggctcccnaa atcctnncgc 480 ctctnaaagc nccgtnacgn gtnttanctc nncanancgc anaanctccn cnnccacnct 540 caccaancct ngccnctnct cncccccccn actncgccnn ncatccnaca cactngnntg 600 caccnctcca caccccccac ccgnngcccn cctcccccct cntngatngt acnnccncac 660 cccncacgcc ancgcgcatc tncnntccct cgnctacncc cacccccnca ccttccnncc 720 nnctnatnna ccnnctatcc gnaacacccc ccncccctcc gcacncgctc ccncncgcgg 780 tncaccctnn tcnnaacnnn cccccacnaa acccncacct ntacctaacn acccctannc 840 nnccccnccc antacnaccc cccancacna cacttcccnt cncnccacnc ntgnaacacn 900 tcacantcgn nctcanncta ccnnancncn nctatncnnc ccctatnaga natcacnncc 960 tccnacnnac gacctacacc tncnncanna cacncannnc agnnnctccc tctaccatca 1020 nntgccactc cacatacatg ncctnaccnn tanngcacca ccnatnncnt canantcanc 1080 gcatntaatg cntnnnctcg cacannacgc atncacanat cacanctnta caagngnnnn 1140 ncacctcatc cgtcacgtca gncnatgcgc nacgacgcca tcgnacntcc ncntcnnctt 1200 cccngcnctc tncctgnctn nntnctatgn cacaacatnn nccc 1244 <210> SEQ ID NO 2 <211> LENGTH: 1142 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 5, 6, 18, 19, 29, 33, 53, 55, 74, 82, 90, 91, 93, 100, 102, 278, 398, 620, 646, 659, 690, 694, 722, 758, 761, 766, 767, 774, 782, 795, 796, 805, 811, 813, 818, 829, 833, 844, 855, 868, 870, 876, 878, 882, 893, 900, 930, 933, 934, 945 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 948, 955, 958, 959, 963, 966, 971, 973, 977, 994, 1004, 1010, 1014, 1027, 1028, 1030, 1031, 1043, 1046, 1049, 1053, 1056, 1069, 1073, 1076, 1080, 1081, 1083, 1099, 1101, 1105, 1108, 1114, 1115, 1121, 1123, 1128, 1129, 1132, 1133, 1138 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1139, 1142 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 2 ttaanncctt ttaagccnnt gctcgggcnc cgncagtgtg acggatatct gcngnaattc 60 ggcttactat aggncacgcg tngtcgacgn ntngggctgn tncttgttaa aaatacgatt 120 ctaagcccca tcccaggctt tccgactctg ggattaaggc ccagaaatct gtattttaaa 180 agctgctcta tgtgcagcaa actttgggag ctcctattcc catgcttatt attaagtaca 240 tagtaccttc tggaccatta tacttagcca tttgtagnta attacctgta catcttatct 300 ccccatctat attaaacaca accattttcc tcatacatac cagttagcat atacttcttt 360 gtaattttga gtcggatatc cagtaggctt catggtgnga tgtctggata attgacagaa 420 cttaatgatc atgtttataa ttccagtgcc cagcaggatg ctgtttttga attaatttcc 480 atgggattaa gccgaattcc agcacactgg cggccgttac tagtggatcc gagctcggta 540 ccaagcttga tgcatagctt gagtattcta tagtgtcacc taaatagctt ggcgtaatca 600 tggtcatagc tgtttcctgn gtgaaattgt tatccgctca caattncaca caacatacna 660 gccggaagca taaagggcaa agcccggggn gccnaatgag tgagctaact cacattaatg 720 cnttgcgctc actgcccgct tccagtcggg aaacctgntc nctgcnnctg catnaacgga 780 ancggccaac gcgcnncgag aggcngtttg ngnattgngc gctctttcnc ttnctcgcat 840 cacntaactc ctggnccccg gtcgctcngn ctgccncnag cngcttcagc tcntttaaan 900 gcggttactc cgtatattcc cagaaatcan ggnntcaacg catgnaanga acatngtnng 960 canaangtcc ncnatanggc ccccgaaccc ctanaaaggc cctngttggn tgcntttttc 1020 ccttgcnncn ncccccttgc ganctnccna aanctncccc ctcctcccnt ggnggntacn 1080 nanccgcagg atttatacng ncccngcntt tccnntcgca ncntcctnnt cnngctcnnc 1140 cn 1142 <210> SEQ ID NO 3 <211> LENGTH: 1210 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 13, 23, 30, 40, 46, 48, 51, 60, 88, 97, 100, 106, 110, 119, 120, 155, 197, 296, 327, 353, 362, 382, 385, 406, 422, 433, 434, 440, 446, 448, 449, 450, 454, 470, 474, 476, 495, 496, 498, 499, 502, 504, 521, 523, 539, 552, 559, 561, 577 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 578, 595, 599, 601, 604, 610, 613, 615, 638, 642, 646, 648, 652, 653, 659, 660, 662, 678, 686, 687, 688, 689, 690, 694, 695, 706, 717, 718, 719, 725, 728, 738, 739, 745, 751, 757, 764, 767, 769, 770, 783, 784, 785, 805, 810, 814, 818 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 822, 823, 828, 832, 836, 842, 843, 846, 854, 859, 860, 867, 868, 872, 878, 880, 886, 888, 893, 898, 901, 909, 921, 927, 934, 949, 955, 958, 966, 969, 980, 982, 987, 989, 991, 994, 998, 1002, 1008, 1019, 1021, 1023, 1026, 1035, 1036 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1048, 1052, 1055, 1056, 1068, 1072, 1078, 1083, 1086, 1090, 1103, 1106, 1123, 1128, 1133, 1135, 1144, 1145, 1148, 1153, 1155, 1167, 1170, 1172, 1176, 1188, 1193, 1203, 1210 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 3 ttaaaccccc ttntaaaacc ctnctgaaan gtcccactan agtttncnca nactatgccn 60 caagcttggt accgagcttg gtatccanta gcaacgnttn gccagngttn tggaattcnn 120 cttaatccca tggaaattaa ttcaaaaaca gcatnctgct gggcactgga attataaaca 180 tgatcattaa gttctgncaa ttatccagac atcacaccat gaagcctact ggatatccga 240 ctcaaaatta caaagaagta tatgctaact ggtatgtatg aggaaaatgg ttgtgnttaa 300 tatagatggg gagataagat gtacagnctc ttaactacaa atggctaagc ctnatggccc 360 anaaggccca cctccttaat antangcatg ggaataggac cttccncaag ttccctgcac 420 anagagcagc ctnnaaactn tcagantnnn tggncctcaa tccccagagn ctcnanagcc 480 tgggatgggg tctcnnannt cntncttcta acaagcacca ncnccgggcc cgtcgcccnc 540 gcctgccccc anacacacnc ncgaaactcc tgcactnnaa ccatccacac cgccncccnt 600 ncanagcacn cancncaagg gcccccttcc cctcaacncc gncccntncc cnnctctann 660 tnccccccct tcacaccntc gcagcnnnnn cccnnccccc gtcctnccac atttccnnnc 720 ccctncanca cctctccnnt ctctnactac ncggccncca cagnccncnn ccttcaccac 780 ccnnnccctc ttccccccac ttcgntcaan ctcnactntc tnnacccnct cncctncccc 840 tnnccncatc taanctctnn ctccccnngc cntctatncn ccaccntncc ccnctcancc 900 nccccgccnt cctaccaccc ntttccncac cttntctccc tacccctant ggccncgncc 960 ttcctnctnc acaccctctn cngtccnana nccngctnac cncctctncg cgcccctcnc 1020 ncnaancccc tcgcnncccg acaccccntc cntcnnttac cacctgtnac cncctacngc 1080 ccnctncgtn cacacctgtc gtntcntcat tctcatccca tcncacgncc ctncntctat 1140 cacnntcnct cantnttacc atcactntcn tncatnctct ctctcctngc acngtctcat 1200 canctccccn 1210 <210> SEQ ID NO 4 <211> LENGTH: 1160 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 5, 6, 24, 25, 26, 28, 38, 39, 46, 52, 53, 92, 102, 524, 549, 558, 669, 670, 692, 740, 748, 779, 801, 803, 812, 826, 831, 841, 865, 869, 879, 885, 893, 904, 916, 926, 932, 936, 946, 958, 960, 965, 966, 974, 981, 1000, 1007, 1009, 1014 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1017, 1018, 1037, 1051, 1064, 1066, 1076, 1077, 1082, 1091, 1092, 1099, 1105, 1108, 1110, 1121, 1122, 1134, 1135, 1150, 1155, 1156, 1160 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 4 ttaanncctt taaaaccttt taannngncc gctcgagnng ccgccntgtg anngatatct 60 gcagtaattc ggcttactat agggcacgcg tnttcgacgg tncgggctgg tacttgttaa 120 aaatacgatt ctaagcccca tcccaggctt tccgactctg ggattaaggc ccagaaatct 180 gtattttaaa agctgctcta tgtgcagtaa actttgggag ctcctattcc catgcttatt 240 attaagtaca tagtaccttc tggaccatta tacttagcca tttgtagtta attacctgta 300 catcttatct ccccatctat attaaacaca accattttcc tcatacatac cagttagcat 360 atacttcttt gtaattttga gtcggatatc cagtaggctt catggtgtga tgtctggata 420 attgacagaa cttaatgatc atgtttataa ttccagtgcc cagcaggatg ctgtttttga 480 attaatttcc atgggattaa gccgaattcc agcacactgg cggncgttac tagtggatcc 540 gagctcggna ccaagctnga tgcatagctt gagtattcta tagtgtcacc taaatagctt 600 ggcgtaatca tggtcatagc tgtttcctgt gtgaaattgt tatccgctca caattccaca 660 caacatacnn agccggaagc ctaaagtgca anggctgggg tgcctaatga gtgagcctaa 720 cttacattaa ttgcgttgcn ctcacttncc cgctttccag ccgggaaaac ctgtcgtgnc 780 cagctgcatt aatgaatcgg ncnacgcgcc gnggcagagg cggttntgcg nattgcgcgc 840 nttttccgct tcctcgctca cctgnctcnc tgcgccttng ccgcnccggc cgngggcgag 900 ccgncattca gctcanttaa aggcgntaat ancggntatc ccccancaat cctggggntn 960 ccccnngaaa acancatgtc nagccacaag ggccagctan aagtccngna accntcnnaa 1020 cgggcccctg ttgttgnccg ttttccatag ngcccggccc cccngnctag cttcannaaa 1080 tncccttcaa nntcatagnt ggcgnaancn ccatcggcct nnccacatcc cctnntgtcc 1140 cccttggtan gattnntccn 1160 <210> SEQ ID NO 5 <211> LENGTH: 1155 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 6, 7, 21, 24, 25, 30, 34, 37, 44, 88, 91, 101, 102, 123, 130, 131, 196, 241, 405, 431, 490, 535, 545, 555, 558, 559, 568, 576, 586, 599, 612, 622, 626, 637, 648, 660, 665, 713, 719, 729, 733, 747, 756, 758, 765, 766, 775, 777, 778 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 782, 792, 798, 799, 809, 816, 828, 830, 850, 858, 867, 868, 876, 878, 893, 905, 916, 927, 929, 932, 934, 938, 943, 950, 956, 957, 959, 963, 964, 967, 980, 981, 986, 994, 996, 1006, 1007, 1008, 1012, 1017, 1023, 1030, 1032, 1036, 1039 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1040, 1041, 1042, 1045, 1047, 1053, 1058, 1063, 1072, 1073, 1083, 1087, 1090, 1094, 1101, 1108, 1110, 1125, 1126, 1130, 1132, 1137, 1139, 1143, 1155 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 5 ttaaanncct tttaaaacct ntgnnaaagn cccncanctt gcanaaagct tgctccgagc 60 ttggatccac ttgtaacggt cgccagtntt ntggaatttt nntactatag ggcacgcgtg 120 ggncgacggn ncgggctggt aaaagctgct ctatgcgcag taaactttgg gagctcctat 180 ccccatgctt attatnaagc acatagtacc ttctggacca ttatacttag ccatttgtag 240 ntaattacct gtacatctta tctccccatc tatattaaac acaaccattt tcctcataca 300 taccagttag catatacttc tttgtaattt tgagtcggat atccagtagg cttcatggtg 360 tgatgtctgg ataattgaca gaacttaatg atcatgttta taatnccagt gcccagcagg 420 atgctgtttt ngaattaatt tccatgggat taagccgaat tctgcagata tccatcacac 480 tggcggccgn tcgagcatgc atctagaggg cccaattcgt cctatagtga gtcgnattac 540 aattnactgg ccgtngtnna caacgccntg actggnaaaa ccctgncgtt acccaactna 600 atcgccttgc ancacatccc cnttcnccag ctggcgnaat agctgaanag gcccgcaccn 660 atcgnccttc ccaacagttg cgcagcctga atggcgaatg gacccgccct gtnccggcnc 720 cattaagcnc ggngggtgtg gcggttnccc gcagcngnga cccgnncact tgccngnncc 780 cnagccccgc tncttagnnt tcttccctnc cttttncggc ccgttcgncn gcttttcccc 840 ccaaaggctn taaaatcngg gcctccnntt tagggntncc caaccagtgc tcnacggcaa 900 cctcnccccc aaaaanctct gatttgngng angnttcncg tancgcccan tcgccnngnt 960 agnncgnttt tcccccttcn nacccnggag cccncncttt ttaaannngg tnctctnggt 1020 ctnaaaactn cncccnccnn nntcntntcc cgnaccantt ctnacctctc tnnaggcatt 1080 ctnctcnctn ctgngcgctt ntcgatanan acagccctcg cattnnccan anctttncnc 1140 gcnctatcta acccn 1155 <210> SEQ ID NO 6 <211> LENGTH: 1157 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 8, 17, 23, 50, 61, 101, 102, 110, 282, 290, 293, 298, 302, 304, 315, 322, 333, 359, 360, 367, 400, 404, 412, 421, 428, 430, 458, 469, 482, 486, 491, 505, 527, 537, 538, 549, 563, 564, 570, 573, 581, 583, 589, 590, 594, 599, 600 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 618, 620, 621, 628, 629, 641, 664, 670, 683, 686, 691, 696, 711, 720, 723, 737, 738, 746, 747, 748, 760, 764, 773, 790, 799, 823, 831, 838, 845, 859, 873, 879, 887, 900, 910, 915, 921, 925, 928, 930, 931, 935, 940, 954, 960, 989, 992 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1000, 1005, 1007, 1015, 1016, 1024, 1032, 1037, 1039, 1072, 1077, 1081, 1089, 1099, 1102, 1113, 1121, 1136, 1143, 1147, 1149, 1157 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 6 tttaaanncc cttttanagc cgnctgctcg ggcgcccgcc agtgtgtatn gcatatctgc 60 ngcaattcgg cttaatccca tggtaaatta attcaaaaac nncatcctgn tgggcactgg 120 aattataaac atgatcatta agttctgtca attatccaga catcacacca tgaagcctac 180 tggatatccg actcaaaatt acaaagaagt atatgctaac tggtatgtat gaggaaaatg 240 gttgtgttta atatagatgg ggagataaga tgtacaggtc ancaactacn aanggctnag 300 tntnatggtc caganggtcc tntgcactta atnataagca tggggatagg agcttccann 360 gcttacngtc catagagcag cttttaccag cccgggccgn cgancacgcc tnccctatag 420 nagccgcntn ccaccacact ggcggccgcc actagtgnat ccccgctcng caccaagctt 480 gntgcntagc ncgcgtctct atagngcccc ctaaatagct tgccctntcc ccgctcnntt 540 gctgtttcng tgtcaaattg ttnncgttcn ctnttcacac ncntatacnn tccnccccnn 600 caagtcgcaa gcctgatngn ncctaacnnc gtcacctctc ncacattaac ttgccgtttc 660 gccnctcccn ccccctcttc cgngcnggaa nccctncgcg gccaccctct nttctgcctn 720 ccnccaccct ccccccnngt cctttnnntt ttcctgaacn tccncccctt tcntcctcca 780 accccttctn tccctcctng cttatcgcct ccggcctcgc ccncccaccg ngcctctntg 840 cgttnattgc ggcttttcnc cttcccgtct ccntccctnc ttccccnctc ttcctcgctn 900 ccccccgccn ccccngaccc nctcnacncn ntccncctgn tcccccccca accntgtccn 960 tccccccgct acgctccttc cctcctcgnc cnccttccgn ccctnanccc cctannggcc 1020 tccnatctct cnctctntnt caattagtcc tccccccctc tccccggcct tncctcntct 1080 nccccctcna tcttctcgng cnctttcccc ctntgcctcc nttcgctcct gcgcgnttcc 1140 ccnccancnc ccccccn 1157 <210> SEQ ID NO 7 <211> LENGTH: 1194 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 13, 20, 36, 39, 43, 50, 57, 84, 96, 102, 107, 117, 140, 151, 152, 189, 194, 205, 245, 293, 294, 295, 314, 315, 316, 324, 333, 335, 345, 355, 358, 359, 361, 364, 365, 367, 371, 376, 378, 391, 392, 393, 400, 403, 409, 411, 414, 416 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 439, 440, 445, 450, 459, 460, 467, 468, 469, 471, 474, 476, 481, 482, 484, 486, 489, 492, 493, 497, 499, 504, 506, 513, 518, 520, 523, 534, 536, 540, 548, 549, 568, 573, 578, 592, 595, 597, 600, 601, 607, 610, 614, 621, 622, 624, 638 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 641, 647, 654, 664, 668, 676, 678, 682, 686, 691, 694, 698, 712, 714, 726, 729, 731, 738, 743, 746, 751, 755, 769, 771, 775, 777, 778, 781, 788, 790, 806, 809, 814, 820, 826, 834, 846, 848, 849, 859, 871, 877, 882, 885, 888, 891, 892 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 893, 900, 910, 920, 922, 925, 938, 940, 941, 946, 950, 957, 968, 978, 987, 991, 993, 999, 1013, 1018, 1026, 1030, 1035, 1037, 1055, 1056, 1061, 1069, 1071, 1072, 1075, 1083, 1090, 1099, 1100, 1101, 1105, 1111, 1119, 1142, 1149, 1151 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1158, 1173, 1174, 1183, 1188, 1189, 1194 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 7 ttaaacncct tgnaaaaccn cctgaaaggt cccacnaant ttncccaagn tatgccncaa 60 gctcggtacc gagcttggaa ccantagcca acgttngcca gngtttntgg aattccnctt 120 aatcccatgg aaattaattn aaaaacagca nnctgctggg cactggaatt ataaacatga 180 tcattaagnt ctgncaatta tccanacatc acgccatgaa gcctactgga tatccgactc 240 aaaantacaa agaagcatat gctaactggt atgtatgagg aaaacggctg cgnnnaatac 300 agaaggggag acannncgcc agcncatcac cgnanctaag ccccntccca gggtntcnna 360 ngcnncnacc nccccnanca agctgcacca nnnaagcccn ctntacgtnc nagnanctcg 420 cgcagcctcc aaccccccnn cccancacan accccccgnn ccctccnnng ncantntacc 480 nngntntcna cnnctcncng cccngncccc ccncatcnan ggncaccatc cccnanctcn 540 cccgcttnnc ccatcaccct cacacccncc ccnactcncc cccaccccaa cnccngngcn 600 ngcaccnccn ccanccccta nncngacccc atctcgtntc ncaccanccc cccnaccccc 660 cccncgtncc aacacncncg cncccnccct ngcngctnca tccccacccc cncnccccca 720 ccccancanc nctccccngc ccnctncccc ncccncaccc ctccccccnc ntcancnncc 780 nccacacncn ccaatcccat cctccnccna cccnccctgn tccccnctac cttncaccac 840 cacccncnnc ctctcccana accccacccc ncttccnccc cnccnccncc nnncccgctn 900 caccatcccn ccctccattn cnganacatc tactatanan nccccncccn ttcaccnttt 960 cacacccncg accctccnac tcatctnccc ncncctctna ccccaccaca ctnacccncc 1020 cccccngccn ccccngnctt acccctcact aaccnnccaa ntctccacnt nncancaccc 1080 aancaccccn tcgcatccnn natcntcttc ncacccacnc cacccaccca tactcccacc 1140 tntccatcna ncatctcnac gctcccctca cannctcatt gcncgccnnc cccn 1194 <210> SEQ ID NO 8 <211> LENGTH: 1158 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 6, 7, 22, 26, 29, 30, 42, 43, 57, 58, 68, 107, 109, 516, 529, 552, 663, 714, 718, 725, 728, 737, 750, 785, 789, 797, 810, 818, 820, 838, 845, 849, 850, 853, 855, 859, 861, 870, 871, 872, 882, 894, 901, 908, 910, 914, 916, 922, 927 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 936, 943, 951, 952, 969, 976, 982, 992, 998, 1000, 1004, 1009, 1012, 1019, 1025, 1041, 1042, 1047, 1055, 1058, 1060, 1062, 1066, 1067, 1071, 1078, 1081, 1083, 1092, 1099, 1104, 1105, 1108, 1113, 1114, 1118, 1119, 1122, 1123, 1136 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1142, 1144, 1147, 1158 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 8 ttaaanncct tttaaaaccc tnttanagnn gcccgctcgg gnngccgcca gtgtgannga 60 tatctgcngt aattcggctt actatagggc acgcgtgttc gacggtncng gctggtaaaa 120 gctgctctat gtgcagtaaa ctttgggagc tcctattccc atgcctatta ttaagtacat 180 agtaccttct ggaccattat acttagccat ttgtagttaa ttacctgtac atcttatctc 240 cccatctata ttaaacacaa ccattttcct catacatacc agttagcata tacttctttg 300 taattttgag tcggatatcc agtaggcttc atggcgtgat gtctggataa ttgacagaac 360 ttaatgatca tgtttataat tccagtgccc agcaggatgc tgtttttgaa ttaatttcca 420 tgggattaag ccgaattcca gcacactggc ggccgttact agtggatccg agctcggtac 480 caagcttgat gcatagcttg agtattctat agtgtnacct aaatagctng gcgtaatcat 540 ggtcatagct gnttcctgtg tgaaattgtt atccgctcac aattccacac aacatacgag 600 ccggaagcat aaagtgtaaa gcctggggcg cctaatgagt gagctaactc acattaattg 660 cgntgcgctc actgcccgct tccagacggg aaactgtcgt gccagctgca ttantganat 720 ccccnacncg ccggggngag ggcggtttgn cgtattgggc gctccttcgc ttcctcgctc 780 actgnctcng ctgcgcntcg gtcgctcggn ttgcgctnan cggttatcag cttcactnaa 840 aaggncggnn atncngctnt nccacagcan nncgggcgat tncccacgga aagnaccctg 900 ngagccanan ggcncncaaa angcccnggg aacccnaaaa aangcccccc nnttgccggt 960 ttttccatng gctccncccc cngccaggca tnccaaanan ttcnccctnc angtcagang 1020 gggcnctacc cctcaggcct nncaagnttc cctcnctntn tncccnngga ngctcctntg 1080 nanctctttc tntttcgcnc ctcnncgntt acnnggannc cnntcgactt ctttcncttg 1140 gngnagncgc gccctccn 1158 <210> SEQ ID NO 9 <211> LENGTH: 1155 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 6, 7, 10, 57, 67, 76, 92, 94, 95, 105, 127, 199, 273, 275, 278, 351, 377, 505, 538, 553, 595, 612, 636, 644, 655, 657, 680, 711, 712, 733, 762, 775, 776, 782, 785, 786, 793, 819, 824, 845, 866, 882, 889, 893, 898, 900, 908, 911, 914 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 924, 933, 950, 963, 972, 978, 980, 984, 986, 987, 990, 993, 999, 1000, 1003, 1009, 1015, 1017, 1024, 1027, 1039, 1040, 1045, 1046, 1085, 1099, 1102, 1114, 1117, 1121, 1133, 1146, 1155 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 9 ttaaannccn tttaaaaacc tctgcaaaag tcccctcaaa ctttgccaaa gcttgcnacc 60 gagcttngat ccactngtaa cggtcgccag tntnntggaa ttttncttac tatagggcac 120 gcgtggncga cggtccgggc tggtctggga tgtccttttg cttcccttct agtcatcttt 180 ccagggacag ttcagattnc atatatacca ttaaaccttc ttaattattc tagcctgaaa 240 caatctctcc tctgaatttg atttttctaa aangntgnat aagagccaca cctttgagaa 300 tcgactgagt acttgttaaa aatacgattc taagccccat cccaggcttt ncgactctgg 360 gattaaggcc cagaaanctg tattttaaaa gctgctctat gtgcagtaaa ctttgggagc 420 tcctattccc atgcttatta ttaagtacat agtaccttct ggaccattat acttagccat 480 ttgtagttaa ttacctgtac atctnatctc cccatctata ttaaacacaa ccattttnct 540 catacatacc agntagcata tacttctttg taatttcgag tcggatatcc agtangcttc 600 atggtgtgat gnctggataa ttgacagaac cttaangatc atgntcataa ttccngngcc 660 cagcacggat gctgttttgn aattaattcc catgggcatc aagccgaaat nntgcagata 720 tccatcacac tgncggcccg cttgagcatg catctagagg gnccccaatt ctccnntagc 780 gngtnntatt acnattcact ggcccgtcgg ttcacaacnc tcgngactgg gaaaaccctg 840 cggtncccaa ctttaatcgg cctgcnagcc attccccttt tntcagctng cgnaatangn 900 aaagaggncc ngtnccttcg ctcnttccaa canctggcgc cagactgaan gccgaaaggc 960 acncccctct tnccggcncn atcnannccn ggngggtgnn ggnggtccnc ccacngngac 1020 cggntcncct tctcagcgnn cctannccgg ctcctctccg catcttccct ctctttctcg 1080 ccggntacgc gctctctcnc cnctcagctc taanctntgg ncccccatta ggnttccctc 1140 tacacnctct taccn 1155 <210> SEQ ID NO 10 <211> LENGTH: 1170 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 1, 8, 21, 34, 40, 94, 97, 105, 357, 499, 503, 504, 510, 530, 535, 546, 552, 567, 568, 575, 596, 601, 614, 616, 623, 631, 635, 637, 640, 643, 650, 654, 656, 662, 663, 665, 671, 679, 683, 690, 695, 705, 712, 716, 735, 737, 741, 743 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 744, 750, 753, 765, 769, 771, 782, 789, 791, 802, 806, 807, 815, 816, 819, 820, 822, 823, 830, 837, 841, 852, 855, 858, 860, 868, 869, 870, 874, 878, 884, 885, 886, 887, 896, 897, 902, 905, 906, 907, 908, 909, 915, 917, 925, 941, 954 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 957, 958, 960, 962, 963, 966, 969, 970, 972, 982, 988, 993, 998, 1000, 1003, 1004, 1010, 1011, 1012, 1015, 1016, 1018, 1024, 1027, 1032, 1034, 1035, 1036, 1037, 1041, 1059, 1061, 1063, 1064, 1066, 1071, 1077, 1078, 1079, 1081, 1083 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1089, 1091, 1093, 1097, 1099, 1100, 1101, 1113, 1114, 1118, 1121, 1126, 1127, 1128, 1131, 1138, 1141, 1144, 1148, 1153, 1162, 1165, 1166 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 10 ntttaaancc cttttatagc ncttgctcgg gcgnccgccn tgtgatggat atctgcagaa 60 ttcggcttaa tcccatggta aattaattca aaancancat cctgntgggc actggaatta 120 taaacatgat cattaagttc tgtcaattat ccagacatca caccatgaag cctactggat 180 atccgactca aaattacaaa gaagtatatg ctaactggta tgtatgagga aaatggttgt 240 gtttaatata gatggggaga taagatgtac aggtaattaa ctacaaatgg ctaagtataa 300 tggtccagaa ggtactatgt acttaataat aagcatggga ataggagctc ccaaagntca 360 ctgcacatag agcagctttt aaaatacaga tttctgggcc ttaatcccag agccggaaag 420 cctgggatgg ggcttagaat cgcattttaa caagtactca gtcgattctc aaaggcgtgg 480 ctcttataca acattttana aanntcaaan tcagaggaga gattgcttcn ggctngaata 540 attaanaagg tntaactggt atatatnnaa ctctnaacct gcccctggaa agatgnctcg 600 naacggaagc aaangncctt ccnagaccca ncccngnccn tcntccactn cctncnccta 660 tnncncagcc naattccanc acnctggctn cccgntactt gtggntcctc ancccngctc 720 caatcttgac gcacncntcg ngnntctatn ggngtccccc acttnctcnc ncttattctt 780 tnctctctnc ntcttccctg cntganntcg ggtcnnccnn cnncttcccn ccttctnccc 840 nccccttaag cnctncantn ccgctccnnn cccncctnaa tggnnnncct tcactnncat 900 tnatnnnnng gcctncnctt cctgnccctt tccccgttct ncaactccgg ctcnccnncn 960 tnntantann cntctccccc tncccccntc ttntcggncn ccnnagtatn nnccnncnct 1020 tccnttnctt gntnnnnctc ntcccttccc ttttcgctnc ncnncncttc nctctcnnnc 1080 ncntactcnc ntnctcngnn nctttcccgt ttnncccnct nctccnnnct ntccctcnct 1140 nctntctncc ttngctccgt cntcnncccc 1170 <210> SEQ ID NO 11 <211> LENGTH: 1176 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 2, 3, 4, 9, 10, 18, 25, 26, 30, 35, 37, 82, 215, 422, 453, 569, 583, 606, 619, 624, 633, 649, 650, 653, 658, 676, 681, 682, 687, 705, 718, 733, 743, 755, 760, 761, 762, 767, 768, 772, 773, 786, 789, 792, 795, 797, 804, 807, 818, 832 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 833, 843, 846, 849, 850, 851, 854, 858, 861, 863, 867, 874, 881, 887, 890, 906, 908, 913, 927, 932, 934, 951, 953, 955, 959, 965, 966, 984, 985, 986, 990, 1001, 1016, 1028, 1040, 1042, 1043, 1045, 1047, 1055, 1058, 1066, 1068, 1069 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1070, 1079, 1080, 1082, 1084, 1085, 1091, 1094, 1101, 1102, 1103, 1107, 1110, 1124, 1126, 1128, 1140, 1149, 1151, 1157, 1158, 1161, 1166, 1169, 1170 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 11 cnnnctctnn ttttaaancc ctttnnaaan ccccngnaat tatatacatg atcattaagt 60 tctgtcaatt atccaggaca tnacaccatg taagcctact ggatatccgt ctcaaaatta 120 caaagaagta tatgctaact ggtatgtatg aggaaaatgg ttgtgtttaa tatagatggg 180 gagataagat gtacaggtaa ttaactacaa atggnctaag tataatggtc cagaaggtac 240 tatgtactta ataataagca tgggaatagg agctcccaaa gtttactgca catagagcag 300 cttttaaaat acagatttct gggccttaat cccagagtcg gaaagcctgg gatggggctt 360 agaatcgtat ttttaacaag tactcagtcg attctcaaag gtgtggctct tatacaacat 420 tntagaaaaa tcaaattcag aggagagatt gtntcaggct agaataatta agaaggttta 480 atggtatata taaaatctga actgtccctg gaaagatgac tagaagggaa gcaaaaggac 540 atcccagacc agcccggccg ttgaccacnc gtgccctata gtngccgaat tccagcacac 600 tggcgnccgt tactagtgna tccnagcctc ggnccaagct tgatgcatnn ctngagtntt 660 tatagtgcca cctcantagc nngccgnaac catggcctta gcttnctcct gcgcgacntt 720 gctatcccct tcncaattcc acnccccata ccganctcgn nngcctnngt gnnacgcctg 780 gcgtgnctna tnagngngct aacnccnatt aatctgcngt tgcgtctccc tnnccgcttt 840 tcncanctnn nganaccngt ncngccnctt cccnttaatg ncttcgnccn tccccccggt 900 gagagntntc tcncgtaatg ggtccgntct tncncctttc tgcctcactt ncncnctcng 960 cccgnncctc tctcggcttc gtgnnngcgn ccttcacctc ncctcacagg ccggtntttc 1020 ctttcatntc cccgcatccn tnntntnccc ttccnacnca cctctncnnn taacgccann 1080 cntnngcctc nacncctcct nnngccntcn tcctcctcct tttncntnta gcttcccccn 1140 cctcgtccnt nttctcnnaa ntcccnccnn caaccc 1176 <210> SEQ ID NO 12 <211> LENGTH: 1164 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 8, 14, 15, 26, 27, 64, 85, 92, 101, 104, 105, 114, 123, 124, 145, 211, 506, 631, 673, 695, 713, 714, 734, 750, 756, 784, 795, 815, 828, 830, 831, 848, 849, 870, 877, 880, 883, 890, 894, 896, 899, 900, 916, 919, 934, 937, 940, 946 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 954, 962, 972, 986, 988, 989, 991, 1008, 1014, 1018, 1029, 1034, 1036, 1042, 1055, 1057, 1058, 1061, 1063, 1093, 1099, 1104, 1105, 1109, 1113, 1121, 1126, 1127, 1138, 1149, 1158, 1161 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 12 tttaaanncc cttnntaaaa accctnntga aaaggtcccc actatagttt actcaagcta 60 tgcntcaagc ttggtaccga gcttngatcc antagcaacg nttnnccagt gttntggaat 120 tcnncttact atagggcacg cgtgntcgac ggcccgggct ggtctgggac gcccttttgc 180 ttcccttcta gtcatctttc cagggacagt ncagatttta tatataccat taaaccttct 240 taattattct agcctgaaac aatctctcct ctgaatttga tttttctaaa atgttgtata 300 agagccacac ctttgagaat cgactgagta cttgttaaaa atacgattct aagccccatc 360 ccaggctttc cgaccctggg attaaggccc agaaatctgt attttaaaag ctgctctatg 420 tgcagtaaac tttgggagct cctattccca tgcttattat taagtacata gtaccttctg 480 gaccattata cttagccatt tgtagntaat tacctgtaca tcttatctcc ccatctatat 540 taaacacaac cattttcctc atacatacca gttagcatat acttctttgt aattctgagt 600 cggatatcca gtaggcttca tggtgtgatg nctggataat tgacagaact taatgatcat 660 gtttataatt ccngcgccca gcaggatgct gcttngaatt aattccatgg gannaagccg 720 aattctgcag atanccatca cactggcggn cgctcnagca tgcatttaga gggcccaact 780 cgcnctatag tgagntgtat tacaattact ggccnacgtt ctacaccntn ngtgactggc 840 aaaacccnng cgtctacccc actttaatcn ccttgcnccn canccccctn ttancncann 900 tggctgtaaa tacggnaang cccgcacctc ttcnccnttn tccacnagtc gccnaaccct 960 gnatggccga cngacccgcc cctgtngnng nggcattaaa gccgcggntg ggtncgcntg 1020 gcctctccnc actngnaccc gntccacctt ctcancnncc ncnccccgtt ctttcgcctt 1080 ccttccctct cantctctng cccnnctcnc cantctcctc nacagnncct acatcggncg 1140 ccctccctnt ggtgtccncc nccc 1164 <210> SEQ ID NO 13 <211> LENGTH: 1160 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 5, 6, 7, 24, 28, 49, 106, 107, 281, 287, 289, 293, 309, 314, 320, 329, 330, 331, 338, 348, 351, 374, 383, 395, 403, 406, 407, 431, 435, 444, 445, 447, 455, 458, 463, 477, 485, 491, 492, 500, 506, 512, 517, 518, 521, 526, 532, 534 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 544, 550, 561, 562, 564, 572, 573, 574, 578, 580, 583, 591, 594, 599, 605, 606, 607, 612, 615, 616, 619, 632, 633, 640, 641, 646, 650, 655, 657, 658, 662, 668, 672, 682, 685, 698, 700, 706, 709, 715, 716, 719, 737, 739, 741, 744, 748 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 749, 758, 767, 769, 773, 774, 775, 787, 789, 793, 800, 812, 813, 816, 833, 840, 845, 847, 855, 872, 875, 880, 882, 899, 905, 909, 910, 913, 914, 917, 918, 926, 935, 941, 948, 966, 967, 969, 971, 972, 976, 986, 987, 997, 999, 1005 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1016, 1017, 1032, 1035, 1042, 1043, 1049, 1050, 1052, 1061, 1063, 1065, 1067, 1073, 1086, 1088, 1093, 1094, 1096, 1098, 1103, 1104, 1109, 1111, 1113, 1125, 1137, 1142, 1148, 1152 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 13 ttnannncct ttaaaaccct tttnaagntg cccgctcggg cggccgccnt gtgacggata 60 tctgcagtaa ttcggcttaa tcccatggga aattaattca aaaacnncat cctgctgggc 120 actggaatta taaacatgat cattaagttc tgtcaattat ccagacatca caccatgaag 180 cctactggat atccgactca aaattacaaa gaagtatatg ctaactggta tgtatgagga 240 aaatggttgt gtttaatata gatggggaga taagatgtac nggtaantna ctncaaatgg 300 ctaagtatna cggnccagan ggtactatnn nctcaatnat aagcatgnga ntaggagctc 360 caacgcttac tgcncataga gcncctttta aaatncagat ttntgnnccc taatcccagg 420 gtcggaacag nctgngatgg ggcnnanaat cgcanttnta acnagccctc agtccgncct 480 ttaanggtgc nncccttatn caaccntttt anacaanncc ncctcngagg ancngaccgt 540 ttcnggctcn actacttaac nngntctaac gnnntctntn canctttaac ncgnctctnc 600 cacgnnncac tngcnntgna cgccaacgct cnnccacccn ngtccngtcn cgtcncnnca 660 cnctcccnct cnccccagcc tnttnttagc accctccncn cgcccnctna gcgcnntcnc 720 cctcgtcccc atcctcncnc nctnctcnng cctccccncc tttctcncnt ccnnnccctt 780 ccctccncnc ccntcccctn tctcccctcc tnnccncttt ctcccttctt ccnttccccn 840 ccccntntct ccccnctccc tcctcccctc tnccncctcn cnccccctcc acccccccnc 900 cctcntccnn tcnnctnncc cccttntcct cttanccacc nctccccncc ctcctccctc 960 tctctnncnt nnttcntctc ttcccnncct ccttccntnt ctccntctcc tctctnntct 1020 tccctttctc cnccnccctc tnnccctcnn tntcctcccc ntncncnctc ccncctcctc 1080 ttcccntnct ctnncntnct tcnncctcnc ntnccccctc cctcnccctc ttcttcntct 1140 cntccacnct cncttccccc 1160 <210> SEQ ID NO 14 <211> LENGTH: 1148 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 8, 23, 25, 32, 33, 34, 36, 40, 56, 84, 103, 104, 112, 169, 180, 192, 198, 232, 237, 271, 274, 315, 324, 391, 487, 523, 528, 534, 535, 536, 565, 577, 613, 644, 657, 666, 678, 679, 680, 773, 783, 784, 789, 838, 843, 857, 860, 864 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 869, 881, 898, 902, 904, 909, 910, 927, 932, 938, 943, 948, 954, 957, 959, 961, 967, 971, 982, 987, 989, 991, 997, 1003, 1005, 1009, 1021, 1023, 1027, 1037, 1038, 1041, 1042, 1048, 1059, 1061, 1073, 1086, 1088, 1090, 1095, 1099, 1108 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1123, 1128, 1135, 1138, 1145 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 14 tttaaanncc cttttaaaaa ccntnttcaa annncncctn aaatattcat gcatcnttaa 60 gttctgtcaa ttatccagca catnacacca tgcaagccta ctnnatatcc gnctcaaaat 120 tacaaagtaa gtatatgcta actggtatgt atgaggaaaa tggttgtgnc ctaatatagn 180 tgcagcttaa tngccttnca gcacatcccc ccttcgccag ctggcgtaat ancgaanagg 240 ccctcaccga tcgcccttcc caacagttgc ncancctgaa tggcgaatgg acgcgccctg 300 tagcggcgca ttaancgcgg cggntgtggt ggttacgcgc agcgtgaccg ctacacttgc 360 cagcgcccta gcgcccgctc ctttcgcttt nttcccttcc tttctcgcca cgttcgccgg 420 ctttccccgt caagctctaa atcgggggct ccctttaggg ttccgattta gtgctttacg 480 gcacctngac cccaaaaaac ttgattaggg tgatggttca cgnagtgngc catnnncctg 540 atagacggtt tttcgccctt tgacnttgga gtccacnttc tttaatagtg gactcttgtt 600 ccaaactgga acnaccctca accctatctc ggtctattct tttnattcat aaggganttt 660 gccganttcc ccctattnnn taaaaaatga gcctgactta acaaaaattt aacgccgaat 720 tttaacaaaa tattaacgct tacaatttcc tgatgcggta tttcctcctt acnccatcct 780 gtnncggtnt ttcacaccct atatggtgca ctctcagtac aatctgctct tgatgccnca 840 tanttaagcc agtcccnacn cccncccanc acccgcctgt ntccccctta ctgctttncc 900 tncncccgnn atccgctcca gacaaanctt tnaccctntc cgnacccncc tgcnttncna 960 natttcnccc ncttccccta anccctncna nccaacngct ccntntaanc cccccttcta 1020 nancctncgt cctacannct nngcctcnta aaacccatng ntcccctttc ccngccaatg 1080 tccccncncn ctttncccna ttttcttnac ccatatcaaa ctnactcncg tcttntcnca 1140 cattnccc 1148 <210> SEQ ID NO 15 <211> LENGTH: 1051 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 13, 15, 28, 83, 154, 208, 231, 238, 249, 270, 272, 273, 278, 288, 290, 292, 304, 315, 319, 329, 330, 334, 336, 337, 338, 344, 358, 363, 370, 378, 383, 384, 390, 400, 403, 408, 411, 412, 414, 420, 423, 426, 427, 431, 434, 436, 444 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 446, 450, 451, 453, 455, 468, 471, 477, 480, 483, 501, 508, 513, 515, 518, 533, 545, 546, 547, 548, 552, 556, 560, 566, 568, 573, 588, 594, 598, 599, 600, 603, 608, 616, 619, 620, 626, 628, 629, 636, 639, 643, 648, 650, 652, 654, 657 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 666, 667, 689, 693, 702, 704, 705, 708, 711, 713, 718, 721, 724, 726, 727, 732, 739, 750, 755, 759, 763, 766, 767, 775, 779, 795, 799, 814, 816, 817, 828, 831, 833, 834, 838, 842, 848, 851, 852, 866, 868, 876, 884, 885, 887, 888, 903 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 906, 907, 910, 922, 928, 930, 936, 941, 942, 960, 962, 969, 973, 974, 976, 982, 991, 995, 1003, 1004, 1010, 1025, 1031, 1038, 1042 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 15 tttgaaaccc ttntnaaagg ccttctanat ttcactcaac tttccatcaa gcttgctacc 60 gagctcggat ccactagtaa cgnccgccag tgtgctggaa ttcggcttgg tgagacttta 120 ttggctagtg ataaatgcgg tgaagcaatc aggnctctcc aagaagcaga aaaattgtat 180 gcaaaggcag aagcactgtg taaagaanat ggagaaacca aaggacctgg nccaacancc 240 aaaccttcng gacatctgtt ttctaggaan cnnggaancc ccgtgaanan cnccctaaaa 300 aaanaacccc ataancccnc cctcgcctnn tggnannnat aacncaaccc tcctcccncc 360 ccntcaattn atccaacncc cgnncctacn ctcacctcgn ttnctcgnta nntncccacn 420 ccnccnnctt ngcntnttcc accncnttcn ngntnttttc ccaattanta nttattnacn 480 ctnctttcct ctcccgctcc nctcaccntc ccntnctnca cccttctctc ccnctaacac 540 tcttnnnncc gnttcncccn ctttcnancc acnatccctc ctcctctnct gccnttannn 600 ccntctcntc accccnccnn aatcancnna cctccntcnt ccncctcncn cngnccnccc 660 ctcaannccc cctcctcctc tcatccccnt ctncttctat cntnncanac ntnaccgnca 720 ntcncnntca tntcctctnt ccaacctctn cattncttnc ttnctnnccc ccacncccnc 780 ttcctcatca catancccnc cccacctccc tacncnntct acctctcncc ncnncccntc 840 tnttctcnac nnccttacat cacccncnct ccctcnatct cacnncnnca atcaccacgc 900 canctnnacn cacaacccct antgtacntn ctttanctct nnaatcttgt cccccccctn 960 cncctctcnc tcnncnaata cncccccctc ncccnccctc aanncactcn actttaatca 1020 cctcnatctc ncatcccnct cnccctcacc t 1051 <210> SEQ ID NO 16 <211> LENGTH: 1030 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 6, 7, 13, 17, 18, 20, 29, 31, 45, 46, 57, 123, 132, 134, 136, 137, 138, 143, 144, 146, 148, 151, 155, 165, 166, 167, 171, 180, 183, 185, 186, 187, 203, 209, 210, 211, 214, 216, 218, 225, 226, 227, 228, 231, 232, 235, 239, 241, 249 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 251, 252, 253, 254, 255, 256, 257, 262, 263, 264, 265, 266, 273, 274, 275, 283, 284, 287, 288, 290, 298, 300, 303, 305, 307, 308, 314, 317, 319, 336, 338, 343, 345, 365, 366, 367, 388, 396, 398, 404, 406, 413, 416, 431, 433, 437, 446 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 448, 455, 459, 466, 469, 470, 480, 483, 489, 499, 507, 519, 524, 549, 552, 568, 571, 572, 573, 574, 582, 586, 592, 600, 606, 610, 615, 616, 625, 632, 633, 639, 641, 642, 668, 673, 679, 682, 685, 687, 693, 698, 708, 710, 728, 740, 744 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 753, 754, 771, 774, 775, 776, 786, 792, 793, 796, 816, 821, 829, 839, 844, 845, 854, 860, 862, 864, 868, 873, 877, 884, 885, 888, 894, 897, 900, 907, 920, 927, 932, 942, 954, 971, 972, 973, 979, 984, 995, 1008, 1015, 1016, 1025 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 16 ttaaanncct tcntctnnan cctgctcgng nggccgccag tgtgnnggat atctgcngca 60 attcggctta agcagtggta acaacgcaga gtactttttt tttttttttt tttttttttt 120 ttnggggggg tntncnnngg ggnncnangt ntccnaaaaa acaannntcc ngagggtttn 180 ccngnnngcc ccggcctttg ggnttcccnn nttntntncc cccgnnnntt nnccnttcna 240 nccaatttnt nnnnnnntgg gnnnnncccc tcnnntcccc ccnnttnntn ccaccccnan 300 aangncnncc cccnccncnc tccacccccc gggggngngg ccncngggcc cccccccccc 360 tcccnnncct ctccccccct ctcgtctntc ttcttncngc cccnanactt ccnggncccc 420 acctaggccc ntncccnccc ctctcncncc gcaancccnt tccctnccnn cccccccccn 480 ccncccctnc tcccccccnc ccttctnctc cccctctcnc cctncccccc ctccactccc 540 cccccctcnc anccccttcc gccccccntc nnnncctccc ancctntctc cnttctgctn 600 ccttcncccn ctccnngtat cccanccctc tnncgtccnc nnccctcacc ttttcacccc 660 ccctctcnct ctncccctnt cntcntnctt ttnccctncc tcttctantn ccctctccct 720 ccctcccntc ctccctcccn cgcncgtccc ccnnccccct ctcttgcccc nccnnncctc 780 ctccanctca cnncantccc ctcatcctcc ctcacnctcc nccctccant ctactccanc 840 tccnntcctc cccncccctn cntncccnac ctncttnctg cctnnccntt cccntcnccn 900 cctctcnccc ccctcacccn cctaccnttc cncccctcct cnttccccct cctncactct 960 ctgccccctc nnncccccnc tccncccctt ccctnttccc cactttcntc ctccnnccct 1020 cccgncccct 1030 <210> SEQ ID NO 17 <211> LENGTH: 1100 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 19, 24, 31, 53, 97, 102, 108, 118, 123, 127, 129, 139, 142, 149, 157, 163, 167, 180, 209, 215, 217, 224, 236, 241, 247, 263, 264, 268, 277, 281, 292, 313, 318, 332, 334, 342, 343, 345, 347, 361, 365, 366, 369, 370, 372, 373, 375 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 377, 380, 383, 388, 392, 397, 399, 400, 403, 404, 406, 408, 409, 410, 414, 417, 418, 421, 424, 428, 430, 433, 436, 437, 438, 443, 445, 448, 449, 451, 454, 468, 469, 470, 472, 473, 480, 481, 482, 484, 487, 492, 494, 496, 497, 500, 505 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 506, 508, 511, 512, 517, 521, 522, 524, 529, 532, 536, 537, 538, 541, 543, 544, 546, 549, 550, 551, 555, 556, 566, 570, 579, 585, 587, 588, 590, 595, 597, 599, 602, 606, 611, 613, 615, 624, 627, 628, 634, 638, 645, 646, 648, 650, 652 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 654, 656, 660, 672, 673, 675, 676, 679, 681, 683, 684, 692, 695, 700, 705, 707, 710, 715, 722, 729, 736, 739, 740, 750, 751, 752, 756, 758, 759, 761, 763, 766, 768, 772, 775, 778, 780, 787, 790, 793, 795, 797, 799, 802, 805, 807, 809 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 811, 822, 826, 830, 831, 834, 839, 842, 848, 854, 863, 864, 867, 871, 872, 875, 877, 879, 881, 885, 889, 890, 892, 894, 895, 900, 902, 912, 914, 915, 919, 920, 921, 923, 925, 930, 931, 935, 943, 946, 948, 951, 955, 967, 976, 977, 978 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 979, 980, 999, 1001, 1008, 1009, 1010, 1011, 1016, 1019, 1024, 1027, 1036, 1037, 1042, 1046, 1051, 1052, 1053, 1059, 1060, 1061, 1066, 1067, 1069, 1082, 1083, 1084, 1086, 1087, 1088, 1089, 1094, 1096, 1097 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 17 gancccccct tttgaaaanc cctntgaaaa ntccacacaa aatttcccta aancttccca 60 tcaagcttgg taccgagctc gggattcact agtaacntcc gncagatntg ctggaatncg 120 gcntggngng gactttatng gntaatgana aatgccntga ggnaatnaag tctttccaan 180 aagcagaaaa acgtatgcaa aggcagaanc accgngnaaa gaanatggag aaaccnaagg 240 ncctggncca acagccaaac ccnncagnca catccgnacc nttaggaaat cnggaaaacc 300 tctcgcaacc aanacccntg aaaaacgccc cnanaagaaa anngncnccc ataactctcc 360 ncaanncann cnnantnccn ccnacccntc tncaccntnn aanntntnnn cganccnnga 420 ntgngctncn gtnggnnntc acncnctnna ncancagccg agccctcnnn cnncttcacn 480 nnanctnata antncnnccn ataanntnct nnccggnaaa nncnacacna cncccnnnca 540 ncnncnctnn nccanncccc cacacncccn cccctccanc gcttnannan taacnantnc 600 cnatcnacca ngnanctcct cccntcnnac cttncgancg acccnncntn cncntntctn 660 gcccctccta cnncnnccna ncnncttgca tnacnacacn ccacnancan ccaancacca 720 tnacccccng cacacntann tcgcaaatcn nncccngnnt ngnaancnca tnacncgntn 780 caagccnctn acnancngng cnccncncna ncgccctcat cncccnaccn ncangcctnc 840 cnctcccncc cagncgccct aannctnccc nnacncncna ncccncctnn cngnnccaan 900 cnccgtacag cncnncccnn ncncngccgn nctancaccc acnccncnca nctanagctg 960 actcagnaga cacccnnnnn caccgcacct ccactctcnc nccccccnnn ncaccngcnc 1020 cccncantca aaccanncct cnacancccc nnncgaaann nccttnncna gcctcccaca 1080 annntnnnna ccgnanncct 1100 <210> SEQ ID NO 18 <211> LENGTH: 1063 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 15, 21, 28, 29, 38, 41, 52, 82, 90, 128, 129, 135, 140, 142, 144, 155, 156, 158, 159, 162, 177, 178, 180, 181, 182, 188, 194, 200, 203, 206, 207, 217, 219, 220, 222, 227, 229, 235, 236, 242, 243, 245, 246, 248, 250, 254, 261, 267 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 269, 275, 280, 283, 287, 288, 295, 297, 306, 309, 310, 313, 314, 324, 332, 339, 352, 372, 375, 377, 379, 381, 383, 384, 385, 390, 398, 399, 402, 405, 406, 412, 426, 444, 445, 448, 454, 462, 474, 478, 484, 490, 495, 498, 500, 503, 515 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 525, 529, 531, 541, 543, 551, 555, 561, 566, 572, 587, 589, 598, 608, 611, 616, 621, 623, 626, 629, 631, 636, 641, 644, 655, 660, 668, 679, 696, 699, 702, 708, 711, 721, 728, 731, 738, 747, 748, 749, 755, 764, 767, 768, 769, 771, 777 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 788, 794, 808, 809, 815, 831, 833, 844, 847, 853, 863, 873, 880, 891, 899, 901, 902, 920, 923, 924, 937, 955, 959, 963, 964, 989, 997, 998, 1007, 1013, 1019, 1021, 1024, 1027, 1028, 1037, 1044, 1056 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 18 accccctttt taaanccctt nctctatnnc atgctcgntg nccgccatgt gntggatatc 60 tgcagaattc ggcttaagca gnggtaacan cgcagagtac tttttttttt tttttttttt 120 tttttttnng ggggnaaaan angncctttt tgggnncnnc tntacccagg gggctcnncn 180 nnagggtncc ccanttcccn aanaannctc cccctangnn tncaccncnc ccccnnttcc 240 cnntnntncn cctntttctc naccacncng ccccnccccn ccncacnnaa tcctncnctt 300 tacggnaann ccnntttcct ttancgccct tnttctttnc ccaccacccc cncccccccc 360 cccgttactc cntcncncnt ncnnnctcan ccccctcnnc tnccnncttt tncaccaacc 420 gcccgncatc ttctcccttc atcnncanta caangcaccc tnatccactc cttnaacnat 480 tcantaaccn aatcnccnan ccnccttcac ccccnccttc ccttncccnt ntcatctttc 540 ntnccccatc nctcncacat ntttgnccta cntctccact cctcccncnc tctccccnct 600 actctaancc nctccnctcc ncnacncanc nccccnagct nccncaccat ccccntcccn 660 cccctccncc cccccctcnc cctctacccc ctcttnctnc tnctaccngc ntccccccct 720 natcacanac ncactcgnct cccctcnnnc tcccntgtat tccntcnnnc nccctcnctc 780 ccctttcncc ctcncactcc cctcatcnnt ccccntcccc ctccactttc nancctacag 840 cccnttnccc ccnccatccc acnatccccc ccntcccgtn atctatcctc ngctcctcnc 900 nntctacctc ctctaccctn ccnnccacct ccacacnaac cctcccctct ctctnctcnc 960 tcnnctcccc ccctccttca cactccccnt cacccgnncc gcccacnctc ccntcctcnc 1020 ntantcnncc atcccanaca cccncaatcc atcctncaca cct 1063 <210> SEQ ID NO 19 <211> LENGTH: 1044 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 21, 28, 32, 38, 41, 52, 62, 71, 88, 99, 130, 138, 160, 272, 294, 328, 337, 347, 348, 352, 358, 363, 366, 369, 379, 381, 387, 395, 399, 405, 408, 428, 429, 430, 432, 435, 439, 440, 441, 447, 452, 453, 457, 459, 461, 462, 468, 470, 475 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 478, 483, 484, 485, 486, 490, 492, 494, 496, 497, 501, 504, 510, 515, 522, 534, 536, 538, 543, 544, 546, 560, 565, 571, 582, 585, 591, 599, 608, 613, 620, 624, 633, 642, 643, 646, 650, 653, 655, 659, 662, 665, 668, 669, 675, 681, 690 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 697, 701, 707, 710, 713, 714, 719, 721, 722, 727, 728, 731, 733, 737, 750, 751, 752, 755, 758, 759, 767, 769, 781, 787, 792, 803, 807, 815, 819, 820, 822, 827, 829, 835, 837, 840, 848, 852, 855, 859, 868, 869, 872, 879, 882, 884, 887 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 898, 904, 906, 911, 915, 919, 920, 924, 927, 931, 936, 951, 963, 965, 968, 969, 972, 975, 1004, 1008, 1020, 1022, 1034 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 19 tttgaacccc cttttaaaaa ngcccttnct anatttcnct naactttcca tnaagcttgc 60 cnaccgagct nggatccact agtaacgncc gccagtgtnc tggaattcgg cttggtgaga 120 ctttattggn tagtgatnaa tgcggtgaag caatcagggn tcttcaagaa gcagaaaaat 180 tgtatgcaaa ggcagaagca ctgtgtaaag aatatggaga aaccaaagga cctggaccaa 240 cagtcaaacc ttcaggacat cctgtttttt angaaacttg gaaaccttgt gaanaacacc 300 ctagaaaaat gccagagaga aaatggantt atttacnttg aaaaaanncc ancagacncc 360 ccncanccng aacttaaanc nccctcncgc tctcncagng cctanacnct tcgaatttct 420 cctacaannn gntanctgnn ncaccanacc cnnccgnang nntctgantn ctctnaanga 480 ccnnnngatn gncncnnccc nacnccctcn aattngtatc cncacttacc ccancncnct 540 ctnntntttt cactatgatn cccgncctac ntttttaaac cnccncctac nccaccttnc 600 ccacacanat ccnatcaccn cctntaccct tcntcaccta cnntantccn ccntnctcna 660 cntcnccnnt ccctnctcta natcaacccn cccgctnacc nctatcnccn ccnnttctnc 720 nnctccnnat ncnttcnctg cccccccccn nnacnccnnt ccttccntnc ccctgtcccc 780 nccctcncct cncctacttt ccntccntac ccccntccnn cnccccncnt ccatncnttn 840 caactatntc antanttcna ccaccctnnc tncctcccnc tncnacnccc ctccctcntc 900 accnanccca nccanttcnn cgantcntct ntctcntccc ctcacccctt ntccttctcc 960 ttntnctnnc tntcntccag tcatctcccc accccaccca gacncccnca tccccatccn 1020 cncctctctc cccnacccac ccct 1044 <210> SEQ ID NO 20 <211> LENGTH: 987 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 1, 5, 7, 12, 13, 14, 15, 26, 39, 52, 87, 120, 121, 122, 123, 124, 125, 128, 130, 132, 133, 137, 141, 151, 152, 154, 160, 167, 174, 182, 184, 187, 189, 190, 192, 198, 200, 205, 219, 220, 221, 222, 225, 231, 233, 237, 238, 242, 246 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 250, 251, 252, 253, 259, 264, 266, 269, 271, 277, 278, 281, 298, 300, 301, 304, 305, 308, 309, 315, 322, 324, 329, 334, 346, 347, 349, 351, 356, 358, 359, 364, 365, 375, 376, 377, 384, 392, 395, 405, 428, 432, 442, 446, 449, 454, 461 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 462, 464, 473, 479, 484, 485, 488, 491, 503, 512, 518, 539, 540, 543, 544, 555, 556, 561, 565, 569, 573, 575, 577, 578, 579, 580, 582, 584, 589, 591, 600, 602, 614, 616, 621, 636, 649, 650, 663, 665, 670, 678, 684, 694, 705, 709, 711 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 712, 717, 718, 720, 723, 734, 737, 755, 756, 760, 762, 764, 765, 773, 785, 789, 797, 798, 799, 800, 804, 807, 822, 823, 825, 826, 830, 831, 837, 848, 852, 868, 875, 887, 893, 904, 907, 908, 911, 932, 939, 946, 954, 962, 971, 974, 976 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 978, 980, 981 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 20 ncccntnctc tnnnncctgc tcgagnggcc gccatgtgnc gggatatctg cngcaattcg 60 gcttaagcag tggtaacaac gcagagnact tttttttttt tttttttttt ttttgggggn 120 nnnnnccngn cnncctnggg nttttggggg nnanaaaagn cccccanggt tttnggggcc 180 cncngancnn tngggggngn aaatncaaag ggtttgggnn nnccnaaccc ntntttnntt 240 tngggncccn nnngggggnt tttngnggna ntttttnnaa ngaaaaaaac cccttttncn 300 ntcnnccnnt tttcnggggg gntntcaana gggnttccaa gctccnnana naccanannc 360 cctnncggtt ccccnnnggc cccncctcct tnggnttttc catcnttctt tacccccgtt 420 tccccccncc cncacacctc tnttgntcnt ggcncaaaac nntntttgct tcncccctnt 480 tttnnccncc nccctattcc ctnccccccc cntttccncc cccttgcggc ccctctttnn 540 ctnnctccct cctcnncccc ncgcntccnc tcncntnnnn cncnccccnc nccccccccn 600 cnacctcccc cccncncccc nccccccccc ctcccntccc ccccccccnn cccccccccc 660 ccncntcccn ccccaccncc cccnccccct ctcncctcat ccccncccnc nnccctnncn 720 ccncccctcc cctnctncta ctcccccccc tcccnncccn cncnncctcc ctntcctccc 780 ctccncccnc ctcctcnnnn ctcnccnccc ccccctcccc cnncnntccn ncccccntcc 840 cactcctncc tncccccccc cttccccnct cctcncgccc ccacccnctc ctnctccccc 900 cctnccnncc nccccctccc cctctctatc tntctctcnc cccccnccct cccnactccc 960 anccccctct ntcncncncn nctccct 987 <210> SEQ ID NO 21 <211> LENGTH: 1038 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 2, 3, 5, 18, 29, 44, 53, 76, 92, 94, 95, 113, 124, 183, 210, 230, 232, 253, 311, 316, 325, 327, 336, 357, 363, 387, 399, 405, 409, 413, 417, 421, 430, 436, 441, 444, 460, 466, 477, 492, 495, 496, 501, 504, 508, 509, 517, 523, 525 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 533, 534, 537, 544, 549, 554, 558, 568, 570, 572, 573, 582, 586, 600, 603, 606, 611, 613, 627, 631, 636, 640, 648, 653, 655, 659, 672, 678, 682, 689, 692, 693, 695, 698, 699, 705, 706, 711, 712, 713, 714, 724, 733, 742, 751, 753, 754 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 765, 766, 772, 780, 782, 787, 792, 797, 814, 815, 816, 821, 827, 831, 837, 838, 840, 841, 856, 858, 879, 880, 889, 892, 899, 903, 910, 914, 925, 926, 927, 933, 940, 943, 947, 949, 964, 974, 975, 978, 986, 987, 1001, 1012, 1017, 1027 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1029, 1032 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 21 anncnccctt tttaaacncc ttttaaaant ccacacaatt ttcnctaaac tanccatcaa 60 gcttggaacc gagctnggat ttcactagta antnncgcca gtgtgctgga atncggctcc 120 ttgnagatgt gttggtacac agcttatgct tactggtacc atggtgagac tttattggct 180 agngataaat gcggtgaagc aatcaggtcn ctccaagaag cagaaaaatn gnatgcaaag 240 gcagaagcac tgngtaaaga atatggagaa accaaaggac ctggaccaac agccaaacct 300 tcaggacatc ngttcnttag gaaantngga aacctngtga agaacaccct agaaaancgt 360 canagagaaa atggatttat ttacttncaa aaactccanc agaancctna canctgnaac 420 ncaaagaacn ccatgntctc ntancgccct atacgtctcn aacttntttt tacaagngtt 480 cagcggacac tnccnncatt nccncctnnt gaccctnacc canangacct ccnnccngac 540 agtnctaanc ccanatcnat gacctaanan gnncacatcc cncgtncagc acccctgacn 600 tcntanaccc ncntagggac actagcngct nctccncccn cctaacanca ccntnttcnc 660 tcctcacact tnacctcnag cnacgcccnc anncntanna ttccnncccc nnnncctctt 720 accntctctc ctngcccctc cnccccccca ntnntccctc ccccnntctc ancttcaccn 780 cncttcnttc cncttcncta ttccccacat cttnnncccc ncacccnccc nctcatnncn 840 ncctctacct tcagancnac ctccccatcc ctcccacann ctccccccnt anccctccnc 900 ttnccccccn tcancccccc ccccnnnctt ctncggcttn tcnacancnc tacttccccc 960 cttnttcatc cccnnccnct cctaanntcc cccacccccc ntcccccccc cnccttnccc 1020 tcctctncnt tntcccct 1038 <210> SEQ ID NO 22 <211> LENGTH: 1048 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 11, 15, 16, 23, 25, 38, 40, 41, 45, 73, 91, 102, 144, 145, 155, 157, 158, 162, 165, 167, 169, 176, 177, 180, 184, 190, 193, 197, 200, 206, 207, 209, 210, 214, 215, 216, 218, 219, 220, 231, 232, 233, 237, 239, 240, 249, 251, 253, 258 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 259, 266, 267, 271, 272, 276, 278, 280, 281, 283, 291, 292, 302, 303, 304, 310, 311, 314, 315, 318, 323, 328, 330, 337, 344, 346, 347, 351, 353, 356, 359, 367, 376, 378, 380, 395, 397, 406, 413, 417, 419, 420, 421, 432, 439, 442, 444 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 453, 454, 457, 463, 464, 465, 471, 472, 474, 475, 476, 477, 487, 490, 497, 500, 501, 505, 513, 514, 520, 524, 526, 529, 531, 534, 536, 538, 540, 546, 552, 556, 572, 573, 579, 580, 581, 583, 586, 590, 591, 594, 605, 611, 612, 615, 623 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 624, 626, 648, 655, 677, 678, 679, 684, 688, 692, 695, 697, 700, 705, 707, 710, 711, 714, 716, 723, 725, 726, 733, 740, 742, 744, 750, 757, 763, 767, 771, 772, 781, 787, 792, 799, 805, 807, 808, 811, 812, 818, 820, 824, 833, 835, 839 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 846, 852, 853, 855, 858, 860, 863, 864, 869, 871, 872, 877, 884, 887, 888, 890, 892, 893, 894, 905, 907, 930, 937, 947, 948, 951, 954, 958, 961, 972, 974, 975, 978, 983, 991, 992, 997, 999, 1001, 1020, 1027, 1039 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 22 cccccttttt naaanncctt ctntnttcca tgctcgtntn nccgncatgt gccggatatc 60 tgcagaattc ggnttctaat acgactcact ntagggcaag cngtggtaac aacgcagagt 120 actttttttt tttttttttt tttnnggggg ggggngnntc cnttngngnc ccaggnnggn 180 gggnaaaaan ccntttnaan aaaaanntnn tttnnnannn ttaaaaaaaa nnntttngnn 240 aaaaaaaanc ngnaattnng gggttnnttt nnttancngn nanaaaaatt nnaaggccag 300 gnnntttttn nggnnatnta gcncccangn ccttttnggg gttngnngcc ngntcnttnc 360 aaggttncac tttttntncn ggttggggct aacancngca attttngggc tcntccngnn 420 naaaaaaaac cnccccccna angnctttgg ggnnccntta cannncttgg nngnnnnaca 480 ctcccangcn tttcacnccn ncccnacccc cannccttcn cttncnctnc nctncntngn 540 ggctcnttgt cnggancttt tccacaatct cnnaaaccnn ntnttntgtn ntancctctt 600 catcncagcc nntcnctccc ccnntnctcc ccacccctcc accaaaancc ctccnctcct 660 tcaccttctc ccttctnnnc aatntccncc cncangntcn ctccnanccn ntcncnccac 720 ctntnntccc ccnctcaacn cncncttttn tcctccntca cgnacanccc nncttcttcc 780 ncccctntcc cncctctcnc ccccncnntc nntccttncn tacnccccct ctncncccnc 840 ctctcntctt cnnancancn ccnntccant nnccctnctc tctnccnncn tnnncgccat 900 ctccntncct tcacccctcc tccttccgcn ccctcanctt acacctnnct ntcncccntc 960 ncacctccca cncnnctncc acncgcccca nnactcncna nttcatccca ctactcagcn 1020 cctctcnccc acactctcnt tcttccct 1048 <210> SEQ ID NO 23 <211> LENGTH: 1033 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 9, 21, 25, 28, 35, 37, 47, 57, 63, 66, 76, 93, 95, 103, 115, 145, 183, 347, 447, 602, 604, 630, 634, 639, 648, 680, 681, 685, 732, 744, 745, 766, 780, 786, 804, 815, 818, 821, 823, 825, 826, 839, 846, 850, 852, 860, 869, 875, 882 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 894, 898, 902, 905, 906, 924, 927, 943, 952, 955, 957, 959, 964, 986, 989, 1029 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 23 ttntaaaanc ccttttaaaa ncctnttnaa aacancngca cctggtntca acagggnaaa 60 ccnttnagga catttnttct ttaggtaaac ttntnaaacc ttntttaaga acacnctaga 120 aaaatgtcag agagggggat ggttngattt actttaaaaa aattccaaca gaagccccac 180 agntggaacc tcaaaacaaa ttatggtctc gtagagccta tacctttcga atttcctcct 240 acaagtgttc agtggacacc agaaacattg gctgcatttg atctcaccaa aagacccaag 300 gatgacagta ctaaacccaa aaaaaaaaaa aaaaaaaaaa aaaaggncct ctgcgttgtt 360 accactgctt aagccgaatt ctgcagatat ccatcacact ggcggccgct cgagcatgca 420 tctagagggc ccaattcgcc ctatagngag tcgtattaca attcactggc cgtcgtttta 480 caacgtcgtg actgggaaaa ccctggcgtt acccaactta atcgccttgc agcacatccc 540 cctttcgcca gctggcgtaa tagcgaagag gcccgcaccg atcgcccttc ccaacagttg 600 cncngcctga atggcgaatg gacgcccccn gtancggcnc attaagcncg gcgggtgtgg 660 tggttacccc agcgtgaccn ntacncttgc cagcgcccta gcgccccgct ccttttcggt 720 tttcttccct tnctttcccg cccnngttcg ccgggttttc cccgtnaagg cttttaaaan 780 cggggncccc cttttagggg ttcncattta atggnttnac ngngnncctt cgacccccna 840 aaaaantttn anttaggggn ggatggctnc accgnaagcg gncccatcgc cccngganag 900 ancgnntttt tcgccctttg gacnctngga gtcccccgtt ttnttaatag gnggncntnt 960 gttnccaact gggaccaaca ctttanacnc ttttttgggc ctattttttt tggatttaaa 1020 aagggattnt ccc 1033 <210> SEQ ID NO 24 <211> LENGTH: 1023 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 8, 9, 15, 25, 26, 32, 35, 37, 51, 52, 64, 88, 92, 99, 101, 102, 110, 120, 130, 139, 143, 144, 146, 166, 171, 190, 227, 269, 286, 321, 340, 369, 382, 407, 533, 579, 591, 635, 662, 668, 684, 692, 709, 713, 728, 731, 766, 773, 774 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 776, 778, 793, 794, 800, 809, 818, 828, 829, 830, 832, 834, 844, 860, 894, 915, 917, 922, 932, 935, 952, 955, 971, 981, 995, 999, 1001, 1002, 1007, 1015 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 24 ttntaaannc ccttntaaaa ccctnntgaa anacncnaca aaaagttagc nnggaaaagg 60 cttnatttac tttcaaaaaa ttccaacngt angccccant nntggaactn aaaacaaatn 120 atggtctcgn ggagccttng ccnntngaat ttcctcctac aagcgntcag nggacaccag 180 aaacattggn tgcatttgat ctcaccaaaa gacccaagga tgacagnact aaacccaaaa 240 aaaaaaaaaa aaaaaaaaaa aaggtcctnt gcgttgttac cactgnttaa gccgaattct 300 gcagatatcc atcacactgg nggccgctcg agcatgcatn tagagggccc aattcgccct 360 atagtgagng gtattacaat tnactggccg ccgttttaca acgtcgngac tgggaaaacc 420 ctggcgttac ccaacttaat cgccttgcag cacatccccc tttcgccagc tggcgtaata 480 gcgaagaggc ccgcaccgat cgcccttccc aacagttgcg cagcctgaat ggngaatgga 540 cgcgccctgt agcggcccat taagcgcggc gggtgtggng gttaccccag ngtgaccgtt 600 acacttgcca gcgccctagc gcccgctcct ttcgntttct tcccttcctt tctcgcccgt 660 tngccggntt tccccgtcaa gctnctaaat cnggggttcc ctttagggnt ccnatttagg 720 gctttccngc nccctgcacc cccaaaaaac ttgattaggg tgaatngttc acnnangngg 780 cccattgccc ctnntagacn gttttttcnc ccctttgncc cttgggcnnn cncntttctt 840 taanagctgg acctctttcn ttccccaaac ttggaaccac acccttaacc cttntttggg 900 gtctattttt tttgnantta tnaaggggga cnttnccccg ctttcggccc tnttngggtt 960 aaaaaaccgc ncctgccttc nacccaaaaa tcttncacnc nnttttnaac aaaanttccg 1020 ccc 1023 <210> SEQ ID NO 25 <211> LENGTH: 1031 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 4, 10, 18, 26, 38, 48, 52, 55, 56, 66, 72, 74, 102, 112, 132, 133, 134, 139, 140, 477, 540, 569, 585, 589, 593, 605, 624, 664, 666, 682, 688, 697, 708, 722, 733, 740, 741, 744, 745, 763, 793, 817, 844, 846, 858, 865, 870, 873, 877 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 878, 880, 881, 883, 884, 904, 909, 913, 920, 922, 927, 928, 949, 952, 966, 969, 981, 998, 1001, 1003, 1023, 1028 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 25 tccntaaaan cccttttnaa aacccnttac ccaggttnca acagacantc cntgnnggac 60 atctgntctt tngntaaact tggtaaacct tgtgcaagaa cntcctagaa anttgtcaga 120 gagaaaatgg annnatttnn tttcaaaaaa ttccaacaga agccccacag ctggaactca 180 aagcacatta tggtctcgta gagcctatac ctttcgaatt tcctcctaca agtgttcagt 240 ggacaccaga aacattggct gcatttgatc tcaccaaaag acccaaggat gacagtacta 300 aacccaaacc agaagaagaa gtgaaacctg tgaaagaacc agacatcaaa cctcaaaagg 360 acactgggtg ctacatctcc taaaatacaa cttgcactta gaatttctct agcagtaaat 420 aagataaacc acagaatttc agttcttatt tctcaaaatg atttctctga agctcgnaga 480 ataactatta tattcagagg gttatctgca ctccagcctg ggcaacagag ggagactccn 540 cctcagaaaa aaaaaaaaaa aaaaaaaang tcctctgcgt tgttncccnc tgnttgccct 600 atagngagtc gtattagaag cccnatttct gcagatatcc atcacactgg cggccgctcg 660 agcntncatc tagaggggcc cnaatttncc cttatangtg agtcggtnta ccaattccct 720 gnccgtccct ttnccaccgn ncgnngactg gggaaaaccc ttngccttcc ccaacttaat 780 cggcttcgca gcncatcccc ctttccccag gtggccntaa tagccgaaga ggctccgccc 840 cgancngcct ttcccaanag tttcnccacn ctncacnncn nannggaccc cccccctgtt 900 acgnccccnt tanccccggn gnggtgnngg tgggtttcct cgccaacgng anccgcttaa 960 ccttgnccng cggccctagc ngcccccctc tcttcccntt ntnttcccct cctttcttcg 1020 gcncacgncc c 1031 <210> SEQ ID NO 26 <211> LENGTH: 1032 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 4, 7, 12, 21, 35, 37, 41, 48, 52, 53, 56, 57, 64, 71, 75, 78, 84, 95, 96, 97, 102, 115, 123, 137, 138, 141, 142, 151, 178, 203, 231, 232, 233, 237, 238, 245, 248, 249, 295, 296, 304, 323, 327, 333, 339, 358, 376, 382, 384, 394 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 397, 431, 432, 462, 472, 476, 478, 479, 482, 490, 498, 518, 523, 524, 527, 544, 548, 560, 563, 585, 590, 592, 604, 605, 612, 615, 619, 620, 642, 643, 653, 657, 666, 678, 681, 686, 687, 691, 692, 694, 699, 702, 709, 711, 727, 735, 736 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 738, 739, 741, 744, 750, 751, 765, 770, 780, 783, 797, 804, 805, 814, 828, 835, 837, 843, 845, 852, 855, 858, 865, 869, 870, 872, 873, 881, 885, 887, 890, 891, 906, 908, 923, 930, 936, 942, 943, 944, 945, 946, 948, 950, 955, 956, 963 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 968, 969, 971, 973, 977, 979, 982, 997, 998, 1003, 1005, 1008, 1011, 1015, 1023, 1028 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 26 ttnnaancct tntaaaaccc nctcaaaagt ccggngnaaa ntggcccnat tnnccnngaa 60 aaantttcaa nagtnttncc catnccgggc aactnnnaga antttatggc cccgnagagc 120 ctngggcttt gggattnntt nntacaagtg ntcaacggac accagaaaca ttggtccnca 180 tttgatctca ccaaaagacc canggatgac agtactaaac ccaaaccaga nnnaganntg 240 aaacntgnna aagaaccaga catcaaacct caaaaggaca ctgggctgct acatnnccta 300 aaanacaact tgcacttaga atntctntag cantaaacna gataaaccac agaatttnag 360 ccttatttct caaaangatt tntntgaagc ttgnccnaat aactattata tttagagggt 420 tatctgcact nnagcctggg caacagaggg agacttcacc tnagaacaaa anaaananna 480 angcacaagn cccctgcnct gttaccactg gttgcccnat agnnagncga attagaagcc 540 tcanttcngc agatatccan ccncctggcc ggccgcttga gcctncctcn cntaggcccc 600 aaannccccc tntanggann cgcatttcca attaactggg cnncgcttta canaccngcg 660 acactnggga aaaacctntg nccgcnnccc nncnctaana cngccttgnc ncccattccc 720 ccttccncca ggctnncnna natncacctn naaagccccc ccacnctctn gcttttcccn 780 canttctccc ccccctnaac cctnnctcgc atcncccttt ctttatcncc ccttnanccc 840 cgngncccca angtngtnta acccnggcnn cnnttcgttc nattntnccn nagcccctaa 900 cgcccncnac cctatccaat ttnttcacan tccttnttcg annnnncngn ccctnntccc 960 ccntctanna ncnaacnanc cnggcccttc ctcacgnncc ccncnctnaa ngccnttacc 1020 ccnccccncc tt 1032 <210> SEQ ID NO 27 <211> LENGTH: 993 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 4, 34, 55, 56, 64, 77, 95, 100, 102, 117, 124, 125, 137, 158, 164, 166, 167, 203, 205, 215, 236, 240, 341, 372, 418, 426, 482, 500, 558, 572, 630, 644, 709, 714, 747, 749, 765, 771, 778, 787, 788, 794, 804, 809, 813, 831, 835, 849 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 850, 866, 877, 878, 880, 894, 899, 900, 906, 907, 908, 911, 915, 919, 921, 927, 933, 939, 940, 958, 963, 967, 968, 970, 971, 976, 977, 983, 987, 989, 991 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 27 tttngaaaac ctcctttgga aacctcctcc aaanatccta cactatttta atccnnaagc 60 tccnccatca agccttngta ccgatctcgg atccnctagn anttgttcgc cagtgtnctg 120 gaanntcggc ttaactngct ttcttgggga gatccatnca aagnanntat gaaacctata 180 gaaaagtaca agacatttta gcntntagaa gaatnagaag aaatattgag tgttcngttn 240 ggaaaaattt tcagattact tttccaggtg tctgaatgaa acttcttgct ctcttccaaa 300 gaatacagtc tggaagagta aactaatcaa atttgaaaag ncaaagaatt aaatgtaaac 360 ttttagacag tnttttaaaa aacctcaagt tcatataaat aactaacctt gtaaaagnga 420 gaaatntgaa tctgctgcat tcttcatcat ttctggatta cagctcaaat cagtgaacag 480 tncaaggagt cgtgccctgn atgacctcaa gtcacttata acagatacaa aaagacagta 540 aagttagctg cactgcantc aatctacata anagtggctt ccaggtttca atgtcaaagc 600 tttaaaacac accacataca cacacgcacn aggtttcaat gtanaagctc taaaccacac 660 acacccatgc acacgcctac cttcctctaa gggattaaca acatggaant taancaggga 720 ctaaaatcta gcgaacaaaa cttctantna cctgtttcaa aagcnttcta nctaaacnaa 780 ccctcanncc aacnaaaagg ggcnaatanc ggnattccaa ttccataatt naaantatct 840 cgtccatgnn tttactctaa aaacantcaa ccaacanncn tgcccctcaa acantgtgnn 900 ggcaannnaa ngaancaana nccctanccc ctncccccnn tttcggctcc tcgaaaanaa 960 gcnaaanntn ncctgnnccc ccntctnana nct 993 <210> SEQ ID NO 28 <211> LENGTH: 955 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 15, 28, 31, 34, 41, 43, 55, 61, 69, 70, 78, 87, 89, 95, 97, 106, 108, 129, 161, 175, 373, 432, 433, 566, 638, 641, 723, 740, 744, 759, 764, 794, 795, 799, 801, 809, 821, 827, 835, 841, 843, 857, 876, 877, 887, 892, 896, 900, 906 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 914, 917, 923, 924, 927, 930, 948, 951, 953 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 28 ttgaccncct tttanaacct ttcctaangc nctntgctcg ntnggccgcc agtgncatgg 60 ntatctgtnn caattcgnct tgtaatncna ctcantntag ggcacncntg gtcgacggcc 120 cgggctggnc tgtttgtaat tggcaataca tacatacttt nttggaataa gcctncttag 180 agttagtact aatcaataag actcaaggga tataccattc aggattaagt ctgtgctctc 240 ttctaaacat cactgctacc ttatagtcta aatctcaaaa gaaaatattt gaaaagttat 300 tctttatcca ctcaacaagt aattttgcat atgtgcttta tcctaggcac ctaccaaatt 360 ctggatatac agnctctact ctcttggtgc ttaccattta aatttagtct ttctttaatg 420 gtttacacat anntcaaggg tctttggcca tacccatgta ttgtaatttc ggaagcctca 480 ctaagctaat tgccttctgg attcgatttg gaactggaat agaaccaagt gaaagctaat 540 gatggagatc taggaattga tatagntgaa gctatactaa taggtgagat ctcaaaagag 600 agaaaaccag aaagccaaag actgaacatt tttggagntg ngaatgaaaa ggagacacag 660 aaaaaaatat aaaaggaact taaaagagac aaggggagca cctggaaaat ttagtggtat 720 tgnaatcaaa ggagaaaatn cttncaagaa ggaaaaggnt gganctataa catttatcgc 780 tatagagaag taannggana ntgtagatna gggagcagtt ncaaaancaa ctgcnggccc 840 ncntttcaca cattctngga tggatatggc cgaatnncct gtcaagnata tntaangcan 900 attcantttc tttnaantat tcnnatnccn cctatttttc aacccttntc ngnct 955 <210> SEQ ID NO 29 <211> LENGTH: 1064 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 5, 6, 16, 21, 24, 25, 33, 39, 72, 110, 209, 214, 231, 232, 235, 237, 238, 244, 245, 246, 256, 282, 292, 297, 306, 319, 321, 323, 330, 334, 340, 349, 354, 355, 363, 372, 376, 378, 397, 405, 432, 437, 454, 455, 457, 458, 459, 468, 470 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 485, 487, 488, 494, 496, 499, 511, 524, 527, 552, 557, 562, 583, 600, 611, 613, 623, 624, 652, 654, 674, 681, 687, 691, 694, 701, 713, 716, 720, 721, 725, 731, 734, 735, 739, 743, 744, 781, 782, 785, 789, 799, 803, 821, 823, 847, 852 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 858, 878, 884, 886, 896, 897, 901, 917, 926, 932, 939, 948, 957, 961, 965, 981, 991, 993, 1001, 1002, 1005, 1011, 1018, 1043, 1047, 1049, 1051, 1054, 1056 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 29 ttttnncccc ctttanaaac ncannttcaa ganccaaang gtggtatcta taacatttat 60 tgctatagga gnaagtaaag gagaatgtag attagggagc agttttattn acaactgatg 120 gccacgtttt acatattctt gatgcatatg ttgaattaca tgtcaaggat atgtaatgta 180 atttcatttt ttaaatattt ttacgcagna tatnttcaca ttttcgcgtt nnatntnngg 240 cgannnaccc cccagnggct ttagaggtga tgacgcaccc tncttcccca cntcccnctc 300 acttcnttcc cgctcccgnt ncnccccctn atcncccctn ccccctccnt cccnncctcc 360 aantcctccc cnctcntnac tccccccccc ctccccnccc ctccnacccc cctccccccc 420 ccccctcccc tnccccnccc ccccccctcc cccnncnnnc ccccctcncn tccccccccc 480 ccccncnncc ctcncnctnc tctccccccc ncccctcccc cccnccnccc cccccccctc 540 ctaccccctc cnccccnccc cncccaaccc cccccccccc tcntctcccc tccctccccn 600 tccccccctc ncnccccccc ccnntccccc tccctccccc cccccccccc cncncccccc 660 tccctccccc cccnccctcc ncccccncct ntcncccccc nccccctcac ctnccncccn 720 nctcnccctc nccnncccnc ccnncttccc ccccctaccc cccccttccc ctcccccccc 780 nnccncccnt ccccccccnc ccnccccccc cctccccccc ncnccccctt ctccctcccc 840 ccttccnccc cntccccnct cctcctccac ctcccccnct cctncnccct cccccnncct 900 ntccctcccc ctctctntcc cccccncccc cncctcccnc ctcccccntc tttcccnccc 960 ntccnccttc tccccccccc ncccctcccc ncnctccctc nnccncctcc nctccccnct 1020 cctccccccc cccccacacc ccnctcncnc nacncnctcc cccc 1064 <210> SEQ ID NO 30 <211> LENGTH: 1058 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 9, 88, 462, 505, 531, 582, 586, 607, 624, 658, 679, 680, 687, 700, 702, 707, 719, 724, 730, 736, 737, 742, 747, 748, 756, 761, 764, 765, 767, 768, 769, 775, 776, 779, 781, 782, 785, 787, 788, 792, 793, 794, 796, 799, 800, 807, 817 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 818, 819, 821, 822, 823, 828, 829, 830, 832, 837, 838, 849, 850, 851, 853, 855, 856, 860, 861, 862, 863, 864, 871, 872, 873, 879, 881, 883, 886, 888, 891, 892, 893, 896, 900, 903, 904, 905, 906, 909, 913, 914, 916, 919, 921, 925, 929 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 930, 931, 950, 951, 954, 957, 963, 965, 966, 967, 968, 969, 973, 980, 981, 984, 988, 990, 991, 994, 996, 998, 999, 1001, 1006, 1008, 1009, 1010, 1017, 1020, 1021, 1023, 1024, 1025, 1027, 1031, 1034, 1035, 1039, 1042, 1043, 1044, 1045 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1046, 1058 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 30 ttttaancnt ttttcagtcc ttatagcgct acaaaaggca gtaaagttag ctgtactgca 60 atcaatctac ataaaagtgg cttccagntt tcaatgtaaa agctttaaaa cacacacaca 120 tacacacacg caccaggttt caatgtaaaa gctttaaaac acacacacgc atgcacatgc 180 ctacctcctc taagggatta acaaatgaat ttaatcagga ctaaatctag agaaaaaatt 240 tctaataact gttttaaaag ttgtagtaaa ataaactcag accaattaaa ggggcaaata 300 atgaattcaa ttacataata aaaatatatg tcaagtttta attaaaaaca atcaaacaaa 360 tgcatgcact taagatgtgg ggaaagaaga ataaaaaact aagcagttca caataagttt 420 cttgaaaaat gaaaatttat ctgtgtatca ttttaatatc tncttgaagt ttctaaacct 480 gacataaaac acaaaaatgt gaaantatac tgcataaaaa tatttaaaaa ntgaaattac 540 attacatatc cttgacatgt aattcaacat atacatcaag antatntaaa acgtggccat 600 cagttgnttt aaaactgctc ctantctaca ttcttctttt ctttctctat agcaatanat 660 gttattggat tcccctttnn cttcttngaa aatattttcn cntttgnttt ccaataacnc 720 taanattttn cacggnncct cnccttnncc tttttnaagt ntcnntnnnt ttttnntcng 780 nnccncnntt cnnntnccnn ccccccnatt tttcctnnnc nnnccttnnn cnttctnncc 840 tcttccccnn ntncnncctn nnnnttcttc nnncccttnt ncnctncntc nnntcncctn 900 tcnnnntcnt tcnncntcnt ntttncctnn nttccctccc cttctcctcn ntcnttnatt 960 tcntnnnnnt tcnctccccn nttntctntn nttncncnnt nccccntnnn cccttantcn 1020 ntnnntnttc ntcnncctnt cnnnnnctct cccccccn 1058 <210> SEQ ID NO 31 <211> LENGTH: 971 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 4, 7, 25, 48, 50, 70, 86, 87, 88, 95, 98, 125, 132, 134, 219, 253, 523, 619, 668, 717, 750, 752, 771, 782, 804, 806, 811, 815, 840, 848, 849, 851, 854, 896, 917, 920, 941, 944, 950, 957, 962, 963, 968, 969 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 31 ttgnacnccc tttttatacc attcnacact atcttaatac tcattctncn catcaacctt 60 ggtaccgatn tcggatccac tagtannngc cgccngtntg ctggaattcg gcttaacttg 120 ctttnttggg tngnttcatc caaagaattt atgaaaccta tagaaaagta caagacattt 180 tagttttaga agaattagaa gaaatattga gtgctctgnt tggaaaaatt ttcagattac 240 ttttccaggt gtntgaatgg aacttcttgc tcttttccaa agaatacagt ctggaagagt 300 aaactaatca aatttgaaaa gtcaaagaat taaatgtaaa cttttagaca gttttttaaa 360 aaacctcaag ttcatataaa taactaacct tgtaaaagtg agaaatatga atctgctgca 420 ttcttcatca tttctggatt acagctcaaa tcagtgaaca gttcaaggag tcgtgccctg 480 gatgacctca agtcacttat aagagataca aaaagacagt aangttagct gtactgcaat 540 caatctacat aaaagtggct tccaggtttc aatgtaaaag ctttaaaaca cacacacata 600 cacacacgca ccaggtttna acgtaaaagc tttaaaacac acacacgcat gcacatgcct 660 acctcctnta agggattaac caaatgaatt taatcaggac taaatctaga gaaaaanttt 720 ctaataactg gttttaaaag gttgcgtaan antaaaccca gccccaatta naagggggcc 780 anataactga attcactcca taantnaaaa ntttnatgtc aaggttttaa ttaaaaccan 840 tcaaaacnna ngcntgcccc ttaagaatgg ggggaaagga agaataacaa aacctnagcc 900 cgttcccaat aagcttnttn gaaaaatgga aaatttatcc ntgnggttcn atttttnaca 960 annccctnnc t 971 <210> SEQ ID NO 32 <211> LENGTH: 950 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 12, 13, 14, 29, 41, 44, 50, 63, 64, 80, 91, 98, 99, 122, 154, 160, 189, 191, 197, 204, 205, 207, 216, 219, 310, 324, 342, 345, 394, 409, 433, 444, 654, 670, 685, 739, 741, 745, 774, 793, 800, 813, 814, 825, 843, 844, 849, 850, 862 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 882, 891, 892, 906, 909, 937, 939, 940, 944, 946 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 32 acnccttttt cnnncttcca tgctcgctng gccgacttgt ncangggatn tctgcagaac 60 cgnnttgtaa tacgactcan tatagggctc ncgtggtnna cggcccgggc tggtctgttt 120 gnaattggta atacatacat actttcttgg aatnagcctn cttagagtta gtactaatca 180 ataagactna ngggatntac catnnangat caagtntgng ctctcttata aacatcactg 240 ctaccttata gtctaaatct caaaagaaaa tatttgaaaa gttattcttt ttccactcaa 300 caagtaattn tgaatatgtg cttnatccta ggcacctacc anatnctgga tatacagcct 360 ctactctctt ggtgcttacc atttaaattt agtntttctt taatggttna cacatattcc 420 aagggtcttt ggncataccc atgnattgta atttcggaag cctcactaag ctaattgcct 480 tctggattcg atttggaact ggaatagaac caagtgaaag ctaatgatgg agatctagga 540 attgatatag ttgaagctat actaataggt gagatctcaa aggagagaaa accagaaagc 600 caaagactga acatttctgg agttgggaat gaaaaggaga cacagaaaaa aatntaaatg 660 gaacttaaan gagacaaggg gagcncctgg aaaattagtg ttattggaat caaaggagaa 720 aataatttca agaaggaana ngggnaccta taacatttat tgctctcgag aagnaaagga 780 gactcccgat tanggagcan ttttaaaaca acnngatggc cacgntccac atattcttga 840 ggnnatggnn gcaattacca tngtccaagg gttacgcccc cntaactttc nnttttttta 900 aattanttnt aatgcagtta tattcctcac attttcncnn tttnanggct 950 <210> SEQ ID NO 33 <211> LENGTH: 1065 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 14, 21, 27, 33, 36, 42, 72, 101, 103, 207, 208, 221, 223, 227, 235, 240, 242, 243, 247, 248, 259, 263, 269, 273, 278, 296, 321, 322, 324, 330, 332, 335, 336, 340, 367, 371, 385, 390, 393, 399, 401, 407, 415, 421, 447, 454, 471, 475 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 479, 494, 501, 508, 511, 513, 525, 539, 540, 579, 596, 605, 623, 624, 633, 653, 654, 656, 658, 664, 670, 679, 711, 713, 721, 729, 735, 743, 747, 748, 754, 776, 778, 779, 780, 783, 798, 802, 808, 810, 813, 814, 820, 822, 824, 825, 838 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 842, 847, 888, 900, 909, 910, 916, 926, 927, 943, 948, 962, 973, 1002, 1005, 1028, 1029, 1034, 1057, 1065 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 33 cccccctttt aaancccttt naaatanctt cangangtaa angtggatct ataacattta 60 ttgctataga gnaagtaaag gagcaatgta gattagggag ntnttttaaa acaactgatg 120 gccacgtttt acatattctt gatgtatatg ttgaattaca tgtcaaggat atgtaatgta 180 atttcatttt ttaaatattt ttatgcnnta tattctcaca ntnttgngtc ccatnccacn 240 tnnaccnnac tccaccgcnc ctntcccanc ccncacancc taaatttcca ctttcncacg 300 caactcactc cccccccccc nntncccccn tnccnncccn ccccccccac ctcctccccc 360 ccccccnctc ncccccctct cttcnccccn ccncctctnc nctcctnccc tcctnttcca 420 nccccccccc cccctccccc ccccctntct ctcncccccc cccctcccct ncccnctcnc 480 accccccttc cccntccccc ntccctcntc ncnccccccc ccccnccccc cctcctctnn 540 ctccctcccc cccccccctc ctctcccccc cctcccccnc cccccttccc cctccncccc 600 ccccnccccc cccccccccc tcnncccccc ccnacccccc cccccccccc ttnncncncc 660 ctcncccccn ccttcccanc cctcctccct ctcccccccc ctccccctcc ncnattcccc 720 nccttcccnc ccccnccccc ccncctnncc ctcncccttc tcccccctcc tccccncnnn 780 ccncccccct cccccccncc cncccttntn acnncccccn cncnnccccc cctcactncc 840 cnccccnccc ccccccctcc cccttccctt cccccctcca tcttctancc cccccccctn 900 ctcccctcnn cccccncccc cctccnntcc cccccccccc tcnctccncc ctcccccccc 960 anccccttcc ccntcccccc cccctctccc tccccctctc tnctntcctt ccccttcatc 1020 ccctccannc ttcncccctc cccctccctc tcccccnccc ccccn 1065 <210> SEQ ID NO 34 <211> LENGTH: 1079 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 11, 21, 28, 38, 40, 41, 91, 99, 531, 566, 582, 589, 590, 615, 616, 620, 624, 629, 637, 643, 653, 655, 659, 663, 667, 700, 702, 710, 720, 727, 734, 735, 743, 747, 748, 749, 759, 761, 768, 769, 773, 779, 781, 784, 787, 792, 793, 794 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 796, 808, 812, 818, 820, 821, 824, 830, 838, 839, 847, 850, 854, 863, 865, 866, 870, 891, 898, 900, 901, 902, 910, 913, 914, 930, 939, 944, 948, 953, 957, 960, 961, 963, 965, 966, 967, 971, 973, 978, 982, 988, 990, 998, 1000, 1002 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 1004, 1007, 1008, 1013, 1020, 1021, 1035, 1039, 1050, 1055, 1057, 1058, 1060, 1068, 1079 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 34 tcnctaaacc ntttaaacct nccctcantc cttatagngn nacaaaaggc agtaaagtta 60 gctgtactgc aatcaatcta cataaaagtg ntttccagnt ttcaatgtaa aagctttaaa 120 acacacacac atacacacac gcaccaggtt tcaacgtaaa agctttaaaa cacacacacg 180 catgcacatg cctacctcct ctaagggatt aacaaatgaa tttaatcagg actaaatcta 240 gagaaaaaat ttctaataac tgttttaaaa gttgtagtaa aataaactca gaccaattaa 300 aggggcaaat aatgaattca attacataat aaaaatatat gtcaagtttt aattaaaaac 360 aatcaaacaa atgcatgcac ttaagatgtg gggaaagaag aataaaaaac taagcagttc 420 acaataagtt tcttgaaaaa tgaaaattta tctgtgtatc attttaatat ctccttgaag 480 tttctaaatc tgacataaaa cacaaaaatg tgaaaatata ctgcataaaa ntatttacaa 540 aaatgaaatt cattacatat ccttgncatg taattcaaca tntacatcnn gcaatatgta 600 aaacgtggcc atcannttgn tttncactnc tccctantct acnttctccc ttncntctnt 660 atngcantac atgtattgat cccacctttt cctttcttgn anattatttn tttccttctn 720 tctccantca cctnnatctc ctncagnnnc ttccctttnt ntttttcnng ctncccccnt 780 ntcntcntcc cnnncntccc ttctcctncc cnccttcncn nctnttctcn ttttcccnnc 840 ttctttnctn ctcncctcct atncnncccn cccttctccc tccttcctcc nccttctncn 900 nntctctctn ctnntcttct tcctcttttn tctccctcnc cccnctcnct tcnctcntcn 960 ncntnnnttc ncnctccntt cncctccncn cctccccncn cntnttnntt ttnttcctcn 1020 ntcctcctct ccctntttnc ctttccttcn tctcncnntn cctcctcncc ctcctcccn 1079 <210> SEQ ID NO 35 <211> LENGTH: 1009 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 8, 29, 31, 33, 59, 78, 79, 87, 95, 96, 98, 105, 106, 127, 134, 135, 475, 734, 738, 739, 740, 773, 797, 806, 813, 822, 847, 848, 854, 857, 864, 878, 879, 880, 883, 898, 905, 918, 919, 927, 944, 947, 951, 956, 960, 963, 979, 984 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 987, 988, 990, 996, 1006 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 35 ttntaaancc cttttgaaac cctttctana nanccgacac tattttacac tcaagctcng 60 catcaagctt ggtaccgnnc tcggatncac tagtnncngc cgccnntgtg ctggaattcg 120 gcttttnagg tatnncaaat atgcttcaag actggctgga aaagaaaata taacagaaca 180 tgaagcaaaa gaagttcatc gaagcctaaa gattgcagct gggattttta aacatttaaa 240 ggaaagtcat ctcccaaaac tcattacacc tgcggaaaaa ggaagagatt tagagtcacg 300 actcatagaa gcatacgtta ttcaatgtca ggctgaagct caagaagtaa caattgctcg 360 agcaattgaa ctaaaacatg ctcctggact aattgctgca ctggcgtatg aaacagccaa 420 tttctatcaa aaagctgttt ggagcctgca tattctgcca aatggagaaa atatnttcac 480 ttgaagatgt gtttctacac agcttatgct tactgttacc atggtgagac tttattggct 540 agtgataaat gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt gtatgcaaag 600 gcagaagcac tgtgtaaaga atatggagaa accaaaggac ctggaccaac agtcaagccg 660 aattctgcag atatccatca cactggcggc cgctcgagca tgcatctaga gggcccaact 720 cgcccctata gtgngtcnnn ttacaattca ctggccctcg ttttacaccg tcntgacttg 780 gggaaaaccc ctggcgntac cccacntaaa tcngccttgc angcacatcc cccttttgcc 840 agctggnnca acanccnaag aggncccgca cccggatnnn ccnttccaaa cagttggncc 900 agccnggaat gggcgaanng gcccccnccc ctggaatcgg cgcnttnagc nccggngggn 960 gtnggtgggt ttccccccna acgnggnncn ctaccntttg gccagnccc 1009 <210> SEQ ID NO 36 <211> LENGTH: 987 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 6, 21, 22, 26, 29, 41, 57, 75, 94, 103, 124, 126, 131, 132, 139, 698, 728, 749, 764, 774, 803, 806, 808, 822, 838, 849, 861, 870, 873, 877, 888, 891, 895, 896, 936, 940, 942, 943, 944, 946, 970, 972, 979 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 36 ttaaanccct acgaaaaccc nntccnaang cccagctcgt ncggccgcca gtgccanggg 60 atatctgcag aattntgctt gactgttggt cctngtcctt tgntttctcc atattcttta 120 cacngngctt nngcctttnc atacaatttt tctgcttctt ggagagacct gattgcttca 180 ccgcatttat cactagccaa taaagtctca ccatggtaac agtaagcata agctgtgtag 240 aaacacatct tcaagtgaag atattttctc catttggcag aatatgcagg ctccaaacag 300 ctttttgata gaaattggct gtttcatacg ccagtgcagc aattagtcca ggagcatgtt 360 ttagttcaat tgctcgagca attgttactt cttgagcttc agcctgacat tgaataacgt 420 atgcttctat gagtcgtgac tctaaatctc ttcctttttc cgcaggtgta atgagttttg 480 ggagatgact ttcctttaaa tgtttaaaaa tcccagctgc aatctttagg cttcgatgaa 540 cttcttttgc ttcatcttct gttatatttt cttttccagc cagtcttgaa gcatatttgg 600 tatacctaaa aagccgaatt ccagcacact ggcggccgtt actagtggat ccgagctcgg 660 taccaagctt gatgcatagc ttgagtattc tatagtgnca cctaaatagc ttggcgtaat 720 catggtcnta gctggttcct gggtgaaant ggtatccctc acanttccac acancatacc 780 agccggaagc ataaagtgta aanccngngg tgcctaatga gngagccaac ctcaccanta 840 attggcgtng ggctcacctg ncccgctttn cangccngga aaccctgncg ngccnncctg 900 catttaatgg aatccgcccc ccccccgggg agaggncggn tnnncnttat tggccgctct 960 ttcccctttn cncccttant tgacccc 987 <210> SEQ ID NO 37 <211> LENGTH: 1010 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 8, 13, 15, 23, 30, 31, 38, 43, 48, 54, 70, 81, 83, 88, 90, 99, 108, 109, 128, 136, 143, 144, 149, 150, 151, 579, 630, 640, 684, 702, 788, 825, 833, 838, 841, 846, 847, 866, 872, 876, 891, 899, 907, 923, 927, 940, 952, 965, 972, 975 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 985, 998, 999, 1001 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 37 tcctaaancc tcntnaaacc ccntccgacn ngtccggncg acnttgcnca gggnatatcc 60 gcgggaattn tgctttttat ngnatacnan atatgcttna agcactgnnt ggaaaagaaa 120 atataacngg ggatgnggca aanntaagnn natcgaagcc taaagattgc agctgggatt 180 tctaaacatt taaaggaaag tcatctccca aaactcatta cacctgcgga aaaaggaaga 240 gatttagagt cacgactcat agaagcatac gttattcaat gtcaggctga agctcaagaa 300 gtaacaattg ctcgagcaat tgaactaaaa catgctcctg gactaattgc tgcactggcg 360 tatgaaacag ccaatttcta tcaaaaagct gatcatactt tatccagttt ggagcctgca 420 tattctgcca aatggagaaa atatcttcac gtgaagatgt gtttctacac agcttatgct 480 tactgttacc atggtgagac tttattggct agtgataaat gcggtgaagc aatcaggtct 540 ctccaagaag cagaaaaatt gtatgcaaag gcagaagcnc tgtgtaaaga atatggagaa 600 accaaaggac ctggaccaac agtcaagccn aattccagcn cactggcggc cgttactagt 660 gggatccgag ctcggtacca agcntggatg catagcttga gnattctata gtgtcaccta 720 aatagcttgg cgtaatcatg ggcatagctg tttcctgtgt gaaaatgttc tccccctcac 780 caattccnca caacatacga gcccggcaag cataaagtgt aaacncccgg ggntgccnta 840 ntgagnngag cctacctccc attaanttgc gntgcncctc acctgccccg ntttccagnc 900 cgggaanacc ctgtccgggc ccncttncat taaatggaan tcgccccccc cncggggagg 960 aggcngcttg cntantggcc gcttnttccg cttcctcnnc nctgactccc 1010 <210> SEQ ID NO 38 <211> LENGTH: 1014 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 9, 47, 66, 76, 83, 91, 94, 114, 124, 125, 129, 135, 136, 143, 148, 385, 388, 531, 552, 565, 627, 628, 645, 697, 698, 706, 715, 718, 723, 730, 739, 751, 769, 788, 803, 806, 809, 810, 811, 822, 827, 834, 841, 850, 855, 863, 869, 875 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 876, 881, 903, 908, 923, 928, 931, 936, 937, 942, 952, 953, 963, 979, 982, 984, 985, 990, 993, 1005, 1006 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 38 tcgcaaaanc ccccgaaacc ctcttacaaa attcaaacta attctcngca tcaagcttgg 60 taccgntctc ggatcnacta gtntcggccg nctntgtgct gtaattcggc tcgngcttct 120 gggnntgcnt gcaanntttc tgnttctngg agagacctga ttgcttcacc gcatcttatc 180 actagccaat aaagtctcac catggtaaca gtaagcataa gctgtgtaga aacacatctt 240 caagtgaaga tattttctcc atttggcaga atatgcaggc tccaaactgg ataaagtatg 300 atcagctttt tgatagaaat tggctgtttc atacgccagt gcagcaatta gtccaggagc 360 atgttttagt tcaattgctc gagcnatngt tacttcttga gcttcagcct gacattgaat 420 aacgtatgct tctatgagtc gtgactctaa atctcttcct ttttccgcag gtgtaatgag 480 ttttgggaga tgactttcct ttaaatgttt aaaaatccca gctgcaatct ntaggctttg 540 acgaacctct tntgcttcat cttcngttat attccctttt ccagccagcc ttgaagcata 600 tttcggtata ccataaagct acattannat cccatggaaa ttaanttcaa aaacagcatc 660 cctgctgggc ccttgggaac cctgtccttt gcaatgnntc accccncttg aaaanttnga 720 atnaagcccn attttgcana tatccttcac nctggccggc cgttcagcnt gccatctaga 780 gggccccnat ttcgccctat agngangcnn nttaccaatt cncctgnccc ctcnctttta 840 ncaacccccn gcacntggga aancccctng ccctnncccc ncctcaaatc gcccttgcac 900 cancatcncc cctttcgccc acnttggncg ntaaannccc anaaaggccc cnncccctat 960 cgnccctttt cccaacaant tncnncatcn ctngaatggc caaanngccc cccc 1014 <210> SEQ ID NO 39 <211> LENGTH: 1024 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 2, 4, 7, 12, 23, 27, 44, 54, 57, 63, 71, 98, 107, 115, 116, 125, 144, 150, 171, 296, 340, 351, 358, 378, 388, 404, 407, 408, 434, 435, 448, 464, 504, 506, 538, 546, 547, 561, 572, 584, 585, 609, 611, 612, 613, 618, 627, 629, 638, 642 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 644, 649, 653, 656, 663, 668, 671, 673, 675, 677, 704, 705, 707, 713, 714, 715, 716, 721, 729, 734, 735, 736, 747, 750, 752, 754, 760, 761, 764, 766, 767, 768, 772, 775, 784, 785, 794, 799, 807, 808, 809, 813, 815, 820, 822, 823, 827 <223> OTHER INFORMATION: n = A,T,C or G <221> NAME/KEY: misc_feature <222> LOCATION: 830, 832, 840, 846, 859, 862, 863, 873, 878, 888, 896, 900, 904, 912, 923, 929, 930, 934, 935, 938, 941, 945, 966, 974, 992, 994, 999, 1020 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 39 tngnaancct tntaaaccct tcngcangtc cggccgaaat tgcnagggat atcngcngaa 60 ttnctttatt naaaattttt gtggactttt acattgtngg acaggtncca agtgnngggc 120 aggtngctga ttttgaatta attnccatgn gatttaatgt agctttatcg nataccaaat 180 atgcttcaag actggctgga aaagaaaata taacagaaga tgaagcaaaa gaagttcatc 240 gaagcctaaa gattgcagct gggattttta aacatttaaa ggaaagtcat ctcccnaaac 300 tcattacacc tgcggaaaaa ggaagagatt tagagtcacn actcatagaa ncatacgnta 360 ttcaatgtca ggctgaanct caagaagnaa caattgctcg agcnatnnaa ctaaaacatg 420 ctcctggact aatnnctgca ctggccgnat gaaacaccca attnctatca aaaagctgat 480 catactttat ccagtttgga gccngnatat tctgccaaaa ggagaaaaca tcttcacntg 540 aagatnngct tctacccacc ntatgccttc cngtcaccat ggcnngactt tattggctag 600 tgacaaaanc nnngacanca atcacgncnc ttccaagncg cncnaacant tgnctnccca 660 aangccgnaa ncncnanccc caccccacga cactcgccgg cccnntncta ggnnnntccc 720 nagcctcgna cccnnnctct cgatccntan cntngaggan nttnannnct gnccncctca 780 ccannccttg gccncaatna tgggccnnnc ttncntcccn cnncgancan tncctatccn 840 ctcacnaatt ccccccccnc annaccagcc cgnaagcnct acacgtgncc acctcntggn 900 ctgnccctac gnagggcacc ccnccctcnn cttnnccngg ngccnggccc ccccccccgc 960 ttttcncctc cgcnacaaca ctttctctcc cncnttgcnt ttaactaatc cgcccccccn 1020 ccct 1024 <210> SEQ ID NO 40 <211> LENGTH: 691 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 40 atctagtact ttgctattca aaagtgtctg gggaccagca gcatcagcat ctcaggtcct 60 gccccaggct attgaattag agcctgcatt ggacaaaacc acccaccccc agaaaacatc 120 tggagaaaat gacccattgg tttcatagga acccattaaa agccacagct cctgtgtctt 180 ttaattacta tggtgtagtc actggccctt ctgcttcaaa aatatgcaat gacttgaggt 240 catccagggc acgactcctt gaactgttca ctgatttgag ctgtaatcca gaaatgatga 300 agaatgcagc agattcatat ttctcacttt tacaaggttt cataaattct ttggatgaat 360 ctacccaaga aagcaagtta cgatatattc aaaatttcaa gtggactgat acattgcaag 420 gacaggttcc aagtataaca gaagatgaag caaaagaagt tcatcgaagc ctaaagattg 480 cagctgggat ttttaaacat ttaaaggaaa gtcatctccc aaaactcatt acacctgcgg 540 aaaaaggaag agatttagag tcacgactca tagaagcata cgttattcaa tgtcaggctg 600 aagctcaaga agtaacaatt gctcgagcaa ttgaactaaa acatgctcct ggactaattg 660 ctgcactggc gtatgaaaca gcccaatttc t 691 <210> SEQ ID NO 41 <211> LENGTH: 681 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 14, 31, 35, 54, 70, 74, 77, 79, 118, 173, 198, 350, 435, 556, 593, 602, 603, 634, 666, 673 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 41 tgggtgggct tttnttggct agggataaat ncggngaagc aatcagggtc tctncaagga 60 gcagagaatn gtangcnang gcagaagcac tgtgtaaaga atatggagga accaaagncc 120 ggggcaacag tcaaaccttc aggacatctg ttctttagga aacttgggaa ccntgtgaag 180 aacaccctag aaaaatgnca gagagaaaat ggatttattt actttcaaaa aattccaaca 240 gaagccccac agctggaact caaagcaaat tatggtctcg tagagcctat acctttcgaa 300 tttcctccta caagtgttca gtggacacca gaaacattgg ctgcatttgn tctcaccaaa 360 agacccaagg atgacagtac taaacccaaa ccagaagaag aagtgaaacc tgtgaaagaa 420 ccagacatca aaccncaaaa ggacactggg tgctacatct cctaaaatac aacttgcact 480 tagaatttct ctagcagtaa ataagataaa ccacagaatt tcagttctta tttctcaaaa 540 tgatttctct gaagcntgta gaataactat tattcagagg gttatctgcc ttnaacttac 600 annttcttaa tttttaatac agcggagatg tttnttgaaa aaaaaaaaaa aaaaaattgc 660 ggccgnaagc ttnaaagggt t 681 <210> SEQ ID NO 42 <211> LENGTH: 759 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 18, 23, 24, 83, 88, 92 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 42 aacccttttg ccctcgcngc cannaattcg gcacgaggcc gatatattgc ccttcttccc 60 ttagaaggaa ctgctgaacc gtntctgngt tnatttgttg tccaaccaaa atctagtact 120 ttgctattca aaagtgtctg gggaccagca gcatcagcat ctcaggtcct gccccaggct 180 attgaattag agcctgcatt ggacaaaacc acccaccccc agaaaacatc tggagaaaat 240 gacccattgg tttcatagga acccattaaa agccacagct cctgtgtctt ttaattacta 300 tggtgtagtc actggccctt ctgcttcaaa aatatgcaat gacttgaggt catccagggc 360 acgactcctt gaactgttca ctgatttgag ctgtaatcca gaaatgatga agaatgcagc 420 agattcatat ttctcacttt tacaaggttt cataaattct ttggatgaat ctacccaaga 480 aagcaagtta cgatatattc aaaatttcaa gtggactgat acattgcaag gacaggttcc 540 aagtataaca gaagatgaag caaaagaagt tcatcgaagc ctaaagattg cagctgggat 600 ttttaaacat ttaaaggaaa gtcatcttcc aaaactcatt acacctgcgg aaaaaggaag 660 agatttagag tcacgactca tagaagcata cgttattcaa tgtcaggctg aagctcaaga 720 agtaacaatt gctcgagcaa ttgaactaaa acatgctcc 759 <210> SEQ ID NO 43 <211> LENGTH: 351 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 8, 26, 54, 57, 62, 66, 73, 77, 81, 105, 129, 134, 212, 284, 292, 294 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 43 ttcctccnac aagtgttcag tggacnccag aaacattggc tgcatttgat ctcnccnaaa 60 gncccnagga tgncagnact naacccaaac cagaagaaga agtgnaacct gtgaaagaac 120 cagacatcna accncaaaag gacactgggt gctacatctc ctaaaataca acttgcactt 180 agaatttctc tagcagtaaa taagataaac cncagaattt cagttcttat ttctcaaaat 240 gatttctctg aagcttgtag aataactatt attcagaggg ttanaagcct tnancttact 300 tgttcttaat ttttaataca gcggagatgt ttcttgaaaa aaaaaaaaaa a 351 <210> SEQ ID NO 44 <211> LENGTH: 763 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 67, 93, 104, 105, 120, 125, 128, 200, 235, 248, 271, 276 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 44 gcacgaggcc gatatattgc ccttcttccc ttagaagaac tgctgaaccg actctgtttt 60 tttgttntcc aaccaaaatc tagtactttg ctnttcaaaa gtgnntgggg accagcagcn 120 tcagnatntc aggtcctgcc ccaggctatt gaattagagc ctgcattgga caaaaccacc 180 cacccccaga aaacatctgn agaaaatgac ccattggttt cataggaacc cattnaaagc 240 cacagctnct gtgtctttta attactatgg ngtagncact ggcccttctg cttcaaaaat 300 atgcaatgac ttgaggtcat ccagggcacg actccttgaa ctgttcactg atttgagctg 360 taatccagaa atgatgaaga atgcagcaga ttcatatttc tcacttttac aaggtttcat 420 aaattctttg gatgaatcta cccaagaaag caagttacga tatattcaaa atttcaagtg 480 gactgataca ttgcaaggac aggttccaag tataacagaa gatgaagcaa aagaagttca 540 tcgaagccta aagattgcag ctgggatttt taaacattta aaggaaagtc atctcccaaa 600 actcattaca cctgcggaaa aaggaagaga tttagagtca cgactcatag aagcatacgt 660 tattcaatgt caggctgaag ctcaagaagt aacaattgct cgagcaattg aactaaaaca 720 tgctcctggg ctaattgctg cactggcgta tgaaacagcc aaa 763 <210> SEQ ID NO 45 <211> LENGTH: 522 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 14, 25, 32, 44, 47, 106, 166, 191, 354, 434, 441, 443, 444, 475, 507, 514 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 45 aaacttggaa accntgtgaa gagcncccta gnaaaatgtc aganagnaaa tggatttatt 60 tactttcaaa aaattccaac agaagcccca cagctggaac tcaaancaaa ttatggtctc 120 gtagagccta tacctttcga atttcctcct acaagtgttc agtggncacc agaaacattg 180 gctgcatttg ntctcaccaa aagacccaag gatgacagta ctaaacccaa accagaagaa 240 gaagtgaaac ctgtgaaaga accagacatc aaacctcaaa aggacactgg gtgctacatc 300 tcctaaaata caacttgcac ttagaatttc tctagcagta aataagataa accncagaat 360 ttcagttctt atttctcaaa atgatttctc tgaagcttgt agaataacta ttattcagag 420 ggttatctgc cttnaactta nannttctta atttttaata cagcggagat gtttnttgaa 480 aaaaaaaaaa aaaaaaattg cggccgnaag cttnaaaggg tt 522 <210> SEQ ID NO 46 <211> LENGTH: 746 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 332, 337 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 46 aggtttcata aattctttgg atgaatctac ccaagaaagc aagttacgat atattcaaaa 60 tttcaagtgg actgatacat tgcaaggaca ggttccaagt gcccagcagg atgctgtttt 120 tgaattaatt tccatgggat ttaatgtggc tttatggtat accaaatatg cttcaagact 180 ggctggagaa gaaaatataa cagaagatga aggaaaagaa gttcatcgaa gcctaaagat 240 tgcagctggg atttttaaac atttaaagga aagtcatctc ccaaaactca ttacacctga 300 cggaaaaagg aagagattta gagtcacgac tncatanaag catacgttat tccaatgtca 360 ggctgaagct caagaagtaa caattgctcg agcaattgaa ctaaaacatg ctcctggact 420 aattgctgca ctggcgtatg aaacagccaa tttctatcaa aaagctgatc atactttatc 480 cagtttggag cctgcatatt ctgccaaatg gagaaaatat cttcacttga agatgtgttt 540 ctacacagct tatgcttact gttaccatgg tgagacttta ttggctagtg ataaatgcgg 600 tgaagcaatc aggtctctcc aagaagcaga aaaattgtat gcaaaggcag aagcactgtg 660 taaagaatat ggagaaacca aaggacctgg accaacagtc aaaccttcag gacatctgtt 720 ctttaggaaa cttggaaacc ttgtga 746 <210> SEQ ID NO 47 <211> LENGTH: 852 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 39, 71, 90, 94, 136, 813, 816, 832, 843 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 47 acggatatct gcagaattcg gcttatgacc cattggttnc ataggaaccc attaaaagcc 60 acagcttctg ngtcttttaa ttactatggn gtantcactg gcccttctgc ttcaaaaata 120 tgcaatgact tgaggncatc cagggcacga ctccttgaac tgttcactga tttgagctgt 180 aatccagaaa tgatgaagaa tccagcagat tcatatttct cacttttaca aggtttcata 240 aattctttgg atgaatctac ccaagaaagc aagttacgat atattcaaaa tttcaagtgg 300 actgatacat tgcaaggaca ggttccaagt gcccagcagg atgctgtttt tgaattaatt 360 tccatgggat ttaatgtagc tttatggtat accaaatatg cttcaagact ggctggaaaa 420 gaaaatataa cagaagatga agcaaaagaa gttcatcgaa gcctaaagat tgcagctggg 480 atttttaaac atttaaagga aagtcatctc ccaaaactca ttacacctgc ggaaaaagga 540 agagatttag agtcacgact catagaagca tacgttattc aatgtcaggc tgaagctcaa 600 gaagtaacaa ttgctcgagc aattgaacta aaacatgctc ctggactaat tgctgcactg 660 gcgtatgaaa cagccaattt ctatcaaaaa gctgatcata ctttatccag tttggagcct 720 gcatattctg ccaaatggag aaaatatctt cacttgaaga tgtgttctac acagcttatg 780 cttactgtac catgggtgag actttattgg ctnggngata aatgcggtga ancaatcagg 840 ctnttcaaga ag 852 <210> SEQ ID NO 48 <211> LENGTH: 881 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 1, 11, 85, 94, 863, 874 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 48 ntcttttaac nctatggtgt agtcactggc ccttctgctt caaaaatatg caatgacttg 60 aggtcatcca gggcacgact ccttnaactg ttcnctgatt tgagctgtaa tccagaaatg 120 atgaagaatc cagcagattc atatttctca cttttacaag gtttcataaa ttctttggat 180 gaatctaccc aagaaagcaa gttacgatat attcaaaatt tcaagtggac tgatacattg 240 caaggacagg ttccaagtgc ccagcaggat gctgtttttg aattaatttc catgggattt 300 aatgtagctt tatggtatac caaatatgct tcaagactgg ctggaaaaga aaatataaca 360 gaagatgaag caaaagaagt tcatcgaagc ctaaagattg cagctgggat ttttaaacat 420 ttaaaggaaa gtcatctccc aaaactcatt acacctgcgg aaaaaggaag agatttagag 480 tcacgactca tagaagcata cgttattcaa tgtcaggctg aagctcaaga agtaacaatt 540 gctcgagcaa ttgaactaaa acatgctcct ggactaattg ctgcactggc gtatgaaaca 600 gccaatttct atcaaaaagc tgatcatact ttatccagtt tggagcctgc atattctgcc 660 aaatggagaa aatatcttca cttgaagatg tgtttctaca cagcttatgc ttactgttac 720 catggtgaga ctttattggc tagtgataaa tgcggtgaag caatcaggtc tctccaagaa 780 gcagaaaaat tgtatgcaaa ggcaagaagc actggtaaag agtatggaga agccaaagga 840 cctggaccaa cagtcaaacc ttnggacatc tgtntttagg a 881 <210> SEQ ID NO 49 <211> LENGTH: 747 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 86, 87, 88, 602, 669, 719, 734, 736, 737 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 49 tttctggttc cttcacaggt ttcacttctt cttctggttt gggtttagta ctgtcatcct 60 tgggtctttt ggtgagatca aatgcnnnca atgtttttgg tgtccactga gcacttgtag 120 gaggaaattc gaaaggtata ggctctacga gaccataatt tgctttgagt tccagctgtg 180 gggcttctgt tggaattttt tgaaagtaaa taaatccatt ttctctctga catttttcta 240 gggtgttctt cacaaggtct ccaagtttcc taaagaacag atgtcctgaa ggtttgactg 300 ttggtccagg tcctttggct tctccatact ctttacacag tgcttctgcc tttgcataca 360 atttttctgc ttcttggaga gacctgattg cttcaccgca tttatcacta gccaataaag 420 tctcaccatg gtaacagtaa gcataagctg tgtagaaaca catcttcaag tgaagatatt 480 ttctccattt ggcagaatat gcaggctcca aactggataa agtatgatca gctttttgat 540 agaaattggc tgtttcatac gccagtgcag caattagtcc aggagcatgt tttagttcaa 600 tngctcgagc aattgttact tcttgagcct tcagcctgac attgaataac gtatgcttct 660 atgagtcgng actctaaatc tcttcctttt tccgcaggtg taatgagttt gggagatgnc 720 ttttctttaa atgntnnaaa atcccag 747 <210> SEQ ID NO 50 <211> LENGTH: 755 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 25, 32, 66, 70, 80, 144, 191, 434, 462, 601, 603, 673, 719, 745 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 50 gtcaggcttg aagctcaaga agtnnaattg cncgagcaat tgaactaaaa catgctcctg 60 gactanattn ctgcactggn ggtatgaaac agccaatttc tatcaaaaag ctgatcatac 120 tttatccagt ttggagcctg catnttctgc caaatggaga aaatatcttc acttgaagat 180 gtgtttctac ncagcttatg cttactgtta ccatggtaga ctttattggc tagtgataaa 240 tgcggtgaag caatcaggtc tctccaagaa gcagaaaaat tgtatgcaaa ggcagaagca 300 ctgtgtaaag agtatggaga agccaaagga cctggaccaa cagtcaaacc ttcaggacat 360 ctgttcttta ggaaacttgg agaccttgtg aagaacaccc tagaaaaatg tcagagagaa 420 aatggattta tttnctttca aaaaattcca acagaagccc cncagctgga actcaaagca 480 aattatggtc tcgtagagcc tatacctttc gaatttcctc ctacaagtgc tcagtggaca 540 ccagaaacat tggctgcatt tgatctcacc aaaagaccca aggatgacag tactaaaccc 600 nanccagaag aagaagtgaa acctgtgaag gaaccagaca tcaaacctca aaagggctct 660 ggaaaataca tanacaagcc gaattccagc acactgacgg ccgttactag tggatccgng 720 gggggttttt agccaaatgc atagngaagt ttttt 755 <210> SEQ ID NO 51 <211> LENGTH: 499 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 18, 19, 37, 56, 67, 82, 95, 98, 105, 110, 132, 153, 163, 186, 196, 205, 206, 214, 253, 255, 263, 275, 280, 292, 325, 326, 343, 355, 357, 359, 389, 398, 400, 425, 430, 432, 440, 446, 450, 453, 458, 469, 478, 492 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 51 aaaggcccca taggaacnna gtaaaaggga cagcttntgt gacttttaat tactanggcg 60 cagtcantgg ccgttatgct tnaaaaatat gcaangantt gaggncatcn agggcacgac 120 tccttgaact gntcactgat ttgagctgta atncagaaat gangaagaat gcagcagatt 180 catatntctc actttnacaa ggttnnataa attntttgga tgaatctacc caagaaagca 240 agttacgata tananaaaat ttnaagtgga ctganacatn gcaaggacag gntccaagta 300 taacagaaga tgaagcaaaa gaagnncatc gaagcctaaa gantgcagat gggantntna 360 aacatctaaa ggaaagcaac taccaaaant cattacancn gcggaaaaag gaagagatta 420 gaganacgan tnatagaagn atacgntatn aantgatngg ctgaagctna agaagtanaa 480 tcggccgagc anctgaaca 499 <210> SEQ ID NO 52 <211> LENGTH: 850 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 83, 792, 822, 834, 848 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 52 ttttaattac tatggtgtag tcactggccc ttctgcttca aaaatatgca atgacttgag 60 gtcatccagg gcacgactcc ttntactgtt cactgatttg agctgtaatc cagaaatgat 120 gaagaatgca gcagattcat atttctcact tttacaaggt ttcataaatt ctttggatga 180 atctacccaa gaaagcaagt tacgatatat tcaaaatttc aagtggactg atacattgca 240 aggacaggtt ccaagtataa cagaagatga agcaaaagaa gttcatcgaa gcctaaagat 300 tgcagctggg atttttaaac atttaaagga aagtcatctc ccaaaactca ttacacctgc 360 ggaaaaagga agagatttag agtcacgact catagaagca tacgttattc aatgtcaggc 420 tgaagctcaa gaagtaacaa ttgctcgagc aattgaacta aaacatgctc ctggactaat 480 tgctgcactg gcgtatgaaa cagccaattt ctatcaaaaa gctgatcata ctttatccag 540 tttggagcct gcatattctg ccaaatggag aaaatatctt cacttgaaga tgagtttcta 600 cacagcttat gcttactgtt accatggtga gactttattg gctagtgata agtgcggtga 660 agcaatcagg tctctccaag aagcagaaaa attgtatgca aaggcagaag cctgtgtaaa 720 gaatatggga gaagccaaag gacctggacc aacagtcaaa ccttcaggac atctgttctt 780 taggaaactg gnaaccttgt gaagaacacc ctagaaaaat gntagagaga aaangattta 840 ttactttnaa 850 <210> SEQ ID NO 53 <211> LENGTH: 868 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 17, 41, 51, 68, 142, 167, 770, 771 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 53 ggatgantct cccaagnaag caagttcgat atattcaaat nttcaagtgg nctgatacat 60 tgcaaggnca ggttccaaga taacagaaga tgaagcaaaa gaagttcatc gaagcctaaa 120 gattgcagct gggattttta ancatttaaa ggaaagtcat ctcccanaac tcattacacc 180 tgcggaaaaa ggaagagatt tagagtcacg actcatagaa gcatacgtta ttcaatgtca 240 ggctgaagct caagaagtaa caattgctcg agcaattgaa ctaaaacatg ctcctggact 300 aattgctgca ctggcgtatg aaacagccaa tttctatcaa aaagctgatc atactttatc 360 cagtttggag cctgcatatt ctgccaaatg gagaaaatat cttcacttga agatgagttt 420 ctacacagct tatgcttact gttaccatgg tgagacttta ttggctagtg ataagtgcgg 480 tgaagcaatc aggtctctcc aagaagcaga aaaattgtat gcaaaggcag aagcactgtg 540 taaagaatat ggagaagcca aaggacctgg accaacagtc aaaccttcag gacatctgtt 600 ctttaggaaa cttggaaacc ttgtgaagaa caccctagaa aaatgttaga gagaaaatgg 660 atttatttac tttcaaaaaa ttccaacaga agccccacag ctggaactca aagcaaatta 720 tggtctcgta gagcctatac ctttcgaatt tcctcctaca agtgtccagn ngacaccaaa 780 aacattggct gcatttgatc tcaccaaaag acccaaggat gacagtacta aacccaaacc 840 agaagaagaa gtgaaacctg tgaaagag 868 <210> SEQ ID NO 54 <211> LENGTH: 862 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 5, 37, 40, 41, 51, 75, 87, 104, 113, 160, 360, 782, 812, 827, 856, 857 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 54 gcaanagaag ttcgtcgaag gcctaaagat tgcagcnggn ntttttagac ntttaaagga 60 gagtcatctc ccaanactca ttacacntgg gaaaaagaag aganttagag tcncgactca 120 tagaagcata cgttattcaa tgtcaggctg aagctcaagn agtaacaatt gctcgagcaa 180 ttgaactaaa acatgctcct ggactaattg ctgcactggc gtatgaaaca gccaatttct 240 atcaaaaagc tgatcatact ttatccagtt tggagcctgc atattctgcc aaatggagaa 300 aatatcttca cttgaagatg agtttctaca cagcttatgc ttactgttac catggtgagn 360 ctttattggc tagtgataag tgcggtgaag caatcaggtc tctccaagaa gcagaaaaat 420 tgtatgcaaa ggcagaagca ctgtgtaaag aatatggaga agccaaagga cctggaccaa 480 cagtcaaacc ttcaggacat ctgttcttta ggaaacttgg aaaccttgtg aagaacaccc 540 tagaaaaatg ttagagagaa aatggattta tttactttca aaaaattcca acagaagccc 600 cacagctgga actcaaagca aattatggtc tcgtagagcc tatacctttc gaatttcctc 660 ctacaagtgt ccagtggaca ccagaaacat tggctgcatt tgatctcacc aaaagaccca 720 aggatgacag tactaaaccc aaaccagaag aagaagtgaa acctgtgaaa gaaccagaca 780 tnaaacctca agaggacact gggtgctaca tnctccaagc cgaattnctg cagatatcca 840 tcacactggc ggccgnncga gc 862 <210> SEQ ID NO 55 <211> LENGTH: 876 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 4, 786, 857 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 55 ggcncgccag tgtggatggg atatctgcag gaattcggct tatgacccat tggtttcata 60 ggaacccatt aaaagccaca gcttctgtgt cttttaatta ctatggtgta gtcactggcc 120 cttctgcttc aaaaatatgc aatgacttga ggtcatccag ggcacgactc cttgaactgt 180 tcactgattt gagctgtaat ccagaaatga tgaagaatgc agcagattca tatttctcac 240 ttttacaagg tttcataaat tctttggatg aatctaccca agaaagcaag ttacgatata 300 ttcaaaattt caagtggacg gatacattgc aaggacaggt tccaagaaga tgaagcaaaa 360 gaagttcatc gaagcctaaa gattgcagct gggattttta aacatttaaa ggaaagtcat 420 ctcccaaaac tcattacacc tgcggaaaaa ggaagagatt tagagtcacg actcatagaa 480 gcatacgtta ttcaatgtca ggctgaagct caagaagtaa caattgctcg agcaattgaa 540 ctaaaacatg ctcctggact aattgctgca ctggcgtatg aaacagccaa tttctatcaa 600 aaagctgttt ggggcctgca tattctgcca aatggagaaa atatcttcac ttgaagatgt 660 gtttctacac agcttatgct tactgttacc atggtgagac tttattggct agtgataaat 720 gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt gtatgcaaag gcagaagcac 780 tgtgtnaaga atatggagaa accaaaggac ctggccaaca gacaaacctt caggacattg 840 ttctttagga acttggnaac cttgggaaga acaccc 876 <210> SEQ ID NO 56 <211> LENGTH: 868 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 84, 805 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 56 cttttaatta ctatggtgta gtcactggcc cttctgcttc aaaaatatgc aatgacttga 60 ggtcatccag ggcacgactc cttnaactgt tcactgattt gagctgtaat ccagaaatga 120 tgaagaatgc agcagattca tatttctcac ttttacaagg tttcataaat tctttggatg 180 aatctaccca agaaagcaag ttacgatata ttcaaaattt caagtggacg gatacattgc 240 aaggacaggt tccaagaaga tgaagcaaaa gaagttcatc gaagcctaaa gattgcagct 300 gggattttta aacatttaaa ggaaagtcat ctcccaaaac tcattacacc tgcggaaaaa 360 ggaagagatt tagagtcacg actcatagaa gcatacgtta ttcaatgtca ggctgaagct 420 caagaagtaa caattgctcg agcaattgaa ctaaaacatg ctcctggact aattgctgca 480 ctggcgtatg aaacagccaa tttctatcaa aaagctgttt ggggcctgca tattctgcca 540 aatggagaaa atatcttcac ttgaagatgt gtttctacac agcttatgct tactgttacc 600 atggtgagac tttattggct agtgataaat gcggtgaagc aatcaggtct ctccaagaag 660 cagaaaaatt gtatgcaaag gcagaagcac tgtgtaaaga atatggagaa accaaaggac 720 ctggaccaac agacaaacct tcaggacatc tgttctttag gaaacttgga aaccttgtga 780 agaacaccct agaaaaatgt caagngagaa aatggattta tttactttca aaaaattcca 840 acagaagccc acagctggaa ctcaagca 868 <210> SEQ ID NO 57 <211> LENGTH: 588 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 18, 23, 28, 33, 36, 40, 170, 583 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 57 catgctcctg actaattnct gcnctggngt atnaancagn caatttctat caaaaagctg 60 tttggggcct gcatattctg ccaaatggag aaaatatctt cacttgaaga tgtgtttcta 120 cacagcttat gcttactgtt accatggtga gactttattg gctagtgatn aatgcggtga 180 agcaatcagg tctctccaag aagcagaaaa attgtatgca aaggcagaag cactgtgtaa 240 agaatatgga gaaaccaaag gacctggacc aacagacaaa ccttcaggac atctgttctt 300 taggaaactt ggaaaccttg tgaagaacac cctagaaaaa tgtcagagag aaaatggatt 360 tatttacttt caaaaaattc caacagaagc cccacagctg gaactcaaag caaattatgg 420 tctcgtagag cctatacctt tcgaatttcc tcctacaagt gttcagtgga caccagaaac 480 attggctgca tttgatctca ccaaaagacc caaggatgac agtactaaac ccaaaccaga 540 agaagaagtg aaacctgtga aagaaccaga catcaaacct canaagga 588 <210> SEQ ID NO 58 <211> LENGTH: 551 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 14, 60, 467, 476 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 58 aactaattgc tgcnctggcg tatgaaacag ccaatttcta tcaaaaagct gtttggggcn 60 tgcatattct gccaaatgga gaaaatatct tcacttgaag atgtgtttct acacagctta 120 tgcttactgt taccatggtg agactttatt ggctagtgat aaatgcggtg aagcaatcag 180 gtctctccaa gaagcagaaa aattgtatgc aaaggcagaa gcactgtgta aagaatatgg 240 agaaaccaaa ggacctggac caacagacaa accttcagga catctgttct ttaggaaact 300 tggaaacctt gtgaagaaca ccctagaaaa atgtcagaga gaaaatggat ttatttactt 360 tcaaaaaatt ccaacagaag ccccacagct ggaactcaaa gcaaattatg gtctcgtaga 420 gcctatacct ttcgaatttc ctcctacaag tgttcagtgg acaccanaaa cattgnaagc 480 atttgatctc accaaaagac ccaaggatga cagtactaaa cccaaaccag aagaagaagt 540 gaaacctgtg a 551 <210> SEQ ID NO 59 <211> LENGTH: 485 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 108, 181, 477, 485 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 59 tttgcgaggg ccagggatag gcttaccttc aagctcgccc ttatgaccca ttggtttcat 60 aggaacccat taaaagccac agctcctgtg tcttttaatt actatggngt agtcactggc 120 ccttctgctt caaaaatatg caatgacttg aggtcatcca gggcacgact ccttgaactg 180 ntcactgatt tgagctgtaa tccagaaatg atgaagaatg cagcagattc atatttctca 240 cttttacaag gtttcataaa ttctttggat gaatctaccc aagaaagcaa gttacgatat 300 attcaaaatt tcaagtggac tgatacattg caaggacagg ttccaagtgc ccagcaggat 360 gctgtttttg aattaatttc catgggattt aatgtagctt tatggtatac caaatatgct 420 tcaagactgg ctggaaaaga aaatataaca gaagatgaag caaaagaagt tcatcgnagc 480 ctaan 485 <210> SEQ ID NO 60 <211> LENGTH: 472 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 5, 12, 42, 84, 109, 161, 198, 289, 412, 414 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 60 ccncngattt gngctgtaat ccagaaatga tgaagaatgc ancagattca tatttctcac 60 ttttacaagg tttcataaat tctntggatg aatctaccca agaaagcang ttacgatata 120 ttcaaaattt caagtggact gatacattgc aaggacaggt nccaagtgcc cagcaggatg 180 ctgtttttga attaattncc atgggattta atgtagcttt atggtatacc aaatatgctt 240 caagactggc tggaaaagaa aatataacag aagatgaagc aaaagaagnt catcgaagcc 300 taaagattgc agctgggatt tttaaacatt taaaggaaag tcatctccca aaactcatta 360 cacctgcgga aaaaggaaga gatttagagt cacgactcat agaagcatac gntnttcaat 420 gtcaggctga agctcaagaa gtaacaattg ctcgagcaat tgaactaaaa ca 472 <210> SEQ ID NO 61 <211> LENGTH: 472 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 4, 18, 61, 94, 118, 137, 153, 171, 180, 238, 275, 315, 335, 368, 369, 380, 443, 456 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 61 atgnaacagc caatttcnat caaaaagctg atcatacttt atccagtttg gagcctgcat 60 nttctgccaa atggagtaaa tatcttcact tgangatgtg tttctacgca gcttatgntt 120 actgttacca tggtgangct ttattggcta gtnataaatg cggtgaagca ntcaggtctn 180 tccaagaagc agaaaaattg tatgcaaagg cagaagcact gtgtaaagaa tatggagnta 240 ccaaaggacc tggaccaaca gtcaaacctt caggncatct gttctttagg aaacttggga 300 gccttgtgaa gaacncccta gagaaatgtc agagngaaaa tggatttatt tactttcaaa 360 aaattccnnc agaagcctcn cagctggaac tcaaagcaaa ttatggtctc gtagagccta 420 tacctttcga atttcctcct acnagtgttc agtggnggtc ctgggaaaat gg 472 <210> SEQ ID NO 62 <211> LENGTH: 488 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 26, 35, 36, 38, 113, 118, 120, 195, 301, 329, 394, 406 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 62 gtggagcaat cgaggtctct tccaanaaat cagannanat tgtttgcaga tggcataagc 60 tctgtgtagg ggatatggag aagccaaagg acctggacca acagtcaagc ctncaggncn 120 tctgttcttt aggaaacttg gaaaccttgt gaagaacacc ctagaaaaat gtcagagaga 180 aaatggattt atttnctttc aaaaaattcc aacagaagcc tcacagctgg aactcaaagc 240 aaattatggt ctcgtagagc ctataccttt cgaatttcct cctacaagtg ttcagtggac 300 nccagaaaca ttggctgcat ttgatctcnc cgaaagaccc aaggatgaca gtactaaacc 360 caagccagaa gaagaagtga aacctgtgaa aganccagac atcaancctc aaaaggacac 420 tgggtgctac atctccaagg gcgagcttgt catcgtcatc accggatcca gagcccatgg 480 gtatgtat 488 <210> SEQ ID NO 63 <211> LENGTH: 577 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 2, 207, 387, 522, 540, 562 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 63 cngaactgtt cactgatttg agctgtaatc cagaaatgat gaagaatgca gcagattcat 60 atttctcact tttacaaggt ttcataaatt ctttggatga atctacccaa gaaagcaagt 120 tacgatatat tcaaaatttc aagtggactg atacattgca aggacaggtt ccaagtgccc 180 agcaggatgc tgtttttgaa ttaattncca tgggatttaa tgtagcttta tggtatacca 240 aatatgcttc aagactggct ggaaaagaaa atataacaga aggtgaagca aaagaagttc 300 atcgaagcct aaagattgca gctgggattt ttaaacattt aaaggaaagt catctcccaa 360 aactcattac acctgcggaa aaaggangag atttagagtc acgactcata gaagcatacg 420 ttattcaatg tcaggctgaa gctcaagaag taacaattgc tcgagcaatt gaactaaaac 480 atgctcctgg actaattgct gcactggcgt atgaaacagc cnatttctat caaaaagccn 540 atcatacttt tatccagttt gnagccctgc atattct 577 <210> SEQ ID NO 64 <211> LENGTH: 693 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 4, 30, 35, 43, 44, 46, 65, 80, 111, 149, 152, 435, 502, 685 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 64 agangttcat cgaagcctaa agattgcagn tgggnttttt aanncnttta aaggaaagtc 60 atctnccaaa actcatttcn cctgcgggaa aaagggggag atttagagtc ncgactcata 120 gaaagcatac gttattcaat gtcaggctna angctcagga agtaacaatt gctcgagcaa 180 ttgaactaaa acatgctcct ggactaattg ctgcactggc gtatgaaaca gccgatttct 240 atcaaaaagc tgatcatact ttatccagtt tggagcctgc atattctgcc aaatggagaa 300 aatatcttca cttgaagatg tgtttctaca cagcttatgc ttactgttac catggtgaga 360 ctttattggc tagtgataaa tgcggtgaag caatcaggtc tctccaagaa gcagaaaaat 420 tgtatgcaaa ggcanaagca ctgtgtaaag aatatggaga aaccaaagga cctggaccaa 480 cagtcaaacc ttcaggacat cngttcttta ggaaacttgg aaaccttgtg aagaacaccc 540 tagaaaaatg tcagagagaa aatggattta tttactttca aaaaattcca acagaagccc 600 cacagctgga actcaaagca aattatggtc tcgtagagcc tatacctttc gaatttcctc 660 ctacaagtgt tcagtggaca ccagnggcat tgg 693 <210> SEQ ID NO 65 <211> LENGTH: 437 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 198, 274, 290, 312, 365, 379, 380, 398, 405, 434 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 65 ttgagagggc tagggatagg cttaccttca agctcgccct tatggaccca ttggtttcat 60 aggaacccat taaaagccac agctcctgtg tcttttaatt actatggtgt agtcactggc 120 ccttctgctt caaaaatatg caatgacttg aggtcatcca gggcacgact ccttgaactg 180 ttcactgatt tgagctgnaa tccagaaatg atgaagaatg cagcagattc atatttctca 240 cttttacaag gtttcataaa ttctttggat gaanctaccc aagaaagcan gttacgatat 300 attcaaaatt tnaagtggac tgatacattg caaggacagg ttccaagtgc ccagcaggat 360 gctgnttttg aattaattnn catgggattt aatgtagntt tatgntatac caaatatgct 420 tcaagactgg ttgnaaa 437 <210> SEQ ID NO 66 <211> LENGTH: 426 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 31, 55, 57, 58, 61, 89, 107, 134, 143, 153, 155, 158, 160, 166, 168, 180, 185, 193, 203, 205, 235, 247, 254, 266, 268, 290, 293, 311, 320, 361, 365, 373, 374, 388, 400 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 66 catcactttt acaaggtttc ataaattctt nggatgaatc tacccaagaa agcangnnac 60 nacatattca aaattccaag aggactgana cattgcaagg acaggcncca agtgcccagc 120 aggatgctgt tttngaatta atntccatgg gancnaangn agctcnangg tataccaaan 180 atgcntcaag acnggctgga aangnaaata taacagaaga tgaagcaaaa gaagntcatc 240 gaagccnaaa gatngcagct gggatntnta aacatttaaa ggaaagacan gtnccaaaac 300 ccactacacc ngcggaaaan ggaagagatt tagagcacga ctcatagaag catacgttat 360 ncaangtcag gcnnaagctc aagaagtnac aaattgctcn agcaactgaa ctaaaacatg 420 ctcctg 426 <210> SEQ ID NO 67 <211> LENGTH: 453 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 12, 32, 33, 57, 144, 156, 188, 245, 308, 317, 366, 409, 417, 418, 445 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 67 aaactcatta cncctgcgga aaaaggaaga gnnttagagt cacgactcat agaagcntac 60 gttattcaat gtcaggctga agctcaagaa gtagcaattg ctcgagcaat tgaactaaaa 120 catgctcctg gactaattgc tgcnctggcg tataanacat gccaatttct atcaaaaagc 180 tggtcatnct ttatccagtt tggagcctgc atattctgtc aaatggagaa aatatcttca 240 cttgnagatg tgtttctaca cagcttatgc ttactgttac catggtgagg ctttattggc 300 tagtgatnaa tgcggtnaag caatcaggtc tctccaagaa gcagaaaaat tgtatgcaaa 360 ggcagnagca ctgtgtaaag aatatggaga aaccaaagga cctggaccna cagtcanncc 420 ttcagggcat ctgttcttta ggaancgtgg ttg 453 <210> SEQ ID NO 68 <211> LENGTH: 560 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 28, 29, 46, 69, 175, 199, 329, 370, 384, 434, 446, 457, 469, 476, 482, 502, 522, 540, 545 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 68 tatcccnact ctctactgtt tctccatnnc cgtttttttg ggctantttt aatttttttt 60 aactttaana aggagatata catacccatg ggctctggat ccggtgatga cgatgacaag 120 ctcgccctta ttggtttcat aggaacccat taaaagccac agctcctgtg tcttntaatt 180 actatggtgt agccactgnc ccttctgctt caaaaatatg caatgacttg aggtcatcca 240 gggcacgact ccttgaactg ttcactgatt tgagctgtaa tccagaaatg atgaagaatg 300 cagcagattc atatttctca cttttacang gtttcataaa ttctttggat gaatctaccc 360 aagaaagcan gttacgatat attnaaaatt tcaagtggac tgatacattg caaggacagg 420 ttccaagtgc ccancaggat gctgtntttg aattaanttc catgggatnt aatgtngctt 480 tntggtatac caaatatgct tnaagactgg ctggaaaaga anatataaca gaagatgaan 540 caatngaagt ctattgtacc 560 <210> SEQ ID NO 69 <211> LENGTH: 516 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 8, 32, 57, 130, 159, 188, 199, 234, 249, 254, 380, 445, 457, 462, 476, 492 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 69 gactccnnga actgttcact gatttgagct gnaatccaga aatgatgaag aatgcancag 60 attcatattt ctcactttta caaggtttca taaattcttt ggatgaatct acccaagaaa 120 gcaagttacn atatattcaa aatttcaagt ggactgatnc attgcaagga caggttccaa 180 gtgcccanca ggatgctgnt tttgaattaa ttcccatggg atttaatgta gctntatggt 240 ataccaaana tgcntcaaga ctggctggaa aagaaaatat aacagaagat gaagcaaaag 300 aagttcatcg aagcctaaag attgcagctg ggatttttaa acatttaaag gaaagtcatc 360 tcccaaaact cattacaccn gcggaaaaag gaagagattt agagtcacga ctcatagaag 420 catacgttat tcaatgtcag gctgnagctc aagaagnaac anttgctcga gcaatntgaa 480 ctaaaacatg cncctggact aactgctgca ctggcg 516 <210> SEQ ID NO 70 <211> LENGTH: 529 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 4, 18, 21, 26, 29, 40, 55, 108, 210, 230, 404, 436, 458, 485, 511, 522, 524, 529 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 70 aggntcgtcg aagcctanag nttgcngcng ggatttttan accttttaaa ggaangtcat 60 ctcccaaaac tcattacacc tgcggaaaaa ggaagagatt tagagtcnca actcatagaa 120 gcatacgtta ttcaatgtca ggctgaagct caagaagtag caattgctcg agcaattgaa 180 ctaaaacatg ctcctggact aattgctgcn ctggcgtatg aaacaggccn atttctacca 240 aaaagctgat catactttat ccagtttgga gcctgcatat tctgccgaat ggagagaata 300 tcttcgcttg aagatgtgtt tctacacagc ttatgcttac tgttgccatg gtgagacttt 360 attggctagt gataaatgcg gtgaagcaat caggtctctc caanaagcag aaaaattgta 420 tgcaaaggca gaagcnctgt gtaaagaata tggagaancc aaaggacctg gaccagcagt 480 caganccttc aggacatctg ttctttagga nacttggaaa cngngtgan 529 <210> SEQ ID NO 71 <211> LENGTH: 514 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 18, 53, 58, 199, 247, 252, 291, 327, 347, 425 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 71 aacatgctcc tgggctantt gcttgcactg gcgtatgaaa cagccaattt ctnccaanaa 60 gctgatcata ctttatccag tttggagcct gcatattctg ccaaatggag aaaatatctt 120 cacttgaaga tgtgtttcta cacagcttat gcttactgtt accatggtga gactttattg 180 gctagtgata aatgcggtna agcaatcagg tctctccaag aagcagaaaa attgtatgca 240 aaggcanaag cnctgtgtaa agaatatgga gaaaccaaag gacctggacc nacagtcaaa 300 ccttcaggac atctgttctt taggaanctt ggaaaccttg tgaagancac cctagaaaaa 360 tgtcagagag aaaatggatt tatactaaac ccaaaccaga agaagaagtg aaacctgtga 420 aaganccaga catcaaacct caaaaggaca ctgggtgcta catctccaag ggcgagcttg 480 aaggtaagcc tatccctaac cctctcctcg gtcg 514 <210> SEQ ID NO 72 <211> LENGTH: 379 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 72 Met Thr His Trp Phe His Arg Asn Pro Leu Lys Ala Thr Ala Pro Val 1 5 10 15 Ser Phe Asn Tyr Tyr Gly Val Val Thr Gly Pro Ser Ala Ser Lys Ile 20 25 30 Cys Asn Asp Leu Arg Ser Ser Arg Ala Arg Leu Leu Glu Leu Phe Thr 35 40 45 Asp Leu Ser Cys Asn Pro Glu Met Met Lys Asn Ala Ala Asp Ser Tyr 50 55 60 Phe Ser Leu Leu Gln Gly Phe Ile Asn Ser Leu Asp Glu Ser Thr Gln 65 70 75 80 Glu Ser Lys Leu Arg Tyr Ile Gln Asn Phe Lys Trp Thr Asp Thr Leu 85 90 95 Gln Gly Gln Val Pro Ser Ile Thr Glu Asp Glu Ala Lys Glu Val His 100 105 110 Arg Ser Leu Lys Ile Ala Ala Gly Ile Phe Lys His Leu Lys Glu Ser 115 120 125 His Leu Pro Lys Leu Ile Thr Pro Ala Glu Lys Gly Arg Asp Leu Glu 130 135 140 Ser Arg Leu Ile Glu Ala Tyr Val Ile Gln Cys Gln Ala Glu Ala Gln 145 150 155 160 Glu Val Thr Ile Ala Arg Ala Ile Glu Leu Lys His Ala Pro Gly Leu 165 170 175 Ile Ala Ala Leu Ala Tyr Glu Thr Ala Asn Phe Tyr Gln Lys Ala Asp 180 185 190 His Thr Leu Ser Ser Leu Glu Pro Ala Tyr Ser Ala Lys Trp Arg Lys 195 200 205 Tyr Leu His Leu Lys Met Cys Phe Tyr Thr Ala Tyr Ala Tyr Cys Tyr 210 215 220 His Gly Glu Thr Leu Leu Ala Ser Asp Lys Cys Gly Glu Ala Ile Arg 225 230 235 240 Ser Leu Gln Glu Ala Glu Lys Leu Tyr Ala Lys Ala Glu Ala Leu Cys 245 250 255 Lys Glu Tyr Gly Glu Thr Lys Gly Pro Gly Pro Thr Val Lys Pro Ser 260 265 270 Gly His Leu Phe Phe Arg Lys Leu Gly Asn Leu Val Lys Asn Thr Leu 275 280 285 Glu Lys Cys Gln Arg Glu Asn Gly Phe Ile Tyr Phe Gln Lys Ile Pro 290 295 300 Thr Glu Ala Pro Gln Leu Glu Leu Lys Ala Asn Tyr Gly Leu Val Glu 305 310 315 320 Pro Ile Pro Phe Glu Phe Pro Pro Thr Ser Val Gln Trp Thr Pro Glu 325 330 335 Thr Leu Ala Ala Phe Asp Leu Thr Lys Arg Pro Lys Asp Asp Ser Thr 340 345 350 Lys Pro Lys Pro Glu Glu Glu Val Lys Pro Val Lys Glu Pro Asp Ile 355 360 365 Lys Pro Gln Lys Asp Thr Gly Cys Tyr Ile Ser 370 375 <210> SEQ ID NO 73 <211> LENGTH: 379 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 73 Met Thr His Trp Phe His Arg Asn Pro Leu Lys Ala Thr Ala Pro Val 1 5 10 15 Ser Phe Asn Tyr Tyr Gly Val Val Thr Gly Pro Ser Ala Ser Lys Ile 20 25 30 Cys Asn Asp Leu Arg Ser Ser Arg Ala Arg Leu Leu Glu Leu Phe Thr 35 40 45 Asp Leu Ser Cys Asn Pro Glu Met Met Lys Asn Ala Ala Asp Ser Tyr 50 55 60 Phe Ser Leu Leu Gln Gly Phe Ile Asn Ser Leu Asp Glu Ser Thr Gln 65 70 75 80 Glu Ser Lys Leu Arg Tyr Ile Gln Asn Phe Lys Trp Thr Asp Thr Leu 85 90 95 Gln Gly Gln Val Pro Ser Ile Thr Glu Asp Glu Ala Lys Glu Val His 100 105 110 Arg Ser Leu Lys Ile Ala Ala Gly Ile Phe Lys His Leu Lys Glu Ser 115 120 125 His Leu Pro Lys Leu Ile Thr Pro Ala Glu Lys Gly Arg Asp Leu Glu 130 135 140 Ser Arg Leu Ile Glu Ala Tyr Val Ile Gln Cys Gln Ala Glu Ala Gln 145 150 155 160 Glu Val Thr Ile Ala Arg Ala Ile Glu Leu Lys His Ala Pro Gly Leu 165 170 175 Ile Ala Ala Leu Ala Tyr Glu Thr Ala Asn Phe Tyr Gln Lys Ala Asp 180 185 190 His Thr Leu Ser Ser Leu Glu Pro Ala Tyr Ser Ala Lys Trp Arg Lys 195 200 205 Tyr Leu His Leu Lys Met Cys Phe Tyr Thr Ala Tyr Ala Tyr Cys Tyr 210 215 220 His Gly Glu Thr Leu Leu Ala Ser Asp Lys Cys Gly Glu Ala Ile Arg 225 230 235 240 Ser Leu Gln Glu Ala Glu Lys Leu Tyr Ala Lys Ala Glu Ala Leu Cys 245 250 255 Lys Glu Tyr Gly Glu Thr Lys Gly Pro Gly Pro Thr Val Lys Pro Ser 260 265 270 Gly His Leu Phe Phe Arg Lys Leu Gly Asn Leu Val Lys Asn Thr Leu 275 280 285 Glu Lys Cys Gln Arg Glu Asn Gly Phe Ile Tyr Phe Gln Lys Ile Pro 290 295 300 Thr Glu Ala Pro Gln Leu Glu Leu Lys Ala Asn Tyr Gly Leu Val Glu 305 310 315 320 Pro Ile Pro Phe Glu Phe Pro Pro Thr Ser Val Gln Trp Thr Pro Glu 325 330 335 Thr Leu Ala Ala Phe Asp Leu Thr Lys Arg Pro Lys Asp Asp Ser Thr 340 345 350 Lys Pro Lys Pro Glu Glu Glu Val Lys Pro Val Lys Glu Pro Asp Ile 355 360 365 Lys Pro Gln Lys Asp Thr Gly Cys Tyr Ile Ser 370 375 <210> SEQ ID NO 74 <211> LENGTH: 411 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: VARIANT <222> LOCATION: 346 <223> OTHER INFORMATION: Xaa = Any Amino Acid <400> SEQUENCE: 74 Met Thr His Trp Phe His Arg Asn Pro Leu Lys Ala Thr Ala Pro Val 1 5 10 15 Ser Phe Asn Tyr Tyr Gly Val Val Thr Gly Pro Ser Ala Ser Lys Ile 20 25 30 Cys Asn Asp Leu Arg Ser Ser Arg Ala Arg Leu Leu Glu Leu Phe Thr 35 40 45 Asp Leu Ser Cys Asn Pro Glu Met Met Lys Asn Ala Ala Asp Ser Tyr 50 55 60 Phe Ser Leu Leu Gln Gly Phe Ile Asn Ser Leu Asp Glu Ser Thr Gln 65 70 75 80 Glu Ser Lys Leu Arg Tyr Ile Gln Asn Phe Lys Trp Thr Asp Thr Leu 85 90 95 Gln Gly Gln Val Pro Ser Ala Gln Gln Asp Ala Val Phe Glu Leu Ile 100 105 110 Ser Met Gly Phe Asn Val Ala Leu Trp Tyr Thr Lys Tyr Ala Ser Arg 115 120 125 Leu Ala Gly Lys Glu Asn Ile Thr Glu Asp Glu Ala Lys Glu Val His 130 135 140 Arg Ser Leu Lys Ile Ala Ala Gly Ile Phe Lys His Leu Lys Glu Ser 145 150 155 160 His Leu Pro Lys Leu Ile Thr Pro Ala Glu Lys Gly Arg Asp Leu Glu 165 170 175 Ser Arg Leu Ile Glu Ala Tyr Val Ile Gln Cys Gln Ala Glu Ala Gln 180 185 190 Glu Val Thr Ile Ala Arg Ala Ile Glu Leu Lys His Ala Pro Gly Leu 195 200 205 Ile Ala Ala Leu Ala Tyr Glu Thr Ala Asn Phe Tyr Gln Lys Ala Asp 210 215 220 His Thr Leu Ser Ser Leu Glu Pro Ala Tyr Ser Ala Lys Trp Arg Lys 225 230 235 240 Tyr Leu His Leu Lys Met Cys Phe Tyr Thr Ala Tyr Ala Tyr Cys Tyr 245 250 255 His Gly Glu Thr Leu Leu Ala Ser Asp Lys Cys Gly Glu Ala Ile Arg 260 265 270 Ser Leu Gln Glu Ala Glu Lys Leu Tyr Ala Lys Ala Glu Ala Leu Cys 275 280 285 Lys Glu Tyr Gly Glu Thr Lys Gly Pro Gly Pro Thr Val Lys Pro Ser 290 295 300 Gly His Leu Phe Phe Arg Lys Leu Gly Asn Leu Val Lys Asn Thr Leu 305 310 315 320 Glu Lys Cys Gln Arg Glu Asn Gly Phe Ile Tyr Phe Gln Lys Ile Pro 325 330 335 Thr Glu Ala Pro Gln Leu Glu Leu Lys Xaa Asn Tyr Gly Leu Val Glu 340 345 350 Pro Ile Pro Phe Glu Phe Pro Pro Thr Ser Val Gln Trp Thr Pro Glu 355 360 365 Thr Leu Ala Ala Phe Asp Leu Thr Lys Arg Pro Lys Asp Asp Ser Thr 370 375 380 Lys Pro Lys Pro Glu Glu Glu Val Lys Pro Val Lys Glu Pro Asp Ile 385 390 395 400 Lys Pro Gln Lys Asp Thr Gly Cys Tyr Ile Ser 405 410 <210> SEQ ID NO 75 <211> LENGTH: 1748 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 29, 30, 95, 103, 1605, 1614, 1615, 1646, 1678, 1685, 1697, 1716, 1745, 1746, 1747, 1748 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 75 ttttaaaacc cttttgccct cgcngccann acttcggcac gaggccgata tattgccctt 60 cttcccttag aagaactgct gaaccgactc tgttnatttg ttntccaacc aaaatctagt 120 actttgctat tcaaaagtgt ctggggacca gcagcatcag catctcaggt cctgccccag 180 gctattgaat tagagcctgc attggacaaa accacccacc cccagaaaac atctggagaa 240 aatgacccat tggtttcata ggaacccatt aaaagccaca gctcctgtgt cttttaatta 300 ctatggtgta gtcactggcc cttctgcttc aaaaatatgc aatgacttga ggtcatccag 360 ggcacgactc cttgaactgt tcactgattt gagctgtaat ccagaaatga tgaagaatgc 420 agcagattca tatttctcac ttttacaagg tttcataaat tctttggatg aatctaccca 480 agaaagcaag ttacgatata ttcaaaattt caagtggact gatacattgc aaggacaggt 540 tccaagtgcc cagcaggatg ctgtttttga attaatttcc atgggattta atgtagcttt 600 atggtatacc aaatatgctt caagactggc tggaaaagaa aatataacag aagatgaagc 660 aaaagaagtt catcgaagcc taaagattgc agctgggatt tttaaacatt taaaggaaag 720 tcatctccca aaactcatta cacctgcgga aaaaggaaga gatttagagt cacgactcat 780 agaagcatac gttattcaat gtcaggctga agctcaagaa gtaacaattg ctcgagcaat 840 tgaactaaaa catgctcctg gactaattgc tgcactggcg tatgaaacag ccaatttcta 900 tcaaaaagct gatcatactt tatccagttt ggagcctgca tattctgcca aatggagaaa 960 atatcttcac ttgaagatgt gtttctacac agcttatgct tactgttacc atggtgagac 1020 tttattggct agtgataaat gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt 1080 gtatgcaaag gcagaagcac tgtgtaaaga atatggagaa accaaaggac ctggaccaac 1140 agtcaaacct tcaggacatc tgttctttag gaaacttgga aaccttgtga agaacaccct 1200 agaaaaatgt cagagagaaa atggatttat ttactttcaa aaaattccaa cagaagccyc 1260 acagctggaa ctcaaagcaa attatggtct cgtagagcct atacctttcg aatttcctcc 1320 tacaagtgtt cagtggacac cagarrcatt ggctgcattt gatctcaccr aaagacccaa 1380 ggatgacagt actaaaccca arccagaaga agaagtgaaa cctgtgaaag aaccagacat 1440 caaacctcaa aaggacactg ggtgctacat ctcctaaaat acaacttgca cttagaattt 1500 ctctagcagt aaataagata aaccacagaa tttcagttct tatttctcaa aatgatttct 1560 ctgaagcttg tagaataact attattcaga gggttatctg ccttnaactt acdnnttctt 1620 aatttttaat acagcggaga tgtttnttga aaaaaaaaaa aaaaaaaatt gcggccgnav 1680 gcttnaaagg gttttangag tcgtattaga agcccnattt ctgcagatat ccatcacact 1740 ggcgnnnn 1748 <210> SEQ ID NO 76 <211> LENGTH: 1648 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 29, 30, 95, 103, 1181, 1509, 1518, 1519, 1550, 1582, 1589, 1601, 1620 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 76 ttttaaaacc cttttgccct cgcngccann acttcggcac gaggccgata tattgccctt 60 cttcccttag aagaactgct gaaccgactc tgttnatttg ttntccaacc aaaatctagt 120 actttgctat tcaaaagtgt ctggggacca gcagcatcag catctcaggt cctgccccag 180 gctattgaat tagagcctgc attggacaaa accacccacc cccagaaaac atctggagaa 240 aatgacccat tggtttcata ggaacccatt aaaagccaca gctcctgtgt cttttaatta 300 ctatggtgta gtcactggcc cttctgcttc aaaaatatgc aatgacttga ggtcatccag 360 ggcacgactc cttgaactgt tcactgattt gagctgtaat ccagaaatga tgaagaatgc 420 agcagattca tatttctcac ttttacaagg tttcataaat tctttggatg aatctaccca 480 agaaagcaag ttacgatata ttcaaaattt caagtggact gatacattgc aaggacaggt 540 tccaagtata acagaagatg aagcaaaaga agttcatcga agcctaaaga ttgcagctgg 600 gatttttaaa catttaaagg aaagtcatct cccaaaactc attacacctg cggaaaaagg 660 aagagattta gagtcacgac tcatagaagc atacgttatt caatgtcagg ctgaagctca 720 agaagtaaca attgctcgag caattgaact aaaacatgct cctggactaa ttgctgcact 780 ggcgtatgaa acagccaatt tctatcaaaa agctgatcat actttatcca gtttggagcc 840 tgcatattct gccaaatgga gaaaatatct tcacttgaag atgtgtttct acacagctta 900 tgcttactgt taccatggtg agactttatt ggctagtgat aaatgcggtg aagcaatcag 960 gtctctccaa gaagcagaaa aattgtatgc aaaggcagaa gcactgtgta aagaatatgg 1020 agaaaccaaa ggacctggac caacagtcaa accttcagga catctgttct ttaggaaact 1080 tggaaacctt gtgaagaaca ccctagaaaa atgtcagaga gaaaatggat ttatttactt 1140 tcaaaaaatt ccaacagaag ccccacagct ggaactcaaa ncaaattatg gtctcgtaga 1200 gcctatacct ttcgaatttc ctcctacaag tgttcagtgg acaccagaaa cattggctgc 1260 atttgatctc accaaaagac ccaaggatga cagtactaaa cccaaaccag aagaagaagt 1320 gaaacctgtg aaagaaccag acatcaaacc tcaaaaggac actgggtgct acatctccta 1380 aaatacaact tgcacttaga atttctctag cagtaaataa gataaaccac agaatttcag 1440 ttcttatttc tcaaaatgat ttctctgaag cttgtagaat aactattatt cagagggtta 1500 tctgccttna acttacdnnt tcttaatttt taatacagcg gagatgtttn ttgaaaaaaa 1560 aaaaaaaaaa aattgcggcc gnavgcttna aagggtttta ngagtcgtat tagaagcccn 1620 atttctgcag atatccatca cactggcg 1648 <210> SEQ ID NO 77 <211> LENGTH: 750 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 19, 29, 44, 65, 136, 137, 145, 153, 163, 164, 185, 192, 193, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 683, 734 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 77 atgcttccgg ctggtatgnt gtgtggaant gtgagggata ccantttcac ccaggaacca 60 gctangacca tgattacgcc aagctattta gsygacacta twkwayactc aagctmtgca 120 tcaagcttgg taccgnnctc ggatncacta gtnacggccg ccnntgtgct ggaattcggc 180 ttttnaggta tnncaaatat gcttcaagac tggctggaaa agaaaatata acagaavatg 240 aagcaaaaga agttcatcga agcctaaaga ttgcagctgg gatttttaaa catttaaagg 300 aaagtcatct cccaaaactc attacacctg cggaaaaagg aagagattta gagtcacgac 360 tcatagaagc atacgttatt caatgtcagg ctgaagctca agaagtaaca attgctcgag 420 caattgaact aaaacatgct cctggactaa ttgctgcact ggcgtatgaa acagccaatt 480 tctatcaaaa agctgnnnnn nnnnnnnnnn ntttggagcc tgcatattct gccaaatgga 540 gaaaatatct tcacttgaag atgtgtttct acacagctta tgcttactgt taccatggtg 600 agactttatt ggctagtgat aaatgcggtg aagcaatcag gtctctccaa gaagcagaaa 660 aattgtatgc aaaggcagaa gcnctgtgta aagaatatgg agaaaccaaa ggacctggac 720 caacagtcaa gccnaattct gcagatatcc 750 <210> SEQ ID NO 78 <211> LENGTH: 1744 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 29, 30, 95, 103, 1605, 1614, 1615, 1646, 1678, 1685, 1697, 1716 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 78 ttttaaaacc cttttgccct cgcngccann acttcggcac gaggccgata tattgccctt 60 cttcccttag aagaactgct gaaccgactc tgttnatttg ttntccaacc aawatcymgw 120 myytykmywk tywmwmswkt cysgkkwyyw ksrgcwwcwk ywwmtywkkt yywrcyyyar 180 gmwrkwgaww tasakmcysm ttgggacdgv ahcvgvtavb chcavhdaca agctcgccct 240 tatgacccat tggtttcata ggaacccatt aaaagccaca gctcctgtgt cttttaatta 300 ctatggtgta gtcactggcc cttctgcttc aaaaatatgc aatgacttga ggtcatccag 360 ggcacgactc cttgaactgt tcactgattt gagctgtaat ccagaaatga tgaagaatgc 420 agcagattca tatttctcac ttttacaagg tttcataaat tctttggatg aatctaccca 480 agaaagcaag ttacgatata ttcaaaattt caagtggact gatacattgc aaggacaggt 540 tccaagtgcc cagcaggatg ctgtttttga attaatttcc atgggattta atgtagcttt 600 atggtatacc aaatatgctt caagactggc tggaaaagaa aatataacag aagatgaagc 660 aaaagaagtt catcgaagcc taaagattgc agctgggatt tttaaacatt taaaggaaag 720 tcatctccca aaactcatta cacctgcgga aaaaggaaga gatttagagt cacgactcat 780 agaagcatac gttattcaat gtcaggctga agctcaagaa gtaacaattg ctcgagcaat 840 tgaactaaaa catgctcctg gactaattgc tgcactggcg tatgaaacag ccaatttcta 900 ycaaaaagct gatcatactt tatccagttt ggagcctgca tattctgcca aatggagaaa 960 atatcttcac ttgaagatgt gtttctacac agcttatgct tactgttacc atggtgagac 1020 tttattggct agtgataaat gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt 1080 gtatgcaaag gcagaagcac tgtgtaaaga atatggagaa accaaaggac ctggaccaac 1140 agtcaaacct tcaggacatc tgttctttag gaaacttgga aaccttgtga agaacaccct 1200 agaaaaatgt cagagagaaa atggatttat wywmwwycma aammwkmmra mrrarksmmm 1260 mcwgykrrar mtcmaracaw mwwayskymw mrkrrmrcyk rkwsctwymk mwyywmsksc 1320 kasmwkkrwk swrwgsmyay cmswaacmyt skcykcrkty gatctcacca aaagacccaa 1380 ggatgacagt actaaaccca aaccagaaga agaagtgaaa cctgtgaaag aaccagacat 1440 caaacctcaa aaggacactg ggtgctacat ctcctaaaat acaacttgca cttagaattt 1500 ctctagcagt aaataagata aaccacagaa tttcagttct tatttctcaa aatgatttct 1560 ctgaagcttg tagaataact attattcaga gggttatctg ccttnaactt acdnnttctt 1620 aatttttaat acagcggaga tgtttnttga aaaaaaaaaa aaaaaaaatt gcggccgnav 1680 gcttnaaagg gttttangag tcgtattaga agcccnattt ctgcagatat ccatcacact 1740 ggcg 1744 <210> SEQ ID NO 79 <211> LENGTH: 1744 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 29, 30, 95, 103, 353, 374, 383, 411, 426, 439, 442, 449, 476, 497, 507, 530, 549, 558, 1605, 1614, 1615, 1646, 1678, 1685, 1697, 1716 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 79 ttttaaaacc cttttgccct cgcngccann acttcggcac gaggccgata tattgccctt 60 cttcccttag aagaactgct gaaccgactc tgttnatttg ttntccaacc aaaatctagt 120 actttgctat tcaaaagtgt ctggggacca gcagcatcag catctcaggt cctgccccag 180 gctattgaat tagagcctgc attggacaaa accacccacs smyakmwrmm rwmtksrgmw 240 watgacccat tggtttcata ggaacccatt aaaagccaca gctyctgtgt cttttaabta 300 ctatggtgta gtcactggcc cttctgcttc aaaaatatgc aatgacttga ggncatccag 360 ggcacgactc cttnaactgt tcnctgmttt taattactat gghghagtca ntggccvttc 420 tgcttnaaaa atatgcaang anttgaggnc atccagggca cgactccttg aactgntcac 480 tgatttgagc tgtaatncag aaatgangaa gaatgcagca gattcatatn tctcactttt 540 acaaggttnc ataaattntt tggatgaatc tacccaagaa agcaagttac gatatattca 600 aadtttcaag tggactgata cattgcaagg acaggttcca agtataacag aagatgaagc 660 aaaagaagtt catcgaagcc taaagattgc agctgggatt tttaaacatt taaaggaaag 720 tcatctccca aaactcatta cacctgcgga aaaaggaaga gatttagagt cacgactcat 780 agaagcatac gttattcaat gtcaggctga agctcaagaa gtaacaattg ctcgagcaat 840 tgaactaaaa catgctcctg gactaattgc tgcactggcg tatgaaacag ccaatttcta 900 tcaaaaagct gatcatactt tatccagttt ggagcctgca tattctgcca aatggagaaa 960 atatcttcac ttgaagatgt gtttctacac agcttatgct tactgttacc atggtgagac 1020 tttattggct agtgataaat gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt 1080 gtatgcaaag gcagaagcac tgtgtaaaga atatggagaa gccaaaggac ctggaccaac 1140 agtcaaacct tcaggacatc tgttctttag gaaacttgga aaccttgtga agaacaccct 1200 agaaaaatgt cagagagaaa atggatttat ttactttcaa aaaattccaa cagaagcccc 1260 acagctggaa ctcaaagcaa attatggtct cgtagagcct atacctttcg aatttcctcc 1320 tacaagtgtt cagtggacac cagaaacatt ggctgcattt gatctcacca aaagacccaa 1380 ggatgacagt actaaaccca aaccagaaga agaagtgaaa cctgtgaaag aaccagacat 1440 caaacctcaa aaggacactg ggtgctacat ctcctaaaat acaacttgca cttagaattt 1500 ctctagcagt aaataagata aaccacagaa tttcagttct tatttctcaa aatgatttct 1560 ctgaagcttg tagaataact attattcaga gggttatctg ccttnaactt acdnnttctt 1620 aatttttaat acagcggaga tgtttnttga aaaaaaaaaa aaaaaaaatt gcggccgnav 1680 gcttnaaagg gttttangag tcgtattaga agcccnattt ctgcagatat ccatcacact 1740 ggcg 1744 <210> SEQ ID NO 80 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 80 tttatggtat accaaatatg cttcaagact 30 <210> SEQ ID NO 81 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 81 cagccagtct tgaagcatat ttggtatacc 30 <210> SEQ ID NO 82 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 82 cttgaagatg tgtttctaca cagcttatgc 30 <210> SEQ ID NO 83 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 83 gactgttggt ccaggtcctt tggtttctcc 30 <210> SEQ ID NO 84 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 84 caggaaacag ctatgaccat gattacgc 28 <210> SEQ ID NO 85 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 85 gtaatacgac tcactatagg gcgaattgg 29 <210> SEQ ID NO 86 <211> LENGTH: 33 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 86 aatcccatgg aaattaattc aaaaacagca tcc 33 <210> SEQ ID NO 87 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 87 ggtgagactt tattggctag tgataaatgc g 31 <210> SEQ ID NO 88 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 88 gtgcttctgc ctttgcatac aatttttctg c 31 <210> SEQ ID NO 89 <211> LENGTH: 32 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 89 tattcaaaat ttcaagtgga ctgatacatt gc 32 <210> SEQ ID NO 90 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 90 ggatgaatct acccaagaaa gcaagttacg 30 <210> SEQ ID NO 91 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 91 aacttgcttt cttgggtaga ttcatccaaa g 31 <210> SEQ ID NO 92 <211> LENGTH: 32 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 92 gtatcagtcc acttgaaatt ttgaatatat cg 32 <210> SEQ ID NO 93 <211> LENGTH: 33 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 93 cagaagatga aggaaaagaa gttcatcgaa gcc 33 <210> SEQ ID NO 94 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 94 ggattggtgg cgacgactcc tggagcccg 29 <210> SEQ ID NO 95 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 95 agaccaactg gtaatggtag cgaccggcgc 30 <210> SEQ ID NO 96 <211> LENGTH: 32 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 96 gcaaaggcag aagcactgtg taaagaatat gg 32 <210> SEQ ID NO 97 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 97 ctgttcttta ggaaacttgg aaaccttgtg 30 <210> SEQ ID NO 98 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 98 ctggaaaatt tagtgttatt ggaatcaaag g 31 <210> SEQ ID NO 99 <211> LENGTH: 33 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 99 tgaacagttc aaggagtcgt gccctggatg acc 33 <210> SEQ ID NO 100 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 100 ccagggcacg actccttgaa ctgttcactg 30 <210> SEQ ID NO 101 <211> LENGTH: 32 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 101 atcccttgag tcttattgat tagtactaac tc 32 <210> SEQ ID NO 102 <211> LENGTH: 33 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 102 cgaatttaat acgactcact atagggaatt tgg 33 <210> SEQ ID NO 103 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 103 tgccaagcta aaattaaccc tcactaaagg 30 <210> SEQ ID NO 104 <211> LENGTH: 29 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 104 tatcaaaaag ctgatcatac tttatccag 29 <210> SEQ ID NO 105 <211> LENGTH: 40 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 105 ttaggagatg tagcacccag tgtccttttg aggtttgatg 40 <210> SEQ ID NO 106 <211> LENGTH: 37 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 106 ggagatgtag cacccagtgt ccttttgagg tttgatg 37 <210> SEQ ID NO 107 <211> LENGTH: 35 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 107 atgacccatt ggtttcatag gaacccatta aaagc 35 <210> SEQ ID NO 108 <211> LENGTH: 47 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 108 cagcaggatg ctgtttttga attaatttcc atgggattta atgtagc 47 <210> SEQ ID NO 109 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 109 aaggacaggt tccaagtata acagaag 27 <210> SEQ ID NO 110 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 110 cacttgtagg aggaaattcg aaaggtatag g 31 <210> SEQ ID NO 111 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 111 ttctggtttg ggtttagtat aaatccattt t 31 <210> SEQ ID NO 112 <211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 112 gctggtaaat gtcctct 17 <210> SEQ ID NO 113 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 113 tctggataat cacaaggttt c 21 <210> SEQ ID NO 114 <211> LENGTH: 1744 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 29, 30, 95, 103, 1605, 1614, 1615, 1646, 1678, 1685, 1697, 1716 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 114 ttttaaaacc cttttgccct cgcngccann acttcggcac gaggccgata tattgccctt 60 cttcccttag aagaactgct gaaccgactc tgttnatttg ttntccaacc aaaatctagt 120 actttgctat tcaaaagtgt ctggggacca gcagcatcag catctcaggt cctgccccag 180 gctattgaat tagagcctgc attggacaaa accacccacc cccagaaaac atctggagaa 240 aatgacccat tggtttcata ggaacccatt aaaagccaca gctcctgtgt cttttaatta 300 ctatggtgta gtcactggcc cttctgcttc aaaaatatgc aatgacttga ggtcatccag 360 ggcacgactc cttgaactgt tcactgattt gagctgtaat ccagaaatga tgaagaatgc 420 agcagattca tatttctcac ttttacaagg tttcataaat tctttggatg aatctaccca 480 agaaagcaag ttacgatata ttcaaaattt caagtggact gatacattgc aaggacaggt 540 tccaagtgcc cagcaggatg ctgtttttga attaatttcc atgggattta atgtagcttt 600 atggtatacc aaatatgctt caagactggc tggaaaagaa aatataacag aagatgaagc 660 aaaagaagtt catcgaagcc taaagattgc agctgggatt tttaaacatt taaaggaaag 720 tcatctccca aaactcatta cacctgcgga aaaaggaaga gatttagagt cacgactcat 780 agaagcatac gttattcaat gtcaggctga agctcaagaa gtaacaattg ctcgagcaat 840 tgaactaaaa catgctcctg gactaattgc tgcactggcg tatgaaacag ccaatttcta 900 tcaaaaagct gatcatactt tatccagttt ggagcctgca tattctgcca aatggagaaa 960 atatcttcac ttgaagatgt gtttctacac agcttatgct tactgttacc atggtgagac 1020 tttattggct agtgataaat gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt 1080 gtatgcaaag gcagaagcac tgtgtaaaga atatggagaa accaaaggac ctggaccaac 1140 agtcaaacct tcaggacatc tgttctttag gaaacttgga aaccttgtga agaacaccct 1200 agaaaaatgt cagagagaaa atggatttat ttactttcaa aaaattccaa cagaagcccc 1260 acagctggaa ctcaaaacaa attatggtct cgtagagcct atacctttcg aatttcctcc 1320 tacaagtgtt cagtggacac cagaaacatt ggctgcattt gatctcacca aaagacccaa 1380 ggatgacagt actaaaccca aaccagaaga agaagtgaaa cctgtgaaag aaccagacat 1440 caaacctcaa aaggacactg ggtgctacat ctcctaaaat acaacttgca cttagaattt 1500 ctctagcagt aaataagata aaccacagaa tttcagttct tatttctcaa aatgatttct 1560 ctgaagcttg tagaataact attattcaga gggttatctg ccttnaactt acdnnttctt 1620 aatttttaat acagcggaga tgtttnttga aaaaaaaaaa aaaaaaaatt gcggccgnav 1680 gcttnaaagg gttttangag tcgtattaga agcccnattt ctgcagatat ccatcacact 1740 ggcg 1744 <210> SEQ ID NO 115 <211> LENGTH: 443 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 66, 139, 435, 443 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 115 atgacccatt ggtttcatag gaacccatta aaagccacag ctcctgtgtc ttttaattac 60 tatggngtag tcactggccc ttctgcttca aaaatatgca atgacttgag gtcatccagg 120 gcacgactcc ttgaactgnt cactgatttg agctgtaatc cagaaatgat gaagaatgca 180 gcagattcat atttctcact tttacaaggt ttcataaatt ctttggatga atctacccaa 240 gaaagcaagt tacgatatat tcaaaatttc aagtggactg atacattgca aggacaggtt 300 ccaagtgccc agcaggatgc tgtttttgaa ttaatttcca tgggatttaa tgtagcttta 360 tggtatacca aatatgcttc aagactggct ggaaaagaaa atataacaga agatgaagca 420 aaagaagttc atcgnagcct aan 443 <210> SEQ ID NO 116 <211> LENGTH: 577 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 2, 207, 387, 522, 540, 562 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 116 cngaactgtt cactgatttg agctgtaatc cagaaatgat gaagaatgca gcagattcat 60 atttctcact tttacaaggt ttcataaatt ctttggatga atctacccaa gaaagcaagt 120 tacgatatat tcaaaatttc aagtggactg atacattgca aggacaggtt ccaagtgccc 180 agcaggatgc tgtttttgaa ttaattncca tgggatttaa tgtagcttta tggtatacca 240 aatatgcttc aagactggct ggaaaagaaa atataacaga aggtgaagca aaagaagttc 300 atcgaagcct aaagattgca gctgggattt ttaaacattt aaaggaaagt catctcccaa 360 aactcattac acctgcggaa aaaggangag atttagagtc acgactcata gaagcatacg 420 ttattcaatg tcaggctgaa gctcaagaag taacaattgc tcgagcaatt gaactaaaac 480 atgctcctgg actaattgct gcactggcgt atgaaacagc cnatttctat caaaaagccn 540 atcatacttt tatccagttt gnagccctgc atattct 577 <210> SEQ ID NO 117 <211> LENGTH: 472 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 5, 12, 42, 84, 109, 161, 198, 289, 412, 414 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 117 ccncngattt gngctgtaat ccagaaatga tgaagaatgc ancagattca tatttctcac 60 ttttacaagg tttcataaat tctntggatg aatctaccca agaaagcang ttacgatata 120 ttcaaaattt caagtggact gatacattgc aaggacaggt nccaagtgcc cagcaggatg 180 ctgtttttga attaattncc atgggattta atgtagcttt atggtatacc aaatatgctt 240 caagactggc tggaaaagaa aatataacag aagatgaagc aaaagaagnt catcgaagcc 300 taaagattgc agctgggatt tttaaacatt taaaggaaag tcatctccca aaactcatta 360 cacctgcgga aaaaggaaga gatttagagt cacgactcat agaagcatac gntnttcaat 420 gtcaggctga agctcaagaa gtaacaattg ctcgagcaat tgaactaaaa ca 472 <210> SEQ ID NO 118 <211> LENGTH: 689 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 4, 30, 35, 43, 45, 64, 79, 109, 146, 149, 431, 498, 681 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 118 agangttcat cgaagcctaa agattgcagn tgggnttttt aancntttaa aggaaagtca 60 tctnccaaaa ctcatttcnc ctgcggaaaa agggggagat ttagagtcnc gactcataga 120 agcatacgtt attcaatgtc aggctnaang ctcagaagta acaattgctc gagcaattga 180 actaaaacat gctcctggac taattgctgc actggcgtat gaaacagccg atttctatca 240 aaaagctgat catactttat ccagtttgga gcctgcatat tctgccaaat ggagaaaata 300 tcttcacttg aagatgtgtt tctacacagc ttatgcttac tgttaccatg gtgagacttt 360 attggctagt gataaatgcg gtgaagcaat caggtctctc caagaagcag aaaaattgta 420 tgcaaaggca naagcactgt gtaaagaata tggagaaacc aaaggacctg gaccaacagt 480 caaaccttca ggacatcngt tctttaggaa acttggaaac cttgtgaaga acaccctaga 540 aaaatgtcag agagaaaatg gatttattta ctttcaaaaa attccaacag aagccccaca 600 gctggaactc aaagcaaatt atggtctcgt agagcctata cctttcgaat ttcctcctac 660 aagtgttcag tggacaccag nggcattgg 689 <210> SEQ ID NO 119 <211> LENGTH: 471 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 4, 18, 61, 94, 118, 137, 153, 171, 180, 238, 275, 315, 335, 368, 369, 380, 443, 456 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 119 atgnaacagc caatttcnat caaaaagctg atcatacttt atccagtttg gagcctgcat 60 nttctgccaa atggagtaaa tatcttcact tgangatgtg tttctacgca gcttatgntt 120 actgttacca tggtgangct ttattggcta gtnataaatg cggtgaagca ntcaggtctn 180 tccaagaagc agaaaaattg tatgcaaagg cagaagcact gtgtaaagaa tatggagnta 240 ccaaaggacc tggaccaaca gtcaaacctt caggncatct gttctttagg aaacttggga 300 gccttgtgaa gaacncccta gagaaatgtc agagngaaaa tggatttatt tactttcaaa 360 aaattccnnc agaagcctcn cagctggaac tcaaagcaaa ttatggtctc gtagagccta 420 tacctttcga atttcctcct acnagtgttc agtggnggtc ctgggaaaat g 471 <210> SEQ ID NO 120 <211> LENGTH: 431 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 32, 34, 108, 113, 115, 190, 296, 324, 389, 401 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 120 gtggagcaat caggtctctc caanaatcag ananattgtt tgcagaggca taagctctgt 60 gtaggggata tggagaagcc aaaggacctg gaccaacagt caagcctnca ggncntctgt 120 tctttaggaa acttggaaac cttgtgaaga acaccctaga aaaatgtcag agagaaaatg 180 gatttatttn ctttcaaaaa attccaacag aagcctcaca gctggaactc aaagcaaatt 240 atggtctcgt agagcctata cctttcgaat ttcctcctac aagtgttcag tggacnccag 300 aaacattggc tgcatttgat ctcnccgaaa gacccaagga tgacagtact aaacccaagc 360 cagaagaaga agtgaaacct gtgaaaganc cagacatcaa ncctcaaaag gacactgggt 420 gctacatctc c 431 <210> SEQ ID NO 121 <211> LENGTH: 779 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 2, 3, 6, 15, 68, 76 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 121 annacntcgg cacgnggccg atatattgcc cttcttccct tagaagaact gctgaaccga 60 ctctgttnat ttgttntcca accaaaatct agtactttgc tattcaaaag tgtctgggga 120 ccagcagcat cagcatctca ggtcctgccc caggctattg aattagagcc tgcattggac 180 aaaaccaccc acccccagaa aacatctgga gaaaatgacc cattggtttc ataggaaccc 240 attaaaagcc acagctcctg tgtcttttaa ttactatggt gtagtcactg gcccttctgc 300 ttcaaaaata tgcaatgact tgaggtcatc cagggcacga ctccttgaac tgttcactga 360 tttgagctgt aatccagaaa tgatgaagaa tgcagcagat tcatatttct cacttttaca 420 aggtttcata aattctttgg atgaatctac ccaagaaagc aagttacgat atattcaaaa 480 tttcaagtgg actgatacat tgcaaggaca ggttccaagt ataacagaag atgaagcaaa 540 agaagttcat cgaagcctaa agattgcagc tgggattttt aaacatttaa aggaaagtca 600 tctcccaaaa ctcattacac ctgcggaaaa aggaagagat ttagagtcac gactcataga 660 agcatacgtt attcaatgtc aggctgaagc tcaagaagta acaattgctc gagcaattga 720 actaaaacat gctcctggac taattgctgc actggcgtat gaaacagcca atttctatc 779 <210> SEQ ID NO 122 <211> LENGTH: 769 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 73, 99, 110, 111, 126, 131, 134, 206, 241, 254, 277, 282 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 122 acttcggcac gaggccgata tattgccctt cttcccttag aagaactgct gaaccgactc 60 tgtttttttg ttntccaacc aaaatctagt actttgctnt tcaaaagtgn ntggggacca 120 gcagcntcag natntcaggt cctgccccag gctattgaat tagagcctgc attggacaaa 180 accacccacc cccagaaaac atctgnagaa aatgacccat tggtttcata ggaacccatt 240 naaagccaca gctnctgtgt cttttaatta ctatggngta gncactggcc cttctgcttc 300 aaaaatatgc aatgacttga ggtcatccag ggcacgactc cttgaactgt tcactgattt 360 gagctgtaat ccagaaatga tgaagaatgc agcagattca tatttctcac ttttacaagg 420 tttcataaat tctttggatg aatctaccca agaaagcaag ttacgatata ttcaaaattt 480 caagtggact gatacattgc aaggacaggt tccaagtata acagaagatg aagcaaaaga 540 agttcatcga agcctaaaga ttgcagctgg gatttttaaa catttaaagg aaagtcatct 600 cccaaaactc attacacctg cggaaaaagg aagagattta gagtcacgac tcatagaagc 660 atacgttatt caatgtcagg ctgaagctca agaagtaaca attgctcgag caattgaact 720 aaaacatgct cctgggctaa ttgctgcact ggcgtatgaa acagccaaa 769 <210> SEQ ID NO 123 <211> LENGTH: 765 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 29, 30, 88, 93, 95 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 123 ttttaaaacc cttttgccct cgcngccann aattcggcac gaggccgata tattgccctt 60 cttcccttag aagaactgct gaaccgtntc tgntnatttg ttgtccaacc aaaatctagt 120 actttgctat tcaaaagtgt ctggggacca gcagcatcag catctcaggt cctgccccag 180 gctattgaat tagagcctgc attggacaaa accacccacc cccagaaaac atctggagaa 240 aatgacccat tggtttcata ggaacccatt aaaagccaca gctcctgtgt cttttaatta 300 ctatggtgta gtcactggcc cttctgcttc aaaaatatgc aatgacttga ggtcatccag 360 ggcacgactc cttgaactgt tcactgattt gagctgtaat ccagaaatga tgaagaatgc 420 agcagattca tatttctcac ttttacaagg tttcataaat tctttggatg aatctaccca 480 agaaagcaag ttacgatata ttcaaaattt caagtggact gatacattgc aaggacaggt 540 tccaagtata acagaagatg aagcaaaaga agttcatcga agcctaaaga ttgcagctgg 600 gatttttaaa catttaaagg aaagtcatct tccaaaactc attacacctg cggaaaaagg 660 aagagattta gagtcacgac tcatagaagc atacgttatt caatgtcagg ctgaagctca 720 agaagtaaca attgctcgag caattgaact aaaacatgct cctgg 765 <210> SEQ ID NO 124 <211> LENGTH: 294 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 53, 97, 108, 115, 135, 145, 161, 164, 165, 191, 192, 204, 220, 260, 262, 294 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 124 ggacagggat tgcagctggg atttttaaac atttaaagga aagtcatctc ccnaaactca 60 ttacacctgc ggaaaaagga agagatttag agtcacnact catagaanca tacgntattc 120 aatgtcaggc tgaanctcaa gaagnaacaa ttgctcgagc natnnaacta aaacatgctc 180 ctggactaat nnctgcactg gcgnatgaaa cacccaattn ctatcaaaaa gctgatcata 240 ctttatccag tttggagccn gnatattctg ccaaaaggag aaaacatctt cacn 294 <210> SEQ ID NO 125 <211> LENGTH: 434 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 19, 32, 53, 196, 199 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 125 acaggttcca agtataacng aagatgaagc anaagaggtt cgtcaaagcc tanagattgc 60 agctgggatt tttaaacatt taaaggaaag tcatctccca aaactcatta cacctgcgga 120 aaaaggaaga gatttagagt cacgactcat agaagcatac gttattcaat gtcaggctga 180 agctcaagaa gtaacnatng ctcgagcaat tgaactaaaa catgctcctg gactaattgc 240 tgcactggcg tatgaaacag ccaatttcta tcaaaaagct gatcatactt tatccagttt 300 ggagcctgca tattctgcca aatggagaaa atatcttcac ttgaagatgt gtttctacac 360 agcttatgct tactgttacc atggtgagac tttattggct agtgataaat gcggtgaagc 420 aatcaggtct ctcc 434 <210> SEQ ID NO 126 <211> LENGTH: 647 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 239 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 126 aggtttcata aattctttgg atgaatctac ccaagaaagc aagttacgat atattcaaaa 60 tttcaagtgg actgatacat tgcaaggaca ggttccaagt ataacagaag atgaaggaaa 120 agaagttcat cgaagcctaa agattgcagc tgggattttt aaacatttaa aggaaagtca 180 tctcccaaaa ctcattacac ctgcggaaaa aggaagagat ttagagtcac gactcatana 240 agcatacgtt attcaatgtc aggctgaagc tcaagaagta acaattgctc gagcaattga 300 actaaaacat gctcctggac taattgctgc actggcgtat gaaacagcca atttctatca 360 aaaagctgat catactttat ccagtttgga gcctgcatat tctgccaaat ggagaaaata 420 tcttcacttg aagatgtgtt tctacacagc ttatgcttac tgttaccatg gtgagacttt 480 attggctagt gataaatgcg gtgaagcaat caggtctctc caagaagcag aaaaattgta 540 tgcaaaggca gaagcactgt gtaaagaata tggagaaacc aaaggacctg gaccaacagt 600 caaaccttca ggacatctgt tctttaggaa acttggaaac cttgtga 647 <210> SEQ ID NO 127 <211> LENGTH: 486 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 428, 435, 436, 441, 443, 464, 473 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 127 tataacagaa gatgaagcaa aagaagttca tcgaagccta aagattgcag ctgggatttt 60 taaacattta aaggaaagtc atctcccaaa actcattaca cctgcggaaa aaggaagaga 120 tttagagtca cgactcatag aagcatacgt tattcaatgt caggctgaag ctcaagaagt 180 aacaattgct cgagcaattg aactaaaaca tgctcctgga ctaattgctg cactggcgta 240 tgaaacagcc aatttctatc aaaaagctgt ttggagcctg catattctgc caaatggaga 300 aaatatcttc acttgaagat gtgtttctac acagcttatg cttactgtta ccatggtgag 360 actttattgg ctagtgataa atgcggtgaa gcaatcaggt ctctccaaga agcagaaaaa 420 ttgtatgnaa aggcnnaagc ncngtgtaaa gaatatggag aaancaaagg acnaggacca 480 acagtc 486 <210> SEQ ID NO 128 <211> LENGTH: 486 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 307 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 128 tataacagaa catgaagcaa aagaagttca tcgaagccta aagattgcag ctgggatttt 60 taaacattta aaggaaagtc atctcccaaa actcattaca cctgcggaaa aaggaagaga 120 tttagagtca cgactcatag aagcatacgt tattcaatgt caggctgaag ctcaagaagt 180 aacaattgct cgagcaattg aactaaaaca tgctcctgga ctaattgctg cactggcgta 240 tgaaacagcc aatttctatc aaaaagctgt ttggagcctg catattctgc caaatggaga 300 aaatatnttc acttgaagat gtgtttctac acagcttatg cttactgtta ccatggtgag 360 actttattgg ctagtgataa atgcggtgaa gcaatcaggt ctctccaaga agcagaaaaa 420 ttgtatgcaa aggcagaagc actgtgtaaa gaatatggag aaaccaaagg acctggacca 480 acagtc 486 <210> SEQ ID NO 129 <211> LENGTH: 474 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 1, 429 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 129 natcgaagcc taaagattgc agctgggatt tctaaacatt taaaggaaag tcatctccca 60 aaactcatta cacctgcgga aaaaggaaga gatttagagt cacgactcat agaagcatac 120 gttattcaat gtcaggctga agctcaagaa gtaacaattg ctcgagcaat tgaactaaaa 180 catgctcctg gactaattgc tgcactggcg tatgaaacag ccaatttcta tcaaaaagct 240 gatcatactt tatccagttt ggagcctgca tattctgcca aatggagaaa atatcttcac 300 gtgaagatgt gtttctacac agcttatgct tactgttacc atggtgagac tttattggct 360 agtgataaat gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt gtatgcaaag 420 gcagaagcnc tgtgtaaaga atatggagaa accaaaggac ctggaccaac agtc 474 <210> SEQ ID NO 130 <211> LENGTH: 277 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 5, 64, 91, 111, 113, 134, 192, 197, 206, 208, 217, 238, 244, 268 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 130 cttgnagatg tgttggtaca cagcttatgc ttactggtac catggtgaga ctttattggc 60 tagngataaa tgcggtgaag caatcaggtc nctccaagaa gcagaaaaat ngnatgcaaa 120 ggcagaagca ctgngtaaag aatatggaga aaccaaagga cctggaccaa cagccaaacc 180 ttcaggacat cngttcntta ggaaantngg aaacctngtg aagaacaccc tagaaaancg 240 tcanagagaa aatggattta tttacttnca aaaactc 277 <210> SEQ ID NO 131 <211> LENGTH: 152 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 47, 101, 124, 131, 142 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 131 tggtgagact ttattggcta gtgataaatg cggtgaagca atcaggnctc tccaagaagc 60 agaaaaattg tatgcaaagg cagaagcact gtgtaaagaa natggagaaa ccaaaggacc 120 tggnccaaca nccaaacctt cnggacatct gt 152 <210> SEQ ID NO 132 <211> LENGTH: 682 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 13, 30, 34, 52, 68, 72, 75, 77, 116, 171, 196, 348, 433, 554, 591, 600, 601, 632, 664, 671 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 132 tggtgggctt ttnttggcta gggataaatn cggngaagca atcaggtctc tncaaggagc 60 agagaatngt angcnanggc agaagcactg tgtaaagaat atggaggaac caaagnccgg 120 ggcaacagtc aaaccttcag gacatctgtt ctttaggaaa cttgggaacc ntgtgaagaa 180 caccctagaa aaatgncaga gagaaaatgg atttatttac tttcaaaaaa ttccaacaga 240 agccccacag ctggaactca aagcaaatta tggtctcgta gagcctatac ctttcgaatt 300 tcctcctaca agtgttcagt ggacaccaga aacattggct gcatttgntc tcaccaaaag 360 acccaaggat gacagtacta aacccaaacc agaagaagaa gtgaaacctg tgaaagaacc 420 agacatcaaa ccncaaaagg acactgggtg ctacatctcc taaaatacaa cttgcactta 480 gaatttctct agcagtaaat aagataaacc acagaatttc agttcttatt tctcaaaatg 540 atttctctga agcntgtaga ataactatta ttcagagggt tatctgcctt naacttacan 600 nttcttaatt tttaatacag cggagatgtt tnttgaaaaa aaaaaaaaaa aaaattgcgg 660 ccgnaagctt naaagggttt ta 682 <210> SEQ ID NO 133 <211> LENGTH: 628 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 2, 35, 53, 69, 78, 87, 90, 117, 128, 135, 147, 150, 209, 269, 294, 457, 537, 544, 546, 547, 578, 610, 617 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 133 gnagcaaaaa aattgtttgc aaaggcagaa gcacngggta aagaatatgg agnaaccagg 60 ggcctgggng acagtcanac cttcagnacn tctgttcttt aggaaacttg gaaaccntgt 120 gaagagcncc ctagnaaaat gtcaganagn aaatggattt atttactttc aaaaaattcc 180 aacagaagcc ccacagctgg aactcaaanc aaattatggt ctcgtagagc ctataccttt 240 cgaatttcct cctacaagtg ttcagtggnc accagaaaca ttggctgcat ttgntctcac 300 caaaagaccc aaggatgaca gtactaaacc caaaccagaa gaagaagtga aacctgtgaa 360 agaaccagac atcaaacctc aaaaggacac tgggtgctac atctcctaaa atacaacttg 420 cacttagaat ttctctagca gtaaataaga taaaccncag aatttcagtt cttatttctc 480 aaaatgattt ctctgaagct tgtagaataa ctattattca gagggttatc tgccttnaac 540 ttanannttc ttaattttta atacagcgga gatgtttntt gaaaaaaaaa aaaaaaaaaa 600 ttgcggccgn aagcttnaaa gggtttta 628 <210> SEQ ID NO 134 <211> LENGTH: 245 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 8, 25, 44, 73, 111 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 134 gacatttntt ctttaggaaa ctttnaaacc tttttaagaa cacnctagaa aaatgtcaga 60 gaggggatgg ttngatttac tttaaaaaaa ttccaacaga agccccacag ntggaactca 120 aaacaaatta tggtctcgta gagcctatac ctttcgaatt tcctcctaca agtgttcagt 180 ggacaccaga aacattggct gcatttgatc tcaccaaaag acccaaggat gacagtacta 240 aaccc 245 <210> SEQ ID NO 135 <211> LENGTH: 504 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 12, 14, 33, 47, 76, 86, 99, 101, 110, 112, 124, 143, 161, 189, 192, 197, 201, 208, 212, 216, 240, 264, 269, 347, 419, 427, 429, 490 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 135 gaaaccntgt gnanagcacc ctagaaaaat gtnagagaaa aaatggnttt atttactttc 60 aaaaaattcc aacagnagcc ccacanctgg aactcaaanc naattatggn cncgtagagc 120 ctanaccctt cgaatttcct ccnacaagtg ttcagtggac nccagaaaca ttggctgcat 180 ttgatctcnc cnaaagnccc naggatgnca gnactnaacc caaaccagaa gaagaagtgn 240 aacctgtgaa agaaccagac atcnaaccnc aaaaggacac tgggtgctac atctcctaaa 300 atacaacttg cacttagaat ttctctagca gtaaataaga taaaccncag aatttcagtt 360 cttatttctc aaaatgattt ctctgaagct tgtagaataa ctattattca gagggttana 420 agccttnanc ttacttgttc ttaattttta atacagcgga gatgtttctt gaaaaaaaaa 480 aaaaaaaaan ttgcggccga aggt 504 <210> SEQ ID NO 136 <211> LENGTH: 505 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 332, 393, 422, 438, 442, 446, 458, 477 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 136 aaaaattcca acagaagccc cacagctgga actcaaagca cattatggtc tcgtagagcc 60 tatacctttc gaatttcctc ctacaagtgt tcagtggaca ccagaaacat tggctgcatt 120 tgatctcacc aaaagaccca aggatgacag tactaaaccc aaaccagaag aagaagtgaa 180 acctgtgaaa gaaccagaca tcaaacctca aaaggacact gggtgctaca tctcctaaaa 240 tacaacttgc acttagaatt tctctagcag taaataagat aaaccacaga atttcagttc 300 ttatttctca aaatgatttc tctgaagctc gnagaataac tattattcag agggttatct 360 gcactccagc ctgggcaaca gagggagact ccncctcaga aaaaaaaaaa aaaaaaaaaa 420 angtcctctg cgttgttncc cnctgnttgc cctatagnga gtcgtattag aagcccnatt 480 tctgcagata tccatcacac tggcg 505 <210> SEQ ID NO 137 <211> LENGTH: 87 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 17, 22, 41, 78 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 137 tttcctccta caagcgntca gnggacacca gaaacattgg ntgcatttga tctcaccaaa 60 agacccaagg atgacagnac taaaccc 87 <210> SEQ ID NO 138 <211> LENGTH: 734 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 19, 29, 44, 65, 95, 654, 661, 662, 667, 669, 690, 699, 718 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 138 atgcttccgg ctggtatgnt gtgtggaant gtgagggata ccantttcac ccaggaacca 60 gctangacca tgattacgcc aagctattta ggtgncacta tagaatactc aagctatgca 120 tcaagcttgg taccgagctc ggatccacta gtaacggccg ccagtgtgct ggaattcggc 180 tttttaggta taccaaatat gcttcaagac tggctggaaa agaaaatata acagaagatg 240 aagcaaaaga agttcatcga agcctaaaga ttgcagctgg gatttttaaa catttaaagg 300 aaagtcatct cccaaaactc attacacctg cggaaaaagg aagagattta gagtcacgac 360 tcatagaagc atacgttatt caatgtcagg ctgaagctca agaagtaaca attgctcgag 420 caattgaact aaaacatgct cctggactaa ttgctgcact ggcgtatgaa acagccaatt 480 tctatcaaaa agctgtttgg agcctgcata ttctgccaaa tggagaaaat atcttcactt 540 gaagatgtgt ttctacacag cttatgctta ctgttaccat ggtgagactt tattggctag 600 tgataaatgc ggtgaagcaa tcaggtctct ccaagaagca gaaaaattgt atgnaaaggc 660 nnaagcncng tgtaaagaat atggagaaan caaaggacna ggaccaacag tcaagcanaa 720 ttctgcagat atcc 734 <210> SEQ ID NO 139 <211> LENGTH: 646 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 1, 3, 29, 48, 49, 57, 65, 66, 68, 75, 76, 97, 104, 105, 445 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 139 nanccgacac tattttacac tcaagctcng catcaagctt ggtaccgnnc tcggatncac 60 tagtnncngc cgccnntgtg ctggaattcg gcttttnagg tatnncaaat atgcttcaag 120 actggctgga aaagaaaata taacagaaca tgaagcaaaa gaagttcatc gaagcctaaa 180 gattgcagct gggattttta aacatttaaa ggaaagtcat ctcccaaaac tcattacacc 240 tgcggaaaaa ggaagagatt tagagtcacg actcatagaa gcatacgtta ttcaatgtca 300 ggctgaagct caagaagtaa caattgctcg agcaattgaa ctaaaacatg ctcctggact 360 aattgctgca ctggcgtatg aaacagccaa tttctatcaa aaagctgttt ggagcctgca 420 tattctgcca aatggagaaa atatnttcac ttgaagatgt gtttctacac agcttatgct 480 tactgttacc atggtgagac tttattggct agtgataaat gcggtgaagc aatcaggtct 540 ctccaagaag cagaaaaatt gtatgcaaag gcagaagcac tgtgtaaaga atatggagaa 600 accaaaggac ctggaccaac agtcaagccg aattctgcag atatcc 646 <210> SEQ ID NO 140 <211> LENGTH: 606 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 1, 2, 9, 14, 19, 25, 41, 52, 54, 59, 61, 70, 79, 80, 99, 107, 114, 115, 120, 121, 122, 550, 601 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 140 nngtccggnc gacnttgcnc agggnatatc cgcgggaatt ntgcttttta tngnatacna 60 natatgcttn aagcactgnn tggaaaagaa aatataacng gggatgnggc aaanntaagn 120 nnatcgaagc ctaaagattg cagctgggat ttctaaacat ttaaaggaaa gtcatctccc 180 aaaactcatt acacctgcgg aaaaaggaag agatttagag tcacgactca tagaagcata 240 cgttattcaa tgtcaggctg aagctcaaga agtaacaatt gctcgagcaa ttgaactaaa 300 acatgctcct ggactaattg ctgcactggc gtatgaaaca gccaatttct atcaaaaagc 360 tgatcatact ttatccagtt tggagcctgc atattctgcc aaatggagaa aatatcttca 420 cgtgaagatg tgtttctaca cagcttatgc ttactgttac catggtgaga ctttattggc 480 tagtgataaa tgcggtgaag caatcaggtc tctccaagaa gcagaaaaat tgtatgcaaa 540 ggcagaagcn ctgtgtaaag aatatggaga aaccaaagga cctggaccaa cagtcaagcc 600 naattc 606 <210> SEQ ID NO 141 <211> LENGTH: 1744 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 29, 30, 95, 103, 1605, 1614, 1615, 1646, 1678, 1685, 1697, 1716 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 141 ttttaaaacc cttttgccct cgcngccann acttcggcac gaggccgata tattgccctt 60 cttcccttag aagaactgct gaaccgactc tgttnatttg ttntccaacc aaaatctagt 120 actttgctat tcaaaagtgt ctggggacca gcagcatcag catctcaggt cctgccccag 180 gctattgaat tagagcctgc attggacaaa accacccacc cccagaaaac atctggagaa 240 aatgacccat tggtttcata ggaacccatt aaaagccaca gctcctgtgt cttttaatta 300 ctatggtgta gtcactggcc cttctgcttc aaaaatatgc aatgacttga ggtcatccag 360 ggcacgactc cttgaactgt tcactgattt gagctgtaat ccagaaatga tgaagaatgc 420 agcagattca tatttctcac ttttacaagg tttcataaat tctttggatg aatctaccca 480 agaaagcaag ttacgatata ttcaaaattt caagtggact gatacattgc aaggacaggt 540 tccaagtgcc cagcaggatg ctgtttttga attaatttcc atgggattta atgtagcttt 600 atggtatacc aaatatgctt caagactggc tggaaaagaa aatataacag aagatgaagc 660 aaaagaagtt catcgaagcc taaagattgc agctgggatt tttaaacatt taaaggaaag 720 tcatctccca aaactcatta cacctgcgga aaaaggaaga gatttagagt cacgactcat 780 agaagcatac gttattcaat gtcaggctga agctcaagaa gtaacaattg ctcgagcaat 840 tgaactaaaa catgctcctg gactaattgc tgcactggcg tatgaaacag ccaatttcta 900 tcaaaaagct gatcatactt tatccagttt ggagcctgca tattctgcca aatggagaaa 960 atatcttcac ttgaagatgt gtttctacac agcttatgct tactgttacc atggtgagac 1020 tttattggct agtgataaat gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt 1080 gtatgcaaag gcagaagcac tgtgtaaaga atatggagaa accaaaggac ctggaccaac 1140 agtcaaacct tcaggacatc tgttctttag gaaacttgga aaccttgtga agaacaccct 1200 agaaaaatgt cagagagaaa atggatttat ttactttcaa aaaattccaa cagaagcccc 1260 acagctggaa ctcaaaacaa attatggtct cgtagagcct atacctttcg aatttcctcc 1320 tacaagtgtt cagtggacac cagaaacatt ggctgcattt gatctcacca aaagacccaa 1380 ggatgacagt actaaaccca aaccagaaga agaagtgaaa cctgtgaaag aaccagacat 1440 caaacctcaa aaggacactg ggtgctacat ctcctaaaat acaacttgca cttagaattt 1500 ctctagcagt aaataagata aaccacagaa tttcagttct tatttctcaa aatgatttct 1560 ctgaagcttg tagaataact attattcaga gggttatctg ccttnaactt acdnnttctt 1620 aatttttaat acagcggaga tgtttnttga aaaaaaaaaa aaaaaaaatt gcggccgnav 1680 gcttnaaagg gttttangag tcgtattaga agcccnattt ctgcagatat ccatcacact 1740 ggcg 1744 <210> SEQ ID NO 142 <211> LENGTH: 560 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 28, 29, 46, 69, 175, 199, 329, 370, 384, 434, 446, 457, 469, 476, 482, 502, 522, 540, 545 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 142 tatcccnact ctctactgtt tctccatnnc cgtttttttg ggctantttt aatttttttt 60 aactttaana aggagatata catacccatg ggctctggat ccggtgatga cgatgacaag 120 ctcgccctta ttggtttcat aggaacccat taaaagccac agctcctgtg tcttntaatt 180 actatggtgt agccactgnc ccttctgctt caaaaatatg caatgacttg aggtcatcca 240 gggcacgact ccttgaactg ttcactgatt tgagctgtaa tccagaaatg atgaagaatg 300 cagcagattc atatttctca cttttacang gtttcataaa ttctttggat gaatctaccc 360 aagaaagcan gttacgatat attnaaaatt tcaagtggac tgatacattg caaggacagg 420 ttccaagtgc ccancaggat gctgtntttg aattaanttc catgggatnt aatgtngctt 480 tntggtatac caaatatgct tnaagactgg ctggaaaaga anatataaca gaagatgaan 540 caatngaagt ctattgtacc 560 <210> SEQ ID NO 143 <211> LENGTH: 436 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 197, 273, 289, 311, 364, 378, 379, 397, 404, 433 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 143 ttgagagggc tagggatagg cttaccttca agctcgccct tatgacccat tggtttcata 60 ggaacccatt aaaagccaca gctcctgtgt cttttaatta ctatggtgta gtcactggcc 120 cttctgcttc aaaaatatgc aatgacttga ggtcatccag ggcacgactc cttgaactgt 180 tcactgattt gagctgnaat ccagaaatga tgaagaatgc agcagattca tatttctcac 240 ttttacaagg tttcataaat tctttggatg aanctaccca agaaagcang ttacgatata 300 ttcaaaattt naagtggact gatacattgc aaggacaggt tccaagtgcc cagcaggatg 360 ctgnttttga attaattnnc atgggattta atgtagnttt atgntatacc aaatatgctt 420 caagactggt tgnaaa 436 <210> SEQ ID NO 144 <211> LENGTH: 515 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 8, 32, 57, 130, 159, 188, 199, 234, 249, 254, 380, 445, 457, 462, 491 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 144 gactccnnga actgttcact gatttgagct gnaatccaga aatgatgaag aatgcancag 60 attcatattt ctcactttta caaggtttca taaattcttt ggatgaatct acccaagaaa 120 gcaagttacn atatattcaa aatttcaagt ggactgatnc attgcaagga caggttccaa 180 gtgcccanca ggatgctgnt tttgaattaa ttcccatggg atttaatgta gctntatggt 240 ataccaaana tgcntcaaga ctggctggaa aagaaaatat aacagaagat gaagcaaaag 300 aagttcatcg aagcctaaag attgcagctg ggatttttaa acatttaaag gaaagtcatc 360 tcccaaaact cattacaccn gcggaaaaag gaagagattt agagtcacga ctcatagaag 420 catacgttat tcaatgtcag gctgnagctc aagaagnaac anttgctcga gcaattgaac 480 taaaacatgc ncctggacta actgctgcac tggcg 515 <210> SEQ ID NO 145 <211> LENGTH: 425 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 30, 54, 56, 57, 60, 88, 106, 133, 142, 152, 154, 157, 159, 165, 167, 179, 184, 192, 202, 204, 234, 246, 253, 265, 267, 289, 292, 310, 319, 361, 365, 373, 374, 388, 399 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 145 ctcactttta caaggtttca taaattcttn ggatgaatct acccaagaaa gcangnnacn 60 acatattcaa aattccaaga ggactganac attgcaagga caggcnccaa gtgcccagca 120 ggatgctgtt ttngaattaa tntccatggg ancnaangna gctcnanggt ataccaaana 180 tgcntcaaga cnggctggaa angnaaatat aacagaagat gaagcaaaag aagntcatcg 240 aagccnaaag atngcagctg ggatntntaa acatttaaag gaaagacang tnccaaaacc 300 cactacaccn gcggaaaang gaagagattt agagtcacga ctcatagaag catacgttat 360 ncaangtcag gcnnaagctc aagaagtnac aattgctcna gcaactgaac taaaacatgc 420 tcctg 425 <210> SEQ ID NO 146 <211> LENGTH: 525 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 3, 17, 20, 25, 28, 39, 53, 106, 208, 227, 401, 433, 455, 507, 518, 520, 525 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 146 agntcgtcga agcctanagn ttgcngcngg gatttttana cctttaaagg aangtcatct 60 cccaaaactc attacacctg cggaaaaagg aagagattta gagtcncaac tcatagaagc 120 atacgttatt caatgtcagg ctgaagctca agaagtagca attgctcgag caattgaact 180 aaaacatgct cctggactaa ttgctgcnct ggcgtatgaa acagccnatt tctaccaaaa 240 agctgatcat actttatcca gtttggagcc tgcatattct gccgaatgga gagaatatct 300 tcgcttgaag atgtgtttct acacagctta tgcttactgt tgccatggtg agactttatt 360 ggctagtgat aaatgcggtg aagcaatcag gtctctccaa naagcagaaa aattgtatgc 420 aaaggcagaa gcnctgtgta aagaatatgg agaanccaaa ggacctggac cagcagtcag 480 accttcagga catctgttct ttagganact tggaaacngn gtgan 525 <210> SEQ ID NO 147 <211> LENGTH: 452 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 12, 32, 33, 57, 144, 156, 187, 244, 307, 316, 365, 408, 416, 417, 444 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 147 aaactcatta cncctgcgga aaaaggaaga gnnttagagt cacgactcat agaagcntac 60 gttattcaat gtcaggctga agctcaagaa gtagcaattg ctcgagcaat tgaactaaaa 120 catgctcctg gactaattgc tgcnctggcg tataanacag ccaatttcta tcaaaaagct 180 ggtcatnctt tatccagttt ggagcctgca tattctgtca aatggagaaa atatcttcac 240 ttgnagatgt gtttctacac agcttatgct tactgttacc atggtgaggc tttattggct 300 agtgatnaat gcggtnaagc aatcaggtct ctccaagaag cagaaaaatt gtatgcaaag 360 gcagnagcac tgtgtaaaga atatggagaa accaaaggac ctggaccnac agtcanncct 420 tcagggcatc tgttctttag gaancgtggt tg 452 <210> SEQ ID NO 148 <211> LENGTH: 513 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 18, 52, 57, 198, 246, 251, 290, 326, 346, 424 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 148 aacatgctcc tgggctantt gctgcactgg cgtatgaaac agccaatttc tnccaanaag 60 ctgatcatac tttatccagt ttggagcctg catattctgc caaatggaga aaatatcttc 120 acttgaagat gtgtttctac acagcttatg cttactgtta ccatggtgag actttattgg 180 ctagtgataa atgcggtnaa gcaatcaggt ctctccaaga agcagaaaaa ttgtatgcaa 240 aggcanaagc nctgtgtaaa gaatatggag aaaccaaagg acctggaccn acagtcaaac 300 cttcaggaca tctgttcttt aggaancttg gaaaccttgt gaagancacc ctagaaaaat 360 gtcagagaga aaatggattt atactaaacc caaaccagaa gaagaagtga aacctgtgaa 420 aganccagac atcaaacctc aaaaggacac tgggtgctac atctccaagg gcgagcttga 480 aggtaagcct atccctaacc ctctcctcgg tcg 513 <210> SEQ ID NO 149 <211> LENGTH: 1744 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 29, 30, 95, 103, 1605, 1614, 1615, 1646, 1678, 1685, 1697, 1716 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 149 ttttaaaacc cttttgccct cgcngccann acttcggcac gaggccgata tattgccctt 60 cttcccttag aagaactgct gaaccgactc tgttnatttg ttntccaacc aaaatctagt 120 actttgctat tcaaaagtgt ctggggacca gcagcatcag catctcaggt cctgccccag 180 gctattgaat tagagcctgc attggacaaa accacccacc cccagaaaac atctggagaa 240 aatgacccat tggtttcata ggaacccatt aaaagccaca gctcctgtgt cttttaatta 300 ctatggtgta gtcactggcc cttctgcttc aaaaatatgc aatgacttga ggtcatccag 360 ggcacgactc cttgaactgt tcactgattt gagctgtaat ccagaaatga tgaagaatgc 420 agcagattca tatttctcac ttttacaagg tttcataaat tctttggatg aatctaccca 480 agaaagcaag ttacgatata ttcaaaattt caagtggact gatacattgc aaggacaggt 540 tccaagtgcc cagcaggatg ctgtttttga attaatttcc atgggattta atgtagcttt 600 atggtatacc aaatatgctt caagactggc tggaaaagaa aatataacag aagatgaagc 660 aaaagaagtt catcgaagcc taaagattgc agctgggatt tttaaacatt taaaggaaag 720 tcatctccca aaactcatta cacctgcgga aaaaggaaga gatttagagt cacgactcat 780 agaagcatac gttattcaat gtcaggctga agctcaagaa gtaacaattg ctcgagcaat 840 tgaactaaaa catgctcctg gactaattgc tgcactggcg tatgaaacag ccaatttcta 900 tcaaaaagct gatcatactt tatccagttt ggagcctgca tattctgcca aatggagaaa 960 atatcttcac ttgaagatgt gtttctacac agcttatgct tactgttacc atggtgagac 1020 tttattggct agtgataaat gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt 1080 gtatgcaaag gcagaagcac tgtgtaaaga atatggagaa accaaaggac ctggaccaac 1140 agtcaaacct tcaggacatc tgttctttag gaaacttgga aaccttgtga agaacaccct 1200 agaaaaatgt cagagagaaa atggatttat ttactttcaa aaaattccaa cagaagcccc 1260 acagctggaa ctcaaaacaa attatggtct cgtagagcct atacctttcg aatttcctcc 1320 tacaagtgtt cagtggacac cagaaacatt ggctgcattt gatctcacca aaagacccaa 1380 ggatgacagt actaaaccca aaccagaaga agaagtgaaa cctgtgaaag aaccagacat 1440 caaacctcaa aaggacactg ggtgctacat ctcctaaaat acaacttgca cttagaattt 1500 ctctagcagt aaataagata aaccacagaa tttcagttct tatttctcaa aatgatttct 1560 ctgaagcttg tagaataact attattcaga gggttatctg ccttnaactt acdnnttctt 1620 aatttttaat acagcggaga tgtttnttga aaaaaaaaaa aaaaaaaatt gcggccgnav 1680 gcttnaaagg gttttangag tcgtattaga agcccnattt ctgcagatat ccatcacact 1740 ggcg 1744 <210> SEQ ID NO 150 <211> LENGTH: 853 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 39, 71, 90, 94, 136, 814, 816, 832, 844 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 150 acggatatct gcagaattcg gcttatgacc cattggttnc ataggaaccc attaaaagcc 60 acagcttctg ngtcttttaa ttactatggn gtantcactg gcccttctgc ttcaaaaata 120 tgcaatgact tgaggncatc cagggcacga ctccttgaac tgttcactga tttgagctgt 180 aatccagaaa tgatgaagaa tccagcagat tcatatttct cacttttaca aggtttcata 240 aattctttgg atgaatctac ccaagaaagc aagttacgat atattcaaaa tttcaagtgg 300 actgatacat tgcaaggaca ggttccaagt gcccagcagg atgctgtttt tgaattaatt 360 tccatgggat ttaatgtagc tttatggtat accaaatatg cttcaagact ggctggaaaa 420 gaaaatataa cagaagatga agcaaaagaa gttcatcgaa gcctaaagat tgcagctggg 480 atttttaaac atttaaagga aagtcatctc ccaaaactca ttacacctgc ggaaaaagga 540 agagatttag agtcacgact catagaagca tacgttattc aatgtcaggc tgaagctcaa 600 gaagtaacaa ttgctcgagc aattgaacta aaacatgctc ctggactaat tgctgcactg 660 gcgtatgaaa cagccaattt ctatcaaaaa gctgatcata ctttatccag tttggagcct 720 gcatattctg ccaaatggag aaaatatctt cacttgaaga tgtgtttcta cacagcttat 780 gcttactgtt accatggtga gactttattg gctngngata aatgcggtga ancaatcagg 840 tctnttcaag aag 853 <210> SEQ ID NO 151 <211> LENGTH: 884 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 1, 11, 86, 95, 865, 876 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 151 ntcttttaac nactatggtg tagtcactgg cccttctgct tcaaaaatat gcaatgactt 60 gaggtcatcc agggcacgac tccttnaact gttcnctgat ttgagctgta atccagaaat 120 gatgaagaat ccagcagatt catatttctc acttttacaa ggtttcataa attctttgga 180 tgaatctacc caagaaagca agttacgata tattcaaaat ttcaagtgga ctgatacatt 240 gcaaggacag gttccaagtg cccagcagga tgctgttttt gaattaattt ccatgggatt 300 taatgtagct ttatggtata ccaaatatgc ttcaagactg gctggaaaag aaaatataac 360 agaagatgaa gcaaaagaag ttcatcgaag cctaaagatt gcagctggga tttttaaaca 420 tttaaaggaa agtcatctcc caaaactcat tacacctgcg gaaaaaggaa gagatttaga 480 gtcacgactc atagaagcat acgttattca atgtcaggct gaagctcaag aagtaacaat 540 tgctcgagca attgaactaa aacatgctcc tggactaatt gctgcactgg cgtatgaaac 600 agccaatttc tatcaaaaag ctgatcatac tttatccagt ttggagcctg catattctgc 660 caaatggaga aaatatcttc acttgaagat gtgtttctac acagcttatg cttactgtta 720 ccatggtgag actttattgg ctagtgataa atgcggtgaa gcaatcaggt ctctccaaga 780 agcagaaaaa ttgtatgcaa aggcagaagc actgtgtaaa gagtatggag aagccaaagg 840 acctggacca acagtcaaac cttcnggaca tctgtncttt agga 884 <210> SEQ ID NO 152 <211> LENGTH: 879 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 4, 786, 860 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 152 ggcncgccag tgtggatggg atatctgcag gaattcggct tatgacccat tggtttcata 60 ggaacccatt aaaagccaca gcttctgtgt cttttaatta ctatggtgta gtcactggcc 120 cttctgcttc aaaaatatgc aatgacttga ggtcatccag ggcacgactc cttgaactgt 180 tcactgattt gagctgtaat ccagaaatga tgaagaatgc agcagattca tatttctcac 240 ttttacaagg tttcataaat tctttggatg aatctaccca agaaagcaag ttacgatata 300 ttcaaaattt caagtggacg gatacattgc aaggacaggt tccaagaaga tgaagcaaaa 360 gaagttcatc gaagcctaaa gattgcagct gggattttta aacatttaaa ggaaagtcat 420 ctcccaaaac tcattacacc tgcggaaaaa ggaagagatt tagagtcacg actcatagaa 480 gcatacgtta ttcaatgtca ggctgaagct caagaagtaa caattgctcg agcaattgaa 540 ctaaaacatg ctcctggact aattgctgca ctggcgtatg aaacagccaa tttctatcaa 600 aaagctgttt ggggcctgca tattctgcca aatggagaaa atatcttcac ttgaagatgt 660 gtttctacac agcttatgct tactgttacc atggtgagac tttattggct agtgataaat 720 gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt gtatgcaaag gcagaagcac 780 tgtgtnaaga atatggagaa accaaaggac ctggaccaac agacaaacct tcaggacatc 840 tgttctttag gaaacttggn aaccttggga agaacaccc 879 <210> SEQ ID NO 153 <211> LENGTH: 484 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 18, 19, 37, 56, 67, 82, 95, 98, 105, 110, 132, 153, 163, 186, 196, 205, 206, 214, 253, 255, 263, 275, 280, 292, 325, 326, 343, 355, 357, 359, 390, 399, 401, 427, 432, 434, 442, 448, 452, 455, 460, 471, 481 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 153 aaaggcccca taggaacnna gtaaaaggga cagcttntgt gacttttaat tactanggcg 60 cagtcantgg ccgttatgct tnaaaaatat gcaangantt gaggncatcn agggcacgac 120 tccttgaact gntcactgat ttgagctgta atncagaaat gangaagaat gcagcagatt 180 catatntctc actttnacaa ggttnnataa attntttgga tgaatctacc caagaaagca 240 agttacgata tananaaaat ttnaagtgga ctganacatn gcaaggacag gntccaagta 300 taacagaaga tgaagcaaaa gaagnncatc gaagcctaaa gantgcagat gggantntna 360 aacatctaaa ggaaagtcaa ctaccaaaan tcattacanc ngcggaaaaa ggaagagatt 420 tagaganacg antnatagaa gnatacgnta tnaantgatn ggctgaagct naagaagtaa 480 naat 484 <210> SEQ ID NO 154 <211> LENGTH: 853 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 83, 792, 823, 835, 851 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 154 ttttaattac tatggtgtag tcactggccc ttctgcttca aaaatatgca atgacttgag 60 gtcatccagg gcacgactcc ttntactgtt cactgatttg agctgtaatc cagaaatgat 120 gaagaatgca gcagattcat atttctcact tttacaaggt ttcataaatt ctttggatga 180 atctacccaa gaaagcaagt tacgatatat tcaaaatttc aagtggactg atacattgca 240 aggacaggtt ccaagtataa cagaagatga agcaaaagaa gttcatcgaa gcctaaagat 300 tgcagctggg atttttaaac atttaaagga aagtcatctc ccaaaactca ttacacctgc 360 ggaaaaagga agagatttag agtcacgact catagaagca tacgttattc aatgtcaggc 420 tgaagctcaa gaagtaacaa ttgctcgagc aattgaacta aaacatgctc ctggactaat 480 tgctgcactg gcgtatgaaa cagccaattt ctatcaaaaa gctgatcata ctttatccag 540 tttggagcct gcatattctg ccaaatggag aaaatatctt cacttgaaga tgagtttcta 600 cacagcttat gcttactgtt accatggtga gactttattg gctagtgata agtgcggtga 660 agcaatcagg tctctccaag aagcagaaaa attgtatgca aaggcagaag cactgtgtaa 720 agaatatgga gaagccaaag gacctggacc aacagtcaaa ccttcaggac atctgttctt 780 taggaaactg gnaaaccttg tgaagaacac cctagaaaaa tgntagagag aaaanggatt 840 tatttacttt naa 853 <210> SEQ ID NO 155 <211> LENGTH: 869 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 84, 804 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 155 cttttaatta ctatggtgta gtcactggcc cttctgcttc aaaaatatgc aatgacttga 60 ggtcatccag ggcacgactc cttnaactgt tcactgattt gagctgtaat ccagaaatga 120 tgaagaatgc agcagattca tatttctcac ttttacaagg tttcataaat tctttggatg 180 aatctaccca agaaagcaag ttacgatata ttcaaaattt caagtggacg gatacattgc 240 aaggacaggt tccaagaaga tgaagcaaaa gaagttcatc gaagcctaaa gattgcagct 300 gggattttta aacatttaaa ggaaagtcat ctcccaaaac tcattacacc tgcggaaaaa 360 ggaagagatt tagagtcacg actcatagaa gcatacgtta ttcaatgtca ggctgaagct 420 caagaagtaa caattgctcg agcaattgaa ctaaaacatg ctcctggact aattgctgca 480 ctggcgtatg aaacagccaa tttctatcaa aaagctgttt ggggcctgca tattctgcca 540 aatggagaaa atatcttcac ttgaagatgt gtttctacac agcttatgct tactgttacc 600 atggtgagac tttattggct agtgataaat gcggtgaagc aatcaggtct ctccaagaag 660 cagaaaaatt gtatgcaaag gcagaagcac tgtgtaaaga atatggagaa accaaaggac 720 ctggaccaac agacaaacct tcaggacatc tgttctttag gaaacttgga aaccttgtga 780 agaacaccct agaaaaatgt cagngagaaa atggatttat ttactttcaa aaaattccaa 840 cagaagcccc acagctggaa ctcaaagca 869 <210> SEQ ID NO 156 <211> LENGTH: 871 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 7, 18, 43, 53, 70, 145, 170, 773, 774 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 156 ggatgantct acccaagnaa gcaagttacg atatattcaa atnttcaagt ggnctgatac 60 attgcaaggn caggttccaa gtataacaga agatgaagca aaagaagttc atcgaagcct 120 aaagattgca gctgggattt ttaancattt aaaggaaagt catctcccan aactcattac 180 acctgcggaa aaaggaagag atttagagtc acgactcata gaagcatacg ttattcaatg 240 tcaggctgaa gctcaagaag taacaattgc tcgagcaatt gaactaaaac atgctcctgg 300 actaattgct gcactggcgt atgaaacagc caatttctat caaaaagctg atcatacttt 360 atccagtttg gagcctgcat attctgccaa atggagaaaa tatcttcact tgaagatgag 420 tttctacaca gcttatgctt actgttacca tggtgagact ttattggcta gtgataagtg 480 cggtgaagca atcaggtctc tccaagaagc agaaaaattg tatgcaaagg cagaagcact 540 gtgtaaagaa tatggagaag ccaaaggacc tggaccaaca gtcaaacctt caggacatct 600 gttctttagg aaacttggaa accttgtgaa gaacacccta gaaaaatgtt agagagaaaa 660 tggatttatt tactttcaaa aaattccaac agaagcccca cagctggaac tcaaagcaaa 720 ttatggtctc gtagagccta tacctttcga atttcctcct acaagtgtcc agnngacacc 780 aaaaacattg gctgcatttg atctcaccaa aagacccaag gatgacagta ctaaacccaa 840 accagaagaa gaagtgaaac ctgtgaaaga g 871 <210> SEQ ID NO 157 <211> LENGTH: 816 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 5, 36, 39, 40, 50, 74, 86, 105, 114, 161, 361, 783 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 157 gcaanagaag ttcgtcgaag cctaaagatt gcagcnggnn tttttagacn tttaaaggag 60 agtcatctcc caanactcat tacacntgcg gaaaaaggaa gaganttaga gtcncgactc 120 atagaagcat acgttattca atgtcaggct gaagctcaag nagtaacaat tgctcgagca 180 attgaactaa aacatgctcc tggactaatt gctgcactgg cgtatgaaac agccaatttc 240 tatcaaaaag ctgatcatac tttatccagt ttggagcctg catattctgc caaatggaga 300 aaatatcttc acttgaagat gagtttctac acagcttatg cttactgtta ccatggtgag 360 nctttattgg ctagtgataa gtgcggtgaa gcaatcaggt ctctccaaga agcagaaaaa 420 ttgtatgcaa aggcagaagc actgtgtaaa gaatatggag aagccaaagg acctggacca 480 acagtcaaac cttcaggaca tctgttcttt aggaaacttg gaaaccttgt gaagaacacc 540 ctagaaaaat gttagagaga aaatggattt atttactttc aaaaaattcc aacagaagcc 600 ccacagctgg aactcaaagc aaattatggt ctcgtagagc ctataccttt cgaatttcct 660 cctacaagtg tccagtggac accagaaaca ttggctgcat ttgatctcac caaaagaccc 720 aaggatgaca gtactaaacc caaaccagaa gaagaagtga aacctgtgaa agaaccagac 780 atnaaacctc aagaggacac tgggtgctac atctcc 816 <210> SEQ ID NO 158 <211> LENGTH: 747 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 11, 12, 14, 29, 80, 146, 660, 661, 662 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 158 ctgggatttt nnancattta aagaaaagnc atctcccaaa actcattaca cctgcggaaa 60 aaggaagaga tttagagtcn cgactcatag aagcatacgt tattcaatgt caggctgaag 120 ctcaagaagt aacaattgct cgagcnattg aactaaaaca tgctcctgga ctaattgctg 180 cactggcgta tgaaacagcc aatttctatc aaaaagctga tcatacttta tccagtttgg 240 agcctgcata ttctgccaaa tggagaaaat atcttcactt gaagatgtgt ttctacacag 300 cttatgctta ctgttaccat ggtgagactt tattggctag tgataaatgc ggtgaagcaa 360 tcaggtctct ccaagaagca gaaaaattgt atgcaaaggc agaagcactg tgtaaagagt 420 atggagaagc caaaggacct ggaccaacag tcaaaccttc aggacatctg ttctttagga 480 aacttggaga ccttgtgaag aacaccctag aaaaatgtca gagagaaaat ggatttattt 540 actttcaaaa aattccaaca gaagccccac agctggaact caaagcaaat tatggtctcg 600 tagagcctat acctttcgaa tttcctccta caagtgctca gtggacacca aaaacattgn 660 nngcatttga tctcaccaaa agacccaagg atgacagtac taaacccaaa ccagaagaag 720 aagtgaaacc tgtgaaggaa ccagaaa 747 <210> SEQ ID NO 159 <211> LENGTH: 654 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 24, 25, 32, 69, 79, 142, 189, 433, 461, 600, 602 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 159 gtcaggctga agctcaagaa gtannaattg cncgagcaat tgaactaaaa catgctcctg 60 gactaattnc tgcactggng tatgaaacag ccaatttcta tcaaaaagct gatcatactt 120 tatccagttt ggagcctgca tnttctgcca aatggagaaa atatcttcac ttgaagatgt 180 gtttctacnc agcttatgct tactgttacc atggtgagac tttattggct agtgataaat 240 gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt gtatgcaaag gcagaagcac 300 tgtgtaaaga gtatggagaa gccaaaggac ctggaccaac agtcaaacct tcaggacatc 360 tgttctttag gaaacttgga gaccttgtga agaacaccct agaaaaatgt cagagagaaa 420 atggatttat ttnctttcaa aaaattccaa cagaagcccc ncagctggaa ctcaaagcaa 480 attatggtct cgtagagcct atacctttcg aatttcctcc tacaagtgct cagtggacac 540 cagaaacatt ggctgcattt gatctcacca aaagacccaa ggatgacagt actaaacccn 600 anccagaaga agaagtgaaa cctgtgaagg aaccagacat caaacctcaa aagg 654 <210> SEQ ID NO 160 <211> LENGTH: 589 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 19, 24, 29, 34, 37, 41, 171, 584 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 160 catgctcctg gactaattnc tgcnctggng tatnaancag ncaatttcta tcaaaaagct 60 gtttggggcc tgcatattct gccaaatgga gaaaatatct tcacttgaag atgtgtttct 120 acacagctta tgcttactgt taccatggtg agactttatt ggctagtgat naatgcggtg 180 aagcaatcag gtctctccaa gaagcagaaa aattgtatgc aaaggcagaa gcactgtgta 240 aagaatatgg agaaaccaaa ggacctggac caacagacaa accttcagga catctgttct 300 ttaggaaact tggaaacctt gtgaagaaca ccctagaaaa atgtcagaga gaaaatggat 360 ttatttactt tcaaaaaatt ccaacagaag ccccacagct ggaactcaaa gcaaattatg 420 gtctcgtaga gcctatacct ttcgaatttc ctcctacaag tgttcagtgg acaccagaaa 480 cattggctgc atttgatctc accaaaagac ccaaggatga cagtactaaa cccaaaccag 540 aagaagaagt gaaacctgtg aaagaaccag acatcaaacc tcanaagga 589 <210> SEQ ID NO 161 <211> LENGTH: 551 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 14, 60, 467, 476 <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 161 aactaattgc tgcnctggcg tatgaaacag ccaatttcta tcaaaaagct gtttggggcn 60 tgcatattct gccaaatgga gaaaatatct tcacttgaag atgtgtttct acacagctta 120 tgcttactgt taccatggtg agactttatt ggctagtgat aaatgcggtg aagcaatcag 180 gtctctccaa gaagcagaaa aattgtatgc aaaggcagaa gcactgtgta aagaatatgg 240 agaaaccaaa ggacctggac caacagacaa accttcagga catctgttct ttaggaaact 300 tggaaacctt gtgaagaaca ccctagaaaa atgtcagaga gaaaatggat ttatttactt 360 tcaaaaaatt ccaacagaag ccccacagct ggaactcaaa gcaaattatg gtctcgtaga 420 gcctatacct ttcgaatttc ctcctacaag tgttcagtgg acaccanaaa cattgnaagc 480 atttgatctc accaaaagac ccaaggatga cagtactaaa cccaaaccag aagaagaagt 540 gaaacctgtg a 551 <210> SEQ ID NO 162 <211> LENGTH: 43 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 162 Leu Gln Gly Phe Ile Asn Ser Leu Asp Glu Ser Thr Gln Glu Ser Lys 1 5 10 15 Leu Arg Tyr Ile Gln Asn Phe Lys Trp Thr Asp Thr Leu Gln Gly Gln 20 25 30 Val Pro Ser Ala Gln Gln Asp Ala Val Phe Glu 35 40 <210> SEQ ID NO 163 <211> LENGTH: 21 <212> TYPE: PRT <213> ORGANISM: Saccharomyces sp. <400> SEQUENCE: 163 Val Gln Phe Ala Ile Asn Lys Val Asp Lys Ile Thr His Glu Ser Lys 1 5 10 15 Leu Arg Tyr Leu Gln 20 <210> SEQ ID NO 164 <211> LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Mus musculus <400> SEQUENCE: 164 Phe His Trp Tyr Asp Ser Leu Thr Gly Val Pro Ala Gln Gln Arg Ala 1 5 10 15 Leu Ala Phe Glu 20 <210> SEQ ID NO 165 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 165 Ala Gln Gln Asp Ala Val 1 5 <210> SEQ ID NO 166 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 166 Phe Tyr Gln Lys Ala 1 5 <210> SEQ ID NO 167 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 167 Lys Tyr Leu His Leu 1 5 <210> SEQ ID NO 168 <211> LENGTH: 308 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 168 Met Lys Ile Gly Pro Ser Phe Lys Ala Asn Ala Ile Thr Asp Ala Gln 1 5 10 15 Gln Asp Ala Val Phe Glu Leu Ile Ser Met Gly Phe Asn Val Ala Leu 20 25 30 Trp Tyr Thr Lys Tyr Ala Ser Arg Leu Ala Gly Lys Glu Asn Ile Thr 35 40 45 Glu Asp Glu Ala Lys Glu Val His Arg Ser Leu Lys Ile Ala Ala Gly 50 55 60 Ile Phe Lys His Leu Lys Glu Ser His Leu Pro Lys Leu Ile Thr Pro 65 70 75 80 Ala Glu Lys Gly Arg Asp Leu Glu Ser Arg Leu Ile Glu Ala Tyr Val 85 90 95 Ile Gln Cys Gln Ala Glu Ala Gln Glu Val Thr Ile Ala Arg Ala Ile 100 105 110 Glu Leu Lys His Ala Pro Gly Leu Ile Ala Ala Leu Ala Tyr Glu Thr 115 120 125 Ala Asn Phe Tyr Gln Lys Ala Ala Lys Tyr Leu His Leu Lys Met Cys 130 135 140 Phe Tyr Thr Ala Tyr Ala Tyr Cys Tyr His Gly Glu Thr Leu Leu Ala 145 150 155 160 Ser Asp Lys Cys Gly Glu Ala Ile Arg Ser Leu Gln Glu Ala Glu Lys 165 170 175 Leu Tyr Ala Lys Ala Glu Ala Leu Cys Lys Glu Tyr Gly Glu Thr Lys 180 185 190 Gly Pro Gly Pro Thr Val Lys Pro Ser Gly His Leu Phe Phe Arg Lys 195 200 205 Leu Gly Asn Leu Val Lys Asn Thr Leu Glu Lys Cys Gln Arg Glu Asn 210 215 220 Gly Phe Ile Tyr Phe Gln Lys Ile Pro Thr Glu Ala Pro Gln Leu Glu 225 230 235 240 Leu Lys Ala Asn Tyr Gly Leu Val Glu Pro Ile Pro Phe Glu Phe Pro 245 250 255 Pro Thr Ser Val Gln Trp Thr Pro Glu Thr Leu Ala Ala Phe Asp Leu 260 265 270 Thr Lys Arg Pro Lys Asp Asp Ser Thr Lys Pro Lys Pro Glu Glu Glu 275 280 285 Val Lys Pro Val Lys Glu Pro Asp Ile Lys Pro Gln Lys Asp Thr Gly 290 295 300 Cys Tyr Ile Ser 305 <210> SEQ ID NO 169 <211> LENGTH: 850 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 169 atgaaaatcg gcccgtcttt taaagccaat gccattaccg atgcccagca ggatgctgtt 60 tttgaattaa tttccatggg atttaatgta gctttatggt ataccaaata tgcttcaaga 120 ctggctggaa aagaaaatat aacagaagat gaagcaaaag aagttcatcg aagcctaaag 180 attgcagctg ggatttttaa acatttaaag gaaagtcatc tcccaaaact cattacacct 240 gcggaaaaag gaagagattt agagtcacga ctcatagaag catacgttat tcaatgtcag 300 gctgaagctc aagaagtaac aattgctcga gcaattgaac taaaacatgc tcctggacta 360 attgctgcac tggcgtatga aacagccaat ttctatcaaa aagctgcaaa atatcttcac 420 ttgaagatgt gtttttacac agcttatgct tactgttacc atggtgagac tttattggct 480 agtgataaat gcggtgaagc aatcaggtct ctccaagaag cagaaaaatt gtatgcaaag 540 gcagaagcac tgtgtaaaga atatggagaa accaaaggac ctggaccaac agtcaaacct 600 tcaggacatc tgttctttag gaaacttgga aaccttgtga agaacaccct agaaaaatgt 660 cagagagaaa atggatttat ttactttcaa aaaattccaa cagaagcccc acagctggaa 720 ctcaaagcaa attatggtct cgtagagcct atacctttcg aatttcctcc tacaagtgtt 780 cagtggacac cagaaacatt ggctgcattt gatctcacca aaagacccaa ggatgacagt 840 actaaaccca 850 <210> SEQ ID NO 170 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 170 Glu Ser Lys Leu Arg Tyr Ile Gln 1 5 <210> SEQ ID NO 171 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: Sacchromyces sp. <400> SEQUENCE: 171 Glu Ser Lys Leu Arg Tyr Leu Gln 1 5 <210> SEQ ID NO 172 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 172 accaaatatg cttcaagact 20 <210> SEQ ID NO 173 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 173 cacgtcatcc agcagagaat ggaaact 27 <210> SEQ ID NO 174 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: PCR primer <400> SEQUENCE: 174 tgaccaagat gttgatgttg gataagag 28 

1. An isolated PAL-18 polypeptide comprising an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of: (a) a sequence recited in SEQ ID NOs:1-71; (b) sequences that hybridize to a sequence recited in SEQ ID NOs:1-71 or 75-79 under moderately stringent conditions; and (c) complements of the polynucleotide sequences of (a) and (b).
 2. An isolated polypeptide according to claim 1, wherein the polypeptide comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in SEQ ID NOs:75-79 or a complement thereof.
 3. An isolated PAL-18 polypeptide comprising SEQ ID NOs:72-74.
 4. A fragment of a PAL-18 polypeptide comprising at least 15 contiguous amino acid residues of SEQ ID NOs:72-74.
 5. An isolated polynucleotide encoding at least 15 amino acid residues of a PAL-18 polypeptide, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the PAL-18 polypeptide comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in SEQ ID NOs:1-71, 75-79 or a complement thereof.
 6. An isolated polynucleotide encoding a PAL-18 polypeptide or a variant thereof, wherein the PAL-18 polypeptide comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in SEQ ID NOs: 1-71, 75-79, a complement thereof, or a sequence having at least 70% identity with SEQ ID NOs: 1-71 or 75-79.
 7. An isolated polynucleotide, comprising a sequence recited in SEQ ID NOs: 1-71 or 75-79.
 8. An isolated polynucleotide, comprising a sequence that hybridizes to a sequence recited in SEQ ID NOs:1-71 or 75-79 under moderately stringent conditions.
 9. An isolated polynucleotide, comprising a sequence having at least 70% identity with SEQ ID NOs:1-71 or 75-79.
 10. An isolated polynucleotide complementary to a polynucleotide according to any one of claims 5-9.
 11. An expression vector, comprising a polynucleotide according to any one of claims 5-9.
 12. A host cell transformed or transfected with an expression vector according to claim
 11. 13. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a PAL-18 polypeptide or fragment thereof that comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in SEQ ID NOs: 1-71, 75-79 or a complement thereof.
 14. A pharmaceutical composition, comprising a physiologically acceptable carrier and at least one component selected from the group consisting of: (a) a polypeptide according to claim 1; (b) a fragment according to claim 4; (c) a polynucleotide according to claim 5; and (d) an antibody according to claim
 13. 15. A method for determining the presence or absence of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with a binding agent that binds to a PAL-18 polypeptide, wherein the PAL-18 polypeptide comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in SEQ ID NOs: 1-71, 75-79 or a complement thereof; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; and (c) comparing the amount of polypeptide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.
 16. The method according to claim 15, wherein the binding agent is an antibody.
 17. The method according to claim 16, wherein the antibody is a monoclonal antibody.
 18. The method according to claim 15, wherein the cancer is prostate or colon cancer.
 19. The method according to claim 15, wherein the cancer is breast cancer.
 20. The method according to claim 15, wherein the detecting step involves detection of various molecular weight isoforms of PAL-18.
 21. The method according to claim 15, wherein the detecting step involves detection of expression levels of PAL-18.
 22. The method according to claim 15, wherein the biological sample is selected from the group consisting of a tissue sample, a urine sample, a blood sample, and a stool sample.
 23. The method according to claim 22, wherein the biological sample is a stool sample.
 24. A method for monitoring the progression of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a PAL-18 polypeptide or fragment thereof, wherein the PAL-18 polypeptide or fragment thereof comprises at least 15 contiguous amino acid residues encoded by a polynucleotide sequence recited in SEQ ID NOs:1-71, 75-79 or a complement thereof; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polypeptide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.
 25. The method according to claim 24, wherein the binding agent is an antibody.
 26. The method according to claim 25, wherein the antibody is a monoclonal antibody.
 27. The method according to claim 24, wherein the cancer is colon cancer or prostate cancer.
 28. The method according to claim 24, wherein the cancer is breast cancer.
 29. The method according to claim 24, wherein the detecting step involves detection of various molecular weight isoforms of PAL-18.
 30. The method according to claim 24, wherein the detection step involves detection of expression levels of PAL-18.
 31. The method according to claim 24, wherein the biological sample is selected from the group consisting of a tissue sample, a urine sample, a blood sample, and a stool sample.
 32. The method according to claim 31, wherein the biological sample is a stool sample.
 33. A method for determining the presence or absence of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a PAL-18 polypeptide or fragment thereof, wherein the PAL-18 polypeptide comprises at least 15 contiguous amino acid residues encoded by a polynucleotide sequence recited in SEQ ID NOs:1-71, 75-79 or a complement thereof and wherein the at least 15 contiguous amino acid residues retain the ability to react with an a PAL18-specific antisera; (b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and (c) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.
 34. The method according to claim 33, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a polymerase chain reaction.
 35. The method according to claim 34, wherein the polymerase chain reaction is RT-PCR.
 36. The method according to claim 34, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.
 37. A method for monitoring the progression of a cancer in a patient, comprising the steps of: (a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a PAL-18 polypeptide or fragment thereof, wherein the PAL-18 polypeptide comprises at least 15 contiguous amino acid residues encoded by a polynucleotide sequence recited in SEQ ID NOs:1-71, 75-79 or a complement thereof and wherein the at least 15 contiguous amino acid residues retain the ability to react with an a PAL-18-specific antisera; (b) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; (c) repeating steps (a) and (b) using a biological sample obtained from the patient at a subsequent point in time; and (d) comparing the amount of polynucleotide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.
 38. The method according to claim 37, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a polymerase chain reaction.
 39. The method according to claim 38, wherein the polymerase chain reaction is RT-PCR.
 40. The method according to claim 38, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.
 41. A diagnostic kit, comprising: (a) one or more antibodies according to claim 13; and (b) a detection reagent comprising a reporter group.
 42. The kit according to claim 41, wherein the antibodies are immobilized on a solid support.
 43. The kit according to claim 41, wherein the detection reagent comprises an anti-immunoglobulin, protein G, protein A or lectin.
 44. The kit according to claim 41, wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.
 45. An oligonucleotide comprising 10 to 40 contiguous nucleotides that hybridize under highly stringent conditions to a polynucleotide that encodes a PAL-18 polypeptide or fragment thereof, wherein the PAL-18 polypeptide or fragment thereof comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NOs:1-71, 75-79 or a complement thereof.
 46. A oligonucleotide according to claim 45, wherein the oligonucleotide comprises 10-40 contiguous nucleotides recited in any one of SEQ ID NOs:75-79.
 47. A diagnostic kit, comprising: (a) an oligonucleotide according to claim 45 or claim 46; and (b) a diagnostic reagent for use in a polymerase chain reaction or hybridization assay.
 48. A method of treating a tumor cell comprising the step of modulating a tumor-associated PAL-18 polypeptide or a nucleic acid molecule encoding said polypeptide, said nucleic acid molecule characterized by the ability of said nucleic acid molecule to hybridize under moderate stringency with any one of SEQ ID NOs:1-71, 75-79, or a complement thereof.
 49. The method according to claim 48, wherein the method comprises the step of modulating the antigen.
 50. The method according to claim 48 or 49, wherein the tumor cell is a colorectal or prostate tumor cell.
 51. An agent that modulates a tumor-associated PAL-18 polypeptide or a nucleic acid molecule encoding said polypeptide, said nucleic acid molecule characterized by the ability of said nucleic acid molecule to hybridize under moderate stringency with any one of SEQ ID NOs:1-71, 75-79, or a complement thereof.
 52. A composition comprising an agent that modulates a PAL-18 polypeptide or a nucleic acid molecule encoding said polypeptide, said nucleic acid molecule characterized by the ability of said nucleic acid molecule to hybridize under moderate stringency with any one of SEQ ID NOs:1-71, 75-79, or a complement thereof, in combination with a pharmaceutically acceptable carrier or diluent.
 53. A method for diagnosing abnormal PAL-18, comprising isolating PAL-18 encoding nucleic acid molecules from a sample and subsequently screening for single nucleotide polymorphisms, whereby detection of a single nucleotide polymorphism indicates an abnormal PAL-18.
 54. A method for in vivo imaging, comprising administering to an animal an binding agent that specifically binds a PAL-18 polypeptide, said binding agent having an imaging agent attached thereto.
 55. The method according to claim 54, wherein the binding agent is an antibody. 